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1. General introduction 
 
By definition, the word natural refers to something that is present in or 
produced by nature and not artificial or man-made. Natural products may be 
extracted from tissue of plants, marine organisms or microorganism 
fermentation broths. 
Structurally, natural products include different classes of compounds as 
terpenoids, polyketides, aminoacids, peptides, proteins, carbohydrates, 
lipids, nucleic acid bases, ribonucleic acid (RNA), deoxyribonucleic acid 
(DNA) and so forth, usually provided with biological and pharmacological 
activity. 
They are considered the most productive source of leads for the 
development of drugs.  
Indeed from 2005 to 2007 thirteen natural product-related drugs were 
approved, particularly as anti-infectives and anticancer agents.1,2 
 
1.1. Tumor: what it is?  
Cancer is a disease characterized by uncontrolled and diffuse multiplication 
of abnormal shape cells in the organism.3 
Biologically, cancer is composed of more than one distinct disease, each 
with its own etiology and pathology, which is most closely related to the 
tissue of origin. 
The treatment of these diseases has involved the development of many 
strategies, together with the discovery of mechanisms that allow disorderly 
cell growth, and many naturally-derived molecules have been found and 
employed to improve therapies. Moreover, natural compounds have often 
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been the starting point of a drug discovery process that was used to better 
understand targets and pathways of tumor onset. 
For this reason, improvements in the area of cancer therapy are essential, 
considering that is forecasted to be major cause of death in the 21st century, 
in particular in industrialized countries.4 
 
1.2. Defects of the mechanisms of cell replication and death. 
During eukaryotic cell division, the mother cell must replicate its 
chromosomes exactly once in the synthetic phase (S phase of cell cycle), 
and then must separate the replicated chromosomes at the end of the mitotic 
phase to the two daughter cells provided with the same genetic heritage of 
the mother cell.  
Defects in the coordination of chromosomes replication and segregation can 
have severe consequences leading to genetic instability and aneuploidy, and 
eventually fostering tumor malignancy. 
To ensure correct transmission of genetic material during cell division, cells 
have evolved cellular regulatory mechanisms termed “cell cycle 
checkpoints”.  
This control system prevents or delays cell cycle progression if certain 
cellular processes or proteins are disrupted, to gain time to repair the 
damage before cell division occurs.  
When the damage is irreparable, the cell undergoes apoptosis through the 
triggering of specific biochemical pathways. 
However, cancer cells often elude the control systems allowing uncontrolled 
cell proliferation, even when cell division does not occur properly. 
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About the 50% of human malignant tumor are induced by mutation of p53 
gene, that codifies for the namesake protein involved in the reparation 
mechanism of DNA.3 
 
1.3. Cancer chemotherapy 
The aim of conventional antitumor therapy to date is to slow and hopefully 
halt the growth and spread of a cancer cells. There are three goals associated 
with the use of the most common anticancer agents: 
• To damage the DNA of cancer cells. 
• To stop cells replication by inhibition of the synthesis of new DNA 
strands. 
• Block of mitosis, or the actual splitting of the original cell into two 
new daughter cells during replication. 
In general, chemotherapy agents can be divided into three main categories 
based on their mechanism of action. 
• Stop of the synthesis of pre-DNA molecule building blocks. 
DNA building blocks are folic acid, heterocyclic bases, and 
nucleotides, which are made naturally in the cells.  
All of these agents work to block some steps in the formation of 
nucleotides or deoxyribonucleotides (necessary for making DNA) 
and without these the cells can’t replicate.  
Examples of drugs in this class include methotrexate (Abitrexate®) 
and fluorouracil (Adrucil®). 
• Direct damage to the DNA in the cell nucleus.  
These agents chemically damage DNA and RNA, either blocking 
totally replication or causing the formation of nonsense DNA or 
RNA (i.e. the new DNA or RNA does not code for anything useful). 
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Examples of drugs in this class include cisplatin (Platinol®) and 
antibiotics such as doxorubicin (Adriamycin®). 
• Effect the synthesis or breakdown of the mitotic spindles. 
Mitotic spindles serve as molecular railroads during cell replication, 
since they help to split the new copied DNA so that every copy goes 
to each of the two new cells during cell division.  
These drugs paclitaxel (Taxol®) and vincristine (Oncovin®) disrupt 
the formation of the spindles and therefore interrupt cell division. 
Mitotic spindle structure is made up of dynamic substructures named 
microtubules.5 
 
1.4. Microtubules 
Microtubules are major dynamic structural components in cells since they 
are involved in very important cellular functions, such as the development 
and maintenance of cell shape, cell reproduction and division, cell 
signalling and movement.  
For this reason, microtubules are the target of structurally different groups 
of anticancer drugs, most of which derive from natural products. 
The mitotic inhibitors represent the single best cancer target identified to 
date.6 
Microtubules are highly dynamic polymers of heterodimers of two closely 
related 55 KDa proteins termed α and β tubulin, arranged parallel to a 
cylindrical axis to form tubes of 25 nm diameter that may be many µm long. 
The proteins are encoded by separate genes or small gene families, whose 
sequences are highly conserved throughout the eukaryotic kingdom. 
Another member of the tubulin family, γ-tubulin, is involved in the 
nucleation and polar orientation of microtubules.  
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It is found primarily in centrosomes and spindle bodies, since there are 
areas of most abundant microtubules nucleation. 
Polymerization of microtubules occurs by a nucleation-elongation 
mechanism in which the formation of a short microtubules “nucleus” is 
followed by elongation phase characterized by reversible, noncovalent 
addition of tubulin dimers to the end of microtubule itself. 
They exhibit complex polymerization dynamics that use energy provided by 
the hydrolysis of GTP. 
Tubulin binds GTP in solution with high affinity, and little by little tubulin-
GTP is added to the end of a growing microtubule, the GTP is gradually 
hydrolyzed to GDP and Pi.  
Ultimately, the Pi dissociates from the microtubules, leaving a microtubule 
core consisting of tubulin with stoichiometrically-bound GDP. The 
nucleotide remains non-dissociable and non-exchangeable until the tubulin 
subunit dissociates from the microtubule. 
Microtubules dynamic is regulated by two phenomena, from one side 
“treadmilling” is the net growth at one microtubule end, on the other side 
“dynamic instability” is a process in which the individual microtubules ends 
switch between phases of relatively slow sustained growth and rapid 
shortening.  
The transition between growth and shortening appears to be regulated by 
the presence or absence of the region of GTP-containing-tubulin at the 
microtubule end. 
A microtubule can grow as long as maintains a stabilizing cap of tubulin-
GTP or tubulin-GDP-Pi at its end. The loss of the cap induces 
depolymerization of microtubules.  
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Hydrolysis of tubulin bound GTP and the subsequent release of Pi establish 
conformational changes in the tubulin molecule, that destabilize the 
microtubule polymer, resulting in “catastrophe” and shortening of the 
microtubules. 
The two ends of microtubules are not equivalent; one end, termed “plus 
end” is kinetically more dynamic than the “minus end” and although both 
ends can either grow or shorten, the changes in length at the first one end 
are much larger than the changes in length at the other one.7,8 
 
 
Figure I-1. (a) Schematization of a microtubule made up of dimers of α and β 
tubulin. (b) Representation of main microtubule dynamics. 
 
1.4.1. How microtubules work throughout the cell division 
cycle  
In a typical cell during the interphase of the cell cycle, the microtubules 
radiate from a central site near the nucleus, called “microtubules-organizing 
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centre” (MTOC). In animal cells, the MTOC consists of a centrosome made 
up of a lattice of MAPs, γ-tubulin and a pair of centrioles.  
While the minus end of the microtubules lies in or near the centrosome, the 
plus end extends out toward the cell periphery. Before of the cell division, 
the cytosol is permeated by a fixed net of microtubules organized in a 
spindle-shape “mitotic spindle” that is the real director of the chromosomes 
segregation at anaphase.9 
Mitotic spindle consists of three kinds of microtubules: 
• Astral microtubules are shorter and stabler  because they link the two 
poles of mitotic spindle to the cell ends. 
• Polar microtubules are longer, rather stable and they look overlaid 
each other because of their structural role during mitosis. 
• Kinetochore microtubules are unstable and directly linked to the 
chromosomes on the equatorial plate. They are the object of dynamic 
instability phenomenon given that the rapid removal of tubulin 
subunit determine the separation of the chromosomes.10 
 
 
Figure I-2. Representation of microtubules network during the separation of 
chromosomes. 
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The interphase microtubules network disassembles at the onset of mitosis 
and is replaced by a new population of spindle microtubules that are 4 to 
100 times more dynamic than microtubules in the interphase cytoskeleton.  
Mitotic spindle exchange its tubulin with that in the soluble pool with half-
times in the order of 10-30 seconds. Recent studies have indicated that 
several antimitotic anticancer drugs appear to inhibit mitosis at the 
methaphase/anaphase transition by suppressing spindle tubules dynamics. 
In the presence of low, but effective drugs concentrations, spindle forms 
and mitosis can progress as far as the methaphase/anaphase transition.  
However, the spindles are completely unable to pass the mitotic cell cycle 
checkpoint and to initiate anaphase movements, or do so only after a long 
period of mitotic blockage, apparently due to their suppressed dynamics. 
Mitotically-blocked cells eventually die by apoptosis.6 
 
1.4.2.  Tubulin binding site 
Tubulin was identified for the first time as the “colchicines-binding protein” 
by Borisy and Taylor in 1967, and the ability of colchicine to block cells in 
prometaphase/metaphase step of mitosis played a key role in the 
development of antimitotic drugs. 
Antitubulin agents are divided into two categories based on their ability to 
bind to tubulin and change the ratio between assembled microtubules and 
dimeric tubulin. 
In vitro, the equilibrium between the dimeric and polymeric forms of 
tubulin can be altered by different effecters, such as DMSO, cofactors [ 
Mg2+, guanosine-5’-triphosphate (GTP), guanosine-5’-diphospahte (GDP)], 
or small molecule, which alter the stability of tubulin dimers or the 
polymerization process.6 
General introduction  
 
10 
Three major classes of tubulin-binding agents have been identified: the 
colchicine-site binding agents, the vinca domain inhibitors, which block 
microtubules growth, taxanes and epothilones binding site inhibitors which 
stabilize microtubules. 
Both the vinca alkaloids and the taxane drugs bind to the tubulin, but at 
different location on the protein: the first group binds to β-tubulin between 
amino acids 175 and 213, while paclitaxel (Taxol®) binds both to N-
terminal unit on β-tubulin and to the region bounded by amino acids 217-
231. 
Colchicine that is not a clinically used drug for cancer binds to the β-subunit 
at the interface with α-monomer of the some tubulin molecule.9 
 
1.4.2.1.  Colchicine binding site 
Colchicine (1), was isolated from the autumn crocus Colchicum autumnale. 
Although colchicine has significant in vitro antitumor effects, its medical 
uses, as well as use of its derivatives, has been limited because of its high 
toxicity, low bioavailability and poor water solubility (fig. I-3).11 
The effect of colchicine on microtubule dynamics depends on drugs 
concentration. Thus, relatively high colchicine concentrations inhibit 
microtubule polymerization and depolymerize preformed microtubules. 
Colchicine binds to soluble tubulin and forms a poorly reversible tubulin-
colchicine (TC) complex, which then is incorporate at the microtubule 
ends.6  
A group of tubulin inhibitors that bind at this site include CA-4 (2) and 
ZD6126, both of which are currently in clinical development. 
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Figure I-3. Structures of colchicine and CA-4. 
 
1.4.2.2.  The vinca domain 
The antimitotic vinca alkaloids vinblastine (3), vincristine (4), vindesine 
and vinorelbine are widely used both as single agent and in combination 
with other antitumor drugs in cancer chemotherapy, particularly in a variety 
of hematologic and solid tumor (fig. I-4). 
The two complex indole alkaloids, vinblastine and vincristine were 
originally isolated from the plant Catharantus Rosea, while vindensine and 
vinorelbine are semisinthetic compounds. 
The binding site of vinblastine on tubulin also binds other compounds 
(hemiasterlins, crytophycins and halicondrins) and this kind of binding 
induces a conformationally change in tubulin that becomes more akin to 
vinblastine with the formation of vinblastine-tubulin spiral oligomers.9 
 
 
 
Figure I.4. Structures of vincristine and vinblastine. 
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1.4.2.3.  Taxol binding site 
Taxol® (paclitaxel, 5) was isolated in 1971 by Well and Wani from the 
pacific yew Taxus Brevifolia and is effective used in the treatment of the 
breast, ovarian, and lung carcinomas.  
Taxol appears to arrest cell in mitosis by stabilizing spindle microtubules, in 
particular this alkaloid induces the formation of morfologically-altered 
tubulin polymers, that organize themselves in 12 protofilaments rather than 
13, both in vitro with pure tubulin and in vivo.6 
Like vinblastine and colchicine, taxol slows and blocks mitosis at the 
metaphase/anaphase transition in a number of cell types, inducing 
accumulation in a metaphase-like state and ultimately apoptosis.12 
The success of paclitaxel has spurred enormous interest in finding better 
pharmacokinetic profile analogs.  
To date the only one approved for clinical use in the U.S. is docetaxel (6) 
that has a semi-synthetic origin. 
 
 
 
 
 
 
 
 
 
Figure I-5. Structure of paclitaxel and docetaxel. 
 
Both paclitaxel and docetaxel occupy the same binding site in the subunit of 
tubulin with a 1:1 stoichiometry.  
In the following tab (Table I-1) are reported the class, at the moment, more 
promising of tubulin inhibitors, most of which are in clinic trials. 
O
O
OR OH
O
OH
O
H
O
O
O
5 R= OCOCH3, R1= NHCOPh
6 R= OH; R1= OtBu
R1
OH
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However, there is an unmet need of new drugs since current therapies suffer 
from limited extension of survival time due to inherent or acquired 
resistance which is often associated with expression of the P-glycoprotein 
drug transporter. 
 
Compound 
class 
Approved 
agents 
Compounds in 
develop 
Effect(s) on 
microtubules 
Taxanes paclitaxel 
docetaxel 
DJ-927 Polymerization 
and/or 
depolymerization 
Epothilones Ixabepilone KOS-1584 
Epothilone B 
 
Vinca alkaloids Vincristine 
Vinblastine 
Vinorelbine 
 Depolymerization 
and/or 
destabilization 
Halicondrin b  Erubiline 
mesylate 
 
Table I-1. Classes of MTIs  
 
1.4.3.  Multi drug resistance 
Multidrug resistance, the principal mechanism by which many cancers 
develop resistance to chemotherapy drugs, is a major factor in the failure of 
many forms of chemotherapy.  
It affects patients with a variety of blood cancers and solid tumors, 
including breast, ovarian, lung, and lower gastrointestinal tract cancers.  
Tumors usually consist of mixed populations of malignant cells, some of 
which are drug-sensitive while others are drug-resistant. Chemotherapy kills 
drug-sensitive cells, but leaves behind a higher proportion of drug-resistant 
cells.  
As the tumor begins to grow again, chemotherapy may fail because the 
remaining tumor cells are now resistant. 
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Resistance to therapy has been correlated to the presence of at least two 
molecular "pumps" in tumor-cell membranes that actively expel 
chemotherapy drugs from the interior. This allows tumor cells to avoid the 
toxic effects of the drug or molecular processes within the nucleus or the 
cytoplasm.  
The two pumps commonly found to confer chemoresistance in cancer are P-
glycoprotein and the so-called multidrug resistance–associated protein 
(MRP).  
Drug resistance is a multifactor phenomenon in which different mechanisms 
are involved as failure of physiologic apoptosis, modified drug activation or 
degradation and modified transport of the drugs through the membrane 
because of a change its permeability. 
Pgp (Fig. I-6) is a trans-membrane protein, product of gene mdr-1, over-
expressed in tumor cells, in particular those targets of chemotherapy. 
The primary structure of this protein is made up of 1280 amino acids, 
organized into two repeated units, everyone of 610 amino acids, linked by a 
bridge. Its trans-membrane domain (TMD) is directly involved in drugs 
binding, but is independent from ATP activity.13 
 
 
Figure I-6. Scheme of P-glycoprotein and its functional domain. Domains directly 
involved in this bond are starred. 
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In this Ph.D. thesis I focused on two modified analogs of natural tubulin 
inhibitors, with the same target but different action mechanism that are 
respectively hemiasterlin and epothilone B. 
These compounds are the result of the drug discovery process starting from 
natural template, aimed at finding new drugs that elude multi-drug 
resistance phenomenon. 
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2. Microtubules depolymerization inducing agents 
 
2.1. Hemiasterlins 
Hemiasterlin (7), hemiasterlins A (8), B (9), and C (10) are members of a 
small family of cytotoxic tri-peptides that have been isolated from a South 
Africa sea sponge Hemiasterella minor (fig. II-1).  
Structurally, hemiasterlins are characterized by the presence of tri- or 
tetramethylated tryptophan, tert-leucine, and N-methylvinylogous valine 
residues. 
 
Figure II-1. Structures of hemiasterlins and relative numeration.  
 
These natural substances show potent in vitro cytotoxicity against murine 
leukemia P388 and human breast, ovarian, colon, and lung cancer cell lines. 
Against human breast cancer MCF7 cells, compounds (7) and (8) are more 
cytotoxic and more potent mitotic blockers than vincristine, paclitaxel and 
nocodazole, while hemiasterlin C is the least potent derivative.14 
The potency of hemiasterlin was also confirmed by the lowest IC50 values 
(about 2 pM) obtained in the human tumor cell lines OVCAR-3 and NCI-
H460. 
It was found that hemiasterlin strongly inhibited tubulin assembly, with 
activity comparable to dolastatin 10 (11) and cryptophycin 1 (12) (IC50 
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values are 0.59, 0.98, and 1.1 µM for dolastatin 10, hemiasterlin, and 
cryptophycin 1, respectively). 
 
 
Figure II-2. Structure of hemiasterlin, cryptophicin 1, dolastatin. Boxed region 
represents areas of common overlap identified through docking studies. 
 
Several experimental studies probing the binding of this class of mitotic 
inhibitors to tubulin have appeared in literature.15 
However, the complexity and diversity of tubulin-ligand binding 
compounded with the lack of corroborating structural evidence have served 
as limitation to an understanding of the detailed molecular interaction 
present in the system under study. 
Rai and Wolff have localized the binding region of the microtubule 
destabilizing agent vinblastine on β-subunit, while the three peptides, 
probably, bind in a site distinct from that at which the vinca alkaloids bind, 
since they all noncompetitively inhibit the binding of radiolabeled vinca 
alkaloids to tubulin. 
           Hemiasterlins: introduction 
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In contrast, hemiasterlin as well as cryptophycin 1 and chiral isomer of 
dolastatin 10 (13) competitively inhibit each other for binding of 
[3H]dolastatin 10 to tubulin (Table II-1).  
 
Table II-1. Inhibition by hemiasterlin and other vinca domain drugs of the binding 
of [3H]vinblastine and [3H]dolastatin 10 to Tubulina  
Drug added 
% inhibition of 
[3H]vinblastine 
binding 
% inhibition of 
[3H]dolastatin 10 
binding 
Hemiasterlin 
Dolastatin 10 
Cryptophicin 1 
Vinblastine  
27 
44 
36 
43 
 
42 
2 
a
 The 0.4 ml reaction mixtures contained 10 µM tubulin, 0.5% DMSO, the 
indicated potential inhibitor at 0.5 µM. Incubation was fro 30 min, and centrifugal 
gel filtrations of duplicated 0.19 ml aliquots were at room temperature. Avarages 
from two independent experiments are presented in the table. Stoichiometry of 
binding in the control reaction mixtures: 0.57 mol vinblastine and 0.59 mol of 
dolastatine 10 per mole of tubulin. 
 
Dolastatin 10 is the most active, but phase I/II clinical trials revealed bone 
marrow toxicity, neuropathy together with a poor therapeutic index.  
Despite their structurally diversity, these antimitotic agents bind at the same 
active site, that is adjacent to the exchangeable GTP site on β-tubulin and is 
composed primarily of residues Ser171, Lys174, Val175, Asp177, Asn204, 
Glu205, Tyr208, Asp209, Phe212, Pro220, and Tyr222.16 
Each of these antimitotic agents destabilizes and depolymerizes 
microtubules, resulting in the formation of aberrant non-microtubules rings 
and oligomers, in this case hemiasterlin-tubulin rings are 45 nm in diameter, 
and both contain 14 tubulin dimers. 
Thanks to molecular dynamics simulations and molecular docking studies it 
was possible to understand which functional groups of the hemiasterlin 
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were important for the interaction with the binding site, comparing the three 
hydrophobic peptides. 
Starting from the N-terminus of the hemiasterlin, the Trp residue provided 
with the two methyl group could be overlaid with the aliphatic side chain, 
while the Val residue probably overlaps the pyrrolidine ring of the 
dolastatin 10 (fig.II-2). 
An overlap can be exist between the carbonyl of Val moieties and the 
aliphatic side chain of the Val, moreover  Dil/Leu residues may show 
structural overlap. These results indicate that the Val and Ile/Leu residues 
may be the common elements forming the pharmacophore.15 
 
2.2.  From Hemiasterlin to HTI-286 
Nieman and co-workers synthetized a number of analogues in order to 
define what portions of the structure were required for cytotoxicity and 
antimitotic activity and to prepare more potent analogs easier to 
synthesize.17 
A great result of this study was the identification of a Synthetic Peptide 
Analogue 110 (SPA 110 or HTI-286, 14), obtained changing indole of 
hemiasterlin with phenyl ring. 
At the moment, HTI-286 is in clinical trial after demonstration of biological 
activity in preclinical cancer models. 
 
 
Figure II-3. Structure of HTI-286. 
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The library of products was prepared considering that the geminal methyl 
couldn’t be removed because they were thought to protect the tripeptide 
from proteolysis and/or to establish a preferred conformation that may be 
critical to biological activity. 
Hemiasterlin has been the object of a series of single-point changes and 
corresponding new compounds have been tested for both antimitotic 
activity in MCF-7 cells expressing a dominant-negative mutant p-53 tumor 
suppressor gene and in vitro cytotoxicity. 
It was found that there was a linear relation between antimitotic and 
cytotoxicity activity over a wide range of structural variations; this 
correlation suggest that, in these cells, cytotoxicity is solely due to 
inhibition of tubulin function at mitosis, and that hemiasterlins are pure 
antimitotic agents. 
 
2.2.1. SAR study on natural hemiasterlin 
C-10 trimethylammonium ion and the substitution of the isopropylic chain 
with a hydrogen atom caused a loss of activity, proving that the two 
functionality are crucial to metabolic stability and/or tubulin binding.  
The same outcome had the hydrogenation of the double bond to give a 
mixture of epimers that reduce the potency by roughly an order of 
magnitude. 
The aromatic function is essential at N-terminus as demonstrated by the loss 
of potency due to the replacement of  the N-methylindole ring with a methyl 
or hydrogen atom to give respectively tert-LEU and Val-hemiasterlins. 
Other modifications are well tolerated resulting in no significant loss in 
potency; these include the conversion of the B residue tert-Leu to Val, 
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formation of the methyl ester at and the replacement of the N-5 methyl 
substituent with a proton. 
Only one change, the replacement of N-methylindole by aromatic ring made 
HTI-286 3-fold more potent than the natural product. 
 
 
Figure II-4. Structural requirement for optimal cytotoxicity (IC50˂ 1 nM) nd 
antimitotic activity (IC50 ˂ 1 NM) 
 
The result of this study has highlighted four regions of hemiasterlins where 
single structural changes are possible without seriously compromising 
antimitotic activity: 
• replacing N-methylindole with phenyl and methyl groups  
• replacing the tert-Leu residue with Valine  
• removing the N-5 methyl substituent  
• making the C-terminal residue methyl ester 
C-11 methyl substituents, the C-10 methylamino group, and the C-4 
isopropyl groups are extremely important structural elements for potent 
antimitotic activity.18 
With HTI-286 in hand, Rush and co-workers from Wyeth have undertaken a 
docking study to better understand the interaction of HTI-286 with the 
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tubulin and according their predictions, there are several important factors 
contributing to the HTI-286/tubulin interaction.  
These include different hydrophobic interactions, hydrogen bonding, and 
electrostatic complementarity. 
It is hypothesized the U-shaped curvature of the backbone of HTI-286, in 
particular the tertiary butyl group is found to occupy a spacious cavity in β-
tubulin, proximal to the location of the guanosine 5’-diphosphate (GDP) 
(fig II.5). 
The binding model finds the C-1 position of HTI-286 to be oriented in a 
region of β-tubulin that is flanked by two ASN residues (residues 186 and 
101 of the β-tubulin subunit) providing hydrogen bonding opportunities 
with the carbonyl or hydroxyl group of the ligand.  
The heteroatoms of the amide backbone of the HTI-286 are seen forming β-
sheet-like interactions with the backbone atoms of nearby amino acids 
residues. 
The interaction between the basic NH group of HTI-286 and the Asp179 
residue of the β-tubulin subunit are quite significant in fact deleting them, 
the enthalpic and desolvatation contributions to binding might be 
perturbated. 
The binding model indicates an association between Ser 174 and Ser 178 of 
the β-tubulin and the C-9, C-6 and N-8 position of the HTI-286 scaffold 
(Fig. II-4).19 
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Figure II-5. Surface view of HTI-286 docked to the β-tubulin portion of the 
interdimer interface, emphasizing the binding pocket. The α-tubulin subunit is not 
shown for clarity. The tubulin surface is colored by lipophilic potential (brown, 
hydrophobic; green, neutral; and blue, hydrophilic). Hydrogens are removed for 
simplicity. The yellow-colored carbon atoms are poised for intramolecular 
interactions, and the tert-butyl carbons are colored purple. 
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3. Scopes and aims 
 
3.1.  Development of synthetic routes for the synthesis of A-
fragment 
In literature there are different total synthesis of hemisterlin, but the first 
one was completed by Andersen and co-workers in 1997 and it is the result 
of a sequence of coupling reactions between three modified amino acids A, 
B and C. Every amino acid apart the commercially available N-Boc-tert-
leucine is synthesized singularly. 
 
 
 
Figure III-1. Retrosynthetic analysis of hemiasterlin. 
 
Structural assignment based on NMR and degradation studies are supported 
by X-ray diffraction analysis of hemiasterlin methyl ester, and it was found 
that the members of this family are known to have L-configuration (Fig. III-
1). 
The hardest step is the synthesis of A-piece (15) because of the 
enantiocontrolled installment of a chiral amine group. 
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The first approach was based on Evans’ oxazolidinone chemistry employing 
the electrophylic nitrogen source triisopropylphenylsulfonyl azide. The 
reduction of azide (23), followed by Boc-protection of amine (24) gave the 
desired functionalized tryptophan (28) in a good enantiomeric excess (> 
98%).14
 
Scheme III-2. Reagents and conditions: (i): KN(SiCH3)2, THF, -78°C to 0°C, 3 h; 
CH3I, -78°C to 0°C, 2 h; (ii): KN(SiCH3)2 (1.5 eq), then as in (i); (iii): i-Bu2AlH, 
Et2O; (iv): TPAP, NMO, CH2Cl2, 4Å sieves; (v): Ph3P=CHOMe, THF, r.t.; (vi): p-
TsOH, H2O, dioxane, 60° C, 16 h; (vii): NaClO2, NaH2PO4, 2-methylbut-2-ene, t-
BuOH, H2O, 0°C; (viii):CH3CCOCl, TEA, THF, -78°C; (ix): KN(SiMe3)2, THF, -
78°C; 2,4,6-triisopropylbenzenesulfonyl azide, THF, -78°C, 1 min; AcOH, 30-40°C, 
1h; (x): SnCl2, dioxane, H2O, r.t., 36 h; (xi): (CH3CO2C)2O, dioxane, H2O, r.t., 16 h; 
(xii): LiOOH, THF, H2O, r.t., 16 h; citric acid, H2O; (xiii): NaH, DMF, CH3I, r.t., 16 
h; (xiv): LiOH, MeOH, H2O, 60°C, 24 h; citric acid, H2O. 
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The reported synthesis of the tryptophan moiety starting from methyl ester 
of 3-indoylacetic acid (18) was 16 steps long and suffered from low yields 
of coupling reactions. 
Several research groups tried to find a successful convergent approach that 
could give analogues more readily. 
This would open the possibility of generating not only significant quantities 
of hemiasterlin itself but also analogues for screening and further biological 
assays. 
 
3.1.1.  Vedej’s synthetic approach to fragment A. 
An improved enantiocontrolled route to the tetramethyltryptophan subunit 
(36) was developed by Vedejs’ group using an asymmetric Strecker 
synthesis (5 steps, 50% yield from 29). 
 
Scheme III-3. Reagents and conditions: (i) Sc(OTf)3, (R)-2-phenylglycinol, 
CH2Cl2, r.t.; Bu3SnCN, 0°C to r.t.; (ii) H2O2, K2CO3, DMSO, MeOH, 45°C; (iii) H2, 
Pd(OH)2/C, MeOH, r.t.; (iv) BtsCl, Na2CO3, CH2Cl2-H2O, 0°C to r.t.; (v) CH3I, 
DMF, 35°C; (vi) BOC2, DMAP,CH3CN, r.t. 
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This method exploits the high reactivity of a Bts-protected amino acid 
chloride in the difficult peptide coupling of sterically hindered amino acids 
residue like BC dipeptide.20 
 
3.1.2.  Durst’s synthetic approach to fragment A. 
The same principle was followed by Durst’s group to get A-piece starting 
from N-methylindole (38), that was reacted with tin tetrachloride mediated 
ring opening cyanoepoxide.  
The treating of the cyanohydrin (39) with NaOH gave the corresponding 
aldehyde (29) that was used in asymmetric Strecker methodology. This 
sequence led to the formation of an 85:15 diastereomeric mixture of α-
cyano amines (41) direct precursor of Andersen intermediate (42).21 
 
 
Scheme III-4. Reagents and conditions: (i) SnCl4, CH2Cl2, -78 °C, 70%; (ii) 
NaOH, EtOH 95%; (iii) (R)-phenylglycinol, CH2Cl2, TMSCN; (iv) 
Pb(OAc)4, MeOH/CH2Cl2; (v) 3 N HCl, Et2O, 55% over two steps; (vi) 
concentrated HCl reflux; (vii) (Boc)2O, Na2CO3, THF/H2O; (viii) NaH, 
MeI, DMF, 65% over three steps. 
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A-piece, whatever its origin, was coupled with the segment BC though 
amide bond formation. 
To date, the first proposed synthetic route was extensively followed for 
SAR studies, but it is resulted poorly versatile, because every structurally 
different A amino acid has to prepared on purpose. 
Moreover, this strategy is hardly scalable to obtain considerable amount of 
product. 
 
3.2.  Toward the synthesis new analogues of HTI-286 
The aim of my Ph.D. project is the possibility to easily access to a series of 
synthetic analogues of HTI-286, opportunely modified at N-terminus. 
Molecular modeling studies, not reported in this context, have highlighted 
the ability of the binding site on the tubulin to host bulky derivatives at N-
terminus.  
For this reason, we considered the use of a common precursor from which a 
series of derivatives with modified A-portion could be obtained with one or 
very few steps. 
Following previous works in the field, we have exploited the synthetic 
potentiality of 2-bromoacyl-peptides as versatile synthetic intermediates in 
reactions in which the pool of natural amino acids is used as starting 
material. 
The modifications were directed mainly N-terminus of hemiastelin 
structure, but also the C-terminus, was involved in SAR studies. 
At first we thought to invert the α,α-dimethylbenzyl group with the α-N-
methyl group in order to get derivatives of the alanine (43) that was 
incorporated in the backbone of the hemiasterlin thanks to two following 
coupling reactions.22 
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Figure III-2. Inversion of methyl group with dimethylbenzyl radical at N-terminus. 
 
From one side, a key role was played by silver oxide as promoter of 
substitution reactions with controlled chemistry, employed to introduce 
particular functional groups at N-terminus.23 
Then, in order to further explore the size of the binding site, bulkier groups 
were introduced at N-terminus, employing bromoacyl peptides (44) derived 
from phenylalanine instead of alanine as starting materials. 
 
 
Figure III-3. General structure of the synthesized products related to HTI-286. 
 
Besides that, we also tried to obtain the direct analogue of natural 
hemiasterlin, bearing 2-(1-methyl-1H-indol-3-yl)propan-2-amine at C-10 of 
the tripeptidic backbone as derivative of alanine, but so far we haven’t 
obtained it. 
New anticancer therapies are based on synergic interaction between drugs 
that have the same action mechanism and pharmacologic effect. 
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Thus, we have thought to take advantage of this principle, planning to 
prepare a conjugate between the most active candidate and stilbene 5c, 
known to inhibit tubulin assembly (IC50 values from 2 to 8 nM) by binding 
to a site different from hemiasterlin, thanks to a linkage easily hydrolysable 
in situ. The idea of a pro-drug came up also from the possible improvement 
of the water-solubility of stilbene 5c.  
By definition two or more agents or substances act in synergy if they 
produce an effect greater than the sum of their individual effects.24,25 
In this context, this CA-4 analog was termed exactly as in a paper published 
by prof. Simoni and al.24,25 
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4.  Results and discussion  
 
4.1.  Potentiality of silver oxide in nucleophile substitution 
reaction 
The research group, in which I carried out this Ph.D. project, has experience 
in the knowledge of the silver oxide chemistry as promoter of nucleophile 
substitution on substrates as peptides, depsi-peptides and pseudo-peptides.26 
These applications are indicative of the great versatility of 2-bromoamides, 
and of the potential involvement of natural aminoacids. 
Thus, the novelty of our synthetic approach is based on the consideration 
that (S)-α-amino-acid (45) can be diazotization and halogenated to give the 
corresponding (S)-α-bromo-acid (47) in turn derivatized to (S)-α-
bromoacylpeptide or (S)-α-bromoacylamide (48) depending on the nature of 
R, maintaining the same configuration of the starting material.27 
 
 
Scheme IV-1. Stereospecific synthesis of (S)-α-bromoacylpeptide from (S)-α-
aminoacid 
 
This is the result of a double inversion of configuration in the sequence (S)-
45 → (R)-46 → (S)-48 in which the unstable lactone is involved. 
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In literature there are some examples that highlight the bromoacylamide 
(48) reactivity towards the substitution of the bromine with a nucleophile, 
according to different factors:  
• nature of the nucleophile 
• solvent characteristics 
• presence of a silver promoter  
• nature of alkylic group in α position 
Thus, the reaction of (S)-48 with an amine gives substitution compounds, 
whose N-terminus bears the side chain of (S)-45. 
In absence or in presence of a soft Lewis acid Ag+, starting from (S)- 
bromoacylpeptide 49 the product with inverted configuration is obtained 
(R)-51. 
This reaction is quite slow, it takes hours to go to an end, and is performed 
with 1°, 2° amines and enolate that are good nucleophiles. 
The combination of Ag+/hindered amine induced the amine to behave both 
as base and as nucleophile, thanks to a shift from a mechanism of 
electrophilic assistance to an alternative one, where Ag+ is responsible of an 
acidity-enhancement mechanism. 
The addition of covalent silver oxide increases the rate of the reaction, in 
fact it was observed that with whatever amine, the product has the same 
configuration (S)-51 of the parent 2-bromoamide 49 in high ee was 
obtained. 
Stereoselectivity depends on a favorable ratio between the rates of two 
competitive mechanisms that can operate. 
By using an insufficient amount of Ag2O, in fact, the optical activity of the 
produced aminoamide decreas, because the rate of promoted and 
unpromoted reaction approach to each other. 
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Interaction between Ag2O and the solution-species would make the 
mechanism a complex one characterized by a labile aziridinone (α-lactam, 
(R)-50). 
 
 
Scheme IV-2. Reagents and conditions: (i) Ag2O; (ii) Nu:; (iii) Nu:, Ag+ 
CF3SO3-  
 
4.2.  Synthesis of the fragment BC 
 
 
Scheme IV-3. Reagents and conditions: (i) CH3I, NaH 60% min. oil, THF; (ii) 
CH3NHOCH3 ·HCl, 1-HOBT, WSC, NMM; (iii) LiAlH4, THF; (iv) PPh3, toluene; 
(v) NaOH; (vi) 57, CH2Cl2; (vii) TFA, CHCl3  
 
The schemes IV-3 and IV-4, show the synthesis of the intermediates (S)(S)-
63a, b as exactly reported in literature for HTI-286.28 
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Boc-N-methyl-(S)-valinale 52 obtained from reduction with LiAlH4 of the 
Weinreb amide (S)-54, was reacted with a stabilized Wittig reagent (57), 
previously prepared from 2-bromoester (56) to get γ-aminoester α,β-
unsaturated (scheme 6). 
The olefination was performed in CH2Cl2 affording stereoselectively the E-
2-alkenoate (59) (scheme IV-3). 
 
After deprotection under acidic conditions, the intermediate (S)-59 was 
coupled with (S)-Boc-Valine 60 or (S)-Boc-Tert-Leucine 61 employing 
TMAC to activate the amino acid (scheme IV-4). 
 
 
Scheme IV-4. Reagents and conditions: (i) TMAC, DIPEA, THF, -78°C, 2h; (ii) 
TFA, CHCl3, r.t. 
 
4.3.  Synthesis of racemic mixtures of bromoderivatives 
From this known intermediates, we started our own project by reacting 
(S)(S)-63a,b with bromide of (R, S)-2-bromo-propionic acid 64 obtaining 2-
Hemiasterlins:result and discussion  
 
38 
bromoacyl-peptides (R,S)(S)(S)-65a,b as diasteromeric mixtures (scheme 
IV-5).  
 
Scheme IV-5. Reagents and conditions: (i) TEA, DCM, 0°C, to r.t. overnight.  
 
At first, the products were synthesized as mixture of diastereoisomers, in 
order to achieve easily both compounds, whose activity might be quickly 
tested and compared to each other. The most promising compounds were 
then prepared as single diasteroisomers in order to establish the identity of 
which one was responsible of the activity. 
In this perspective, silver oxide was employed as coupling agent granting 
good yields and the correct stereochemistry of the product. 
In this case, bromo-derivatives (S)(S)(S)-65a,b are the result of the reaction 
between (S)(S)-63a,b with (S)-2-propanoic acid 67, in turn obtained by 
diazotization-bromination of amino acid (L)-alanine 66.  
Similarly, the (R)(S)(S)-65a,b series display both valine and tert-leucine 
were prepared using (D)-alanine as starting material (scheme IV-6).27  
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Scheme IV-6. Reagents and conditions: (i) NaNO2/H+, KBr; (ii) TMAC, DIPEA, 
THF, -78°C 
 
4.4.  Nucleophilic substitution reaction catalyzed by silver oxide 
The prepared bromoacyl intermediates 65a,b were subsequently reacted 
with different nucleophyles, mainly amines. Some amine were not 
commercial and were synthesized.  
Indeed, most of amines 71a,d-e were prepared treating tertiary alcohol with 
sodium azide and TFA at 0°C, followed by catalytic hydrogenation with 
palladium on charcoal, while non commercially available alcohols 69d-e 
were obtained adding the correspondent ketone 68d-e on to freshly prepared 
Grignard’s reagent.29 
With the aim to understand the importance of the two methyl groups R'' and 
R''', also amines as 71b,c, and N-methyl-indol-3-yl-methanamine 71f, 
yielded by reduction of the corresponding nitrile 73, were employed 
(scheme IV-7). 
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Scheme IV-7. Reagents and conditions: (i) CH3I, Mg, Et2O; (ii) NaN3, TFA, CHCl3; 
(iii) H2, Pd/C; (iv) H2, Pd/C, EtOAc 
 
In the same perspective, cyclohexylamine was used even though its 
structure is different from what is represented in the general scheme IV-7. 
 
4.4.1.  Synthesis of tert-Leucine derivatives  
As regarding the reactivity, only the reaction with benzylamine 71c could 
run without Ag2O, while the other amines have required this promoter as 
they were quite bulky. 
Also water was used as nucleophile even though hydroxy derivatives 
(R,S)(S)(S)-78g and (R,S)(S)(S)-83g were reaction by-products more or less 
present if the environment of the reaction was not strictly dry (scheme IV-
8).22 
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Scheme IV-8. Reagents and conditions: (i) Ag2O, 70a-f, toluene, reflux; (iii) Ag2O, 
Nu: (g: H2O or h:Cyclohexylamine), toluene; (ii) LiOH/MeOH/water, than TFA. 
 
4.4.2.  Synthesis of Valine derivatives  
The following scheme shows the synthesis of some valine derivatives 
(R,S)(S)(S)-81a,c in which only the amine 71a,c were used (scheme IV-9). 
The mixtures (R,S)(S)(S)-75a,c, (R,S)(S)(S)-76a,c and (R,S)(S)(S)-80a,c, 
(R,S)(S)(S)-81a,c weren’t separable either by flash chromatography or 
HPLC, therefore the single diasteroisomers were stereoselectively 
synthetized starting from both (R) and (S)(S)(S)-65a,b thanks to the 
potentiality of Ag2O. 
The de of the products is 95% and was measured by HPLC, 1H NMR and 
comparing the results with those of diasteromeric mixtures previously 
obtained. 
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Scheme IV-9. Reagents and conditions: (i) Ag2O, 71a,c, toluene, reflux; (iii) Ag2O, 
H2O, toluene; (ii) LiOH/MeOH/water, than TFA. 
 
Apart the hydroxy-derivatives (R,S)(S)(S)-78g, 83g, the final products 
(R,S)(S)(S)-76a-f, (R,S)(S)(S)-79h, (R,S)(S)(S)-81a,c were all tested as 
trifluoroacetate salts, after basic hydrolysis of ethyl ester and HPLC 
purification. 
Moreover, we wanted expand our investigation on the versatility of 
synthetic procedure, together with the need of further SAR studies on a 
series of products modified at carboxyl-end position. 
It was, therefore, easily synthetized a compound (R,S)(S)-88 whose 
fragment C was a rigid aromatic derivative of γ-aminoester α,β-unsaturated 
(S)(S)-63b, condensing Boc-(L)-tert-leucine (S)-61 and 3-aminobenzoic 
ethyl ester 84, in order to investigate if a modification at C-terminus might 
afford a series of products modified at this position (scheme IV-10). 
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Scheme IV-10. Reagents and conditions: (i) (1). DIPEA, TMAC, THF, -78°C, (2) 
TFA; (ii) DIPEA, TMAC, (R,S)-2-bromo-propionic acid (iii) Ag2O, toluene, reflux; 
(iv) LiOH, MeOH, H2O, then TFA. 
 
4.4.3.  Synthesis of Phenylalanine derivatives at N-terminus 
Computational studies suggested that the portion of the binding site that 
host the aromatic ring of HTI-286 was enough large to accommodate 
bulkier groups. 
Moreover the most interesting derivatives were those bearing the 
dimethylbenzyl-amino group. 
Thus, a bivalent ligand was prepared, including a further benzylic group at 
N-terminus.  
The two diasteroisomers were synthetized separately following the same 
synthetic route shown in the scheme 12, but in place of alanine, (D) and (L)-
phenylalanine 89 were used, as starting material for the corresponding 
bromo-acids (S)-90 and (R)-90 (scheme IV-11). 
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In the scheme is represented only the synthesis of diasteroisomer (S)(S)(S)-
93, but also the other (R)(S)(S)-93 were obtained. 
 
 
Scheme IV-11. Reagents and conditions: (i) NaNO2/H+, KBr; (ii) TMAC, DIPEA, 
THF; (iii) Ag2O, 71a, toluene, reflux; (iv) LiOH, H2O, MeOH, then TFA. 
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5.  Biological evaluation 
 
Small groups of compounds structurally different to each other were 
synthetized, tested and the biologic results have led us in our SAR study.22 
The first synthetized compounds as racemic mixtures, bearing phenyl group 
at N-terminus apart series g that are hydroxyl-derivative, (R,S)(S)(S)-76a,c, 
(R,S)(S)(S)-81a,c, (R,S)(S)(S)-78g, 83g were tested on lung cancer cells 
A549. 
While (R,S)(S)(S)-81c, (R,S)(S)(S)-78g and (R,S)(S)(S)-83g were inactive at 
the highest concentration used (3 µM), (R,S)(S)(S)-81a at the same 
concentration has shown weak activity. 
On the other hand, tert-leucine derivatives (R,S)(S)(S)-76a and (R,S)(S)(S)-
81a have a very interesting biologic profile, as they inhibit tumor cell 
growth at nanomolar level.  
It was also demonstrate that such concentrations are necessary to 
completely disrupt microtubules network and to arrest cell cycle at G2/M 
phase. 
On purpose, immunofluorescent staining of A549 cells treated with 
(R,S)(S)(S)-76a and (R,S)(S)(S)-81a was performed and it was found that 
when these cells were treated with 100 nM of (R,S)(S)(S)-83g (inactive 
compound), there are no difference from the control cells with fully 
intactive microtubule network and normal mitotic spindles. 
Cells treated with (R,S)(S)(S)-76a were blocked at mitotic phase as evidence 
of condensed chromosomes in DAPI (4’-6’-diammidine-2-phenylindole) 
staining. The same effect was due to cells treatment with (R,S)(S)(S)-81a 
that exhibited a different pattern, in fact the microtubule network is not fully 
disrupted in the non-mitotic cells that are present occasionally. 
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In the mitotic cells identified by DAPI staining, the mitotic spindle shows a 
radial pattern characteristic for monastral spindle. 
Because the structures of (R,S)(S)(S)-76a and (R,S)(S)(S)-81a are very 
similar except an additional methyl group in the B-piece, we thought the 
mechanism of these two compounds should be similar, and the different 
pattern seen in the immunofluorescent staining might be due to the potency. 
The two most active compounds were tested on several cellular panels after 
48 hours incubation and it was observed IC50 values around 10 nM for both 
of them, but the ability of tumor cells growth inhibition of (R,S)(S)(S)-76a is 
higher than (R,S)(S)(S)-81a.  
 
 
Figure V-1. Effect on cell growth of A-549 and H-1299 (cancer lung cells), SNU-
423 (hepatocellular cancer cells), MDA-MB (breast cancer cells), UCI-101 (ovarian 
cancer cells), HCT-116 (colon cancer cells) of compounds (R,S)(S)(S)-76a and 
(R,S)(S)(S)-81a after 48 hours incubation. 
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As (R,S)(S)(S)-76a and (R,S)(S)(S)-81a have proved to have the best 
pharmacologic profile, they were synthetized as single diastereoisomers and 
the cytotoxicty was examined in UCI-101 human ovarian cancer cells. 
Their activity is represented in figure V-2 together with racemic mixtures of 
new derivatives (R,S)(S)-88, (R,S)(S)(S)-76d and (R,S)(S)(S)-79h. 
The two most active compounds are (R)(S)(S)-76a, 81a with IC50 of 20 nM, 
whereas (R,S)(S)(S)-79h and (R,S)(S)-88 have no cytotoxic activity even at 
1 µM. Other two compounds (S)(S)(S)-76a and (R,S)(S)(S)-76d have IC50 at 
200 nM. The fact that (R)(S)(S)-76a and 81a are more potent than 
corresponding stereoisomers (S)(S)(S)-76a and 81a highlights the essential 
role of the (R) configuration at N-terminus. This is not in line with 
taltobulin derivatives stereochemistry, in which (S)(S)(S) configurations are 
reported to have potent activity.  
However, the bulky dimethyl benzyl group in the most active diastereomers 
occupies the same place in both series. It seems, therefore, that the correct 
placement of dimethyl benzyl group is more important than the secondary 
amine to give functional interaction with binding site. 
The poor activity found with the aromatic 2-naphthyl-2-propyl group of 
76d, suggests the presence of a large pocket that could be occupied by an 
aromatic group, similarly to the indole ring in natural parent compound 
hemiasterlin. 
Lack of the aryl portion also seems to be incompatible with growth 
inhibition, which is consistent with the results described in taltobulin series. 
Both other non aromatic substituents at nitrogen of fragment A as 
cyclohexyl and the rigid modified at fragment C analogue (R,S)(S)-88 led to 
loss of activity.  
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Figure V-2. (A) UCI-101 cells were treated with various concentrations of 
compounds for two days. The tumor growth suppression was determined by Alamar 
blue staining and plotted against concentrations of the treated drugs. Each 
concentrations was repeated in triplicates.  
 
The lack of activity of (R,S)(S)(S)-79 h was unexpected as molecular 
modeling studies suggested that the pocket was enough large to host bulky 
groups. This aspect led us to synthetized other compounds aromatic like 
indole (R,S)(S)(S)-76f derivative just to confirm the data previously 
obtained.  
It was found to be completely inactive in E2S cell viability test after 48 
hours incubation.  
Two diastereoisomers bearing p-bromine on the aromatic ring of 
dimethylbenzylamine were tested as they added and modified steric 
bulkiness at N-terminus. 
They were found inactive with IC50  of 600 nM for (R)(S)(S)-76e and 100 
nM for (S)(S)(S)-76e in a MTT cell vitality assay on MCF-7 breast cancer 
cells, and in this case there is a discrepancy referring the data collected so 
far, since diasteroisomer (R)(S)(S) was expected to be more active than the 
other one. 
The same biologic assay was applied to test compounds with only one of 
the geminal methyl groups. With (S)-1-phenylethamine, a further 
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asymmetry centre was introduced at the most investigated region of the 
tripeptide that was tested as racemic mixture (R)(R,S)(S)(S)-76b, but it was 
found to be inactive showing IC50 >100 nM. 
Phenylalanine was employed as source of bromoacyl intermediates for other 
derivatives were examined on MCF-7 with the aim to understand if the 
addition of a further bulky benzylic moiety in place of the simple methyl 
group of the alanine at N-terminus might increase the activity. 
Thus, a couple of diastereoisomers (S)(S)(S)-93 and (R)(S)(S)-93 was 
synthetized and their respective activity compared with (R,S)(S)(S)-76a; 
unfortunately, the preliminary biologic data were not encouraging showing 
IC50 of 367 nM for (R)(S)(S)-93 and 240 nM for the other one in E2S cell 
viability test (figure V-3). Interestingly, in this case the activity of 
diasteroisomers showed that (S) is more active than (R), as for the couple 
bearing bromine, but with less difference.  
In light of the results data, it seems that the presence at N-terminus, of 
bulkier aromatic groups decreases the activity, in fact (R,S)(S)(S)-76f and 
(R,S)(S)(S)-76d are inactive. 
 
 
Figure V-3. Cytotoxicity in ES-2 cells (duplicates, IC50 was calculated using Sigma 
plot).
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6.  Conclusions and perspectives 
 
This Ph.D. thesis reports the synthesis of a small numbers of compounds 
inhibitors of tubulin polymerization, involved in cells replication. 
These product are isosters of patented tripeptide, HTI-286, and have been 
obtained with a modified synthetic route developed in our research group 
regarding mainly the N-terminus end. 
Generally, the modification that we have done, are known in literature, but 
some of them have put forward again, with the aim to obtain compounds 
possibly more active than the parental, considering our modification at N-
terminus. 
Our synthetic approach has been studied to be more versatile thanks to the 
possibility to access to a variety of final products starting from a common 
building block, the bromoacylderivative characterized by a desidered 
stereochemistry. 
The substitution of the bromine with a nucleophile, generally an amine, 
catalyzed by silver oxide, is the key step as it allowed us to obtain the 
derivative both as racemic mixture, both as single diasteroisomers. 
Several compounds were examined in different biologic tests and IC50 
values compared to establish some structural-activity relationships among 
them. 
Our biological result are in line with the SAR data both of Nieman’ s group 
and Zask’s laboratory.17,18 
• Compounds in which the B-piece is a valine aminoacid are less 
active than the corresponding with the tert-leucine. 
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• Both in Valine and in tert-leucine series, the presence of the 
geminal dimethyl group at A-fragment is essential for the activity, 
as demonstrate literature information. 
• Among derivatives with the aromatic ring at N-terminus, the single 
diasteroisomers (R)(S)(S) are more active than the other series with 
(S)(S)(S)stereochemistry, that is also the natural stereochemistry.  
Inverting the groups bound on nitrogen and at C-α, only the first 
series might probably expose the radical in a correct spatial 
conformation, similar to that of HTI-286. 
In the parental compounds, Zask’s group has demonstrate the 
stereochemistry (S)(S)(S) is critical for the activity of HTI-286 
derivatives, in fact (S)(R)(S) and (S)(S)(R) isomers were 
completely inactive in inhibition polymerization tubulin assay.  
• Bulkier groups were introduce on the nitrogen at N-terminus as 
suggested by molecular modeling informations. 
We expected more potent compounds, but unfortunately they 
revealed a weak activity. 
We have supposed, on the basis of the results, that the activity 
could be better related to the two methyl radicals near the bulky 
groups. 
• Modifications at C-terminus that conferred rigidity to the backbone 
of the tripeptide were not tolerated. 
• The most active compound is the (R)(S)(S)-76a with IC50 20 nM, 
value of the same order of magnitude of the referential compound, 
HTI-286. 
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6.1.  Toward the pro-drug with stilbene 5c 
On the basis of the reported results, a further progress in this project 
regarding antitubulin compounds in our research group, has been envisaged 
in the possible development of a pro-drug linking (R)(S)(S)-76a and stilbene 
5c, whose activity is 10 nM in some solid tumor. 
This compound suffers from low water solubility, and in the past our aim 
was to increase its in vivo biologic profile, by a linkage with a water soluble 
carrier. 
As first information, we needed to know of any possible synergic activity 
between stilbene 5c and the most active hemiasterlin derivative.29 
 
6.1.1.  Synergistic effect between (R,S)(S)(S)-76a, (R,S)(S)(S)-
81a and stilbene 5c. 
When the structure model of tubulin bound with colchicine and vinblastine 
was solved, the mechanism of interaction and how colchicine and 
vinblastine affect tubulin polymerization were unveiled. The tubulin-
colchicine complex was kept in a curve conformation and unable to change 
into a straight conformation for polymerization, so that tubulin cannot be 
assembled. 
The formation of a curve conformation in tubulin with colchicine site 
inhibitors also enhances the binding of vincristine by stabilization of the 
vincristine binding site in tubulin.  
This structure information thus suggests a synergistic effect between 
colchicine site inhibitors and vincristine site inhibitors. 
Since stilbene 5c is a colchicine-site tubulin inhibitor and (R,S)(S)(S)-76a 
and (R,S)(S)(S)-81a are inhibitors with non-colchicine related mechanism, 
synergistic effect between the two compounds and stilbene 5c was tested.  
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At first, it was carried out in vitro tubulin polymerization study by 
incubation of 1 µM stilbene 5c and (R,S)(S)(S)-76a individually and in 
combination. This concentration is barely effective in suppressing in vitro 
tubulin polymerization as shown in Figure VI-1. 
However, the combination of both stilbene 5c and (R,S)(S)(S)-76a shows a 
much more robust inhibition of in vitro tubulin polymerization, suggesting a 
synergistic effect between them. 
 
 
Figure VI-1. In vitro tubulin polymerization study. Purified tubulin was incubated 
in a 96-well plate with polymerization buffer and 1 µM stilbene 5c, (R,S)(S)(S)-76a 
individually or in combination. OD340 was measured every min for 30 min in a 
plate reader at 37°C. 
 
6.1.2.  Project for a reciprocal prodrug between stilbene 5c and 
(S)(S)(S) 76a 
In order to further exploit the synergic effects of stilbene and hemiasterlin 
derivatives, as above reported, the synthesis of a mutual prodrug could be 
thought in order to possibly improve farmacokinetic of both components. 
The most important requirement is to find a linkage that is an in vivo 
hydrolysable function. 
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We would exploit the amine group of stilbene 5c and, on the other side, we 
have planned to react the bromo-acylpeptide with an amine conveniently 
bearing a group that is useful to be reacted with a linker (OH, NH2) and, in 
the same time maintaning a high biologic activity. 
 
 
 
Figure VI-2. Model of the pro-drug between stilbene 5c and the compound with the 
best biologic profile. 
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7. Experimental section 
 
7.1. General methods 
1H and 13C NMR spectra were determined with a Mercury Place Varian 
spectroscope at 400 MHz. Chemical shifts (d) are reported in parts per 
million relative to residual chloroform (7.26 ppm) or dimethyl sulfoxide 
(2.49 ppm), TMS (0 ppm) as an internal reference. Coupling constants (J) 
are reported in Hertz (Hz). The peak shapes are denoted as follows: s, 
singlet; d, doublet; dd, double doublet; t, triplet; q, quartet; m, multiplet, br, 
broad. Electrospray (ES) mass spectra were recorded on a Micromass ZMD 
2000 and MALDI mass on a Bruker Omniflex. IR spectra were recorded 
with an FT-IR Perkin Elmer Paragon 1000 using cm-1 as units. Optical 
rotation were determined in a polarimeter with a 10 cm cell, operating at 
589 nm (sodium D line) at 20°C. The concentration was 1-2% in CHCl3. 
Chromatographic purifications were performed by flash chromatography 
using Merck 0.040-0.063 mm silica gel. Thin-layer chromatography (TLC) 
was performed on Merck silica gel precoated plates (Merck F254) using the 
indicated solvent systems. Analytical HPLC was performed with a 
Beckman System Gold with a 166 detector (visualization at 254 nm) and 
was run on a TSK Gel Super ODS (C18) column (4.6 mm x 10 cm, 2 mm) 
using a gradient solvent system (solvent A: 0.1% TFA/H2O, solvent B: 
0.1% TFA/CH3CN). Unless otherwise noted, the gradient was: t = 0 min: 
0% B, t = 25 min: 100% B. Retention times (tR) are reported. Preparative 
HPLC was performed with a Waters Delta Prep 4000 and was run on a 
XTerra (C18) column (30 x 50 mm, 5 mm) using a gradient solvent system 
(solvent A: 0:1% TFA/H2O, solvent B: 0:1% TFA/40% H2O/60% CH3CN). 
Unless otherwise noted, the gradient was: t = 0 min: 0% B, t = 25 min: 50% 
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B, t = 35 min: 100% B. All reactions mixtures were analyzed by HPLC and 
1H NMR to check the diastereomeric distribution before and after column 
chromatography, to avoid wrong conclusions, due to diastereomeric 
enrichment. Reagents and promoters are purchased from Alfa Aesar. 
 
7.2. Experimental procedures and analytical data. 
7.2.1. Synthesis of fragment BC 
(S)-2-(tert-buthoxycarbonyl(methyl)amino)-3-methylbutanoic acid, [(S)-
53] 
To a solution of Boc-L-Valine (14.7 g, 67.7 mmol) in dry THF (350 ml), 
methyl iodide (42.2 ml, 667 mol) was added dropwise. 
At 0°C, NaH 60% min. oil (32.5 g, 667 mol) was added portion wise. The 
mixture was left stirring overnight at r.t. 
After quench with water, the reaction solvent was concentrated in vacuo. 
The crude was suspended 150 ml of water and washed with 50 ml of 
EtOAc. The water phase was acidified with citric acid until pH 3.5, 
extracted with AcOEt (3x100 ml). 
The organic phase, was washed with brine (3x50 ml) and dried over Na2SO4 
to afford (15 g, 60 mmol, 96%) of yellow oil, that was used without any 
purification for the next reaction. 
1H NMR (CDCl3, 200 MHz) : δ 0.90 (d, 3H, J = 6.6 Hz), 1.01 (d, 3H, J = 
6.6 Hz), 1.44 (s, 9H), 2.14 (m, 1H),  2.86 (s, 3H), 4.16 (m, 1H) 
13C NMR (CDCl3, 400 MHz) : δ 19.0, 19.9, 27.7, 28.4, 31.9, 65.6, 80.9, 
157.1, 175.7 
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(S)-tert-butyl 1-(methoxy(methyl)amino)-3-methyl-1-oxobutan-2-
yl)(methyl)carbamate [(S)-54] 
To a cold (0° C.) solution of N-Boc-N-methylvaline (S)-53 (15 g, 65 mmol) 
in 150 ml of DMF, 1-HOBT (9.64 g, 71.4 mmol), EDCI (13.7 g, 71.4 
mmol) and N,O-dimethylhydroxylamine hydrochloride (9.1 g, 91 mmol), 
were added. Then, at 0°C 4-methylmorpholine (17, 86 ml, 162 mmol) was 
added and after 10' the reaction was left stirring overnight at r.t.  
The reaction solvent was remover under vacuo, and the crude was 
suspended in AcOEt (150 ml). After washing with citric acid (2x50 ml) to 
pH 5, the organic layer was washed with NaHCO3 5% (2x50 ml). The 
organic layer was washed with brine, dried with sodium sulfate and the 
solvent was evaporated to get (11 g, 40.14 mmol, 60%) of a yellow oil, that 
was used without any purification for next step.  
1H NMR (CDCl3, 200 MHz): δ 0.85 (d, 3H, J = 4 Hz), 0.89 (d, 3H, J=4 Hz), 
1.44 (s, 9H), 2.25 (m, 1H), 2.81 (s, 3H), 3.19 (s, 3H), 3.70 (s, 3H), 4.66 (m, 
1H). 13C NMR (CDCl3, 400 MHz) : δ 18.6, 19.4, 27.5, 28.3, 31.7, 37.0, 
60.7, 61.6, 19.7, 156.1, 170.2 
Rf (Hexane/EtOAc 6/1): 0.25 
 
(S)-tert-butyl methyl(3-methyl-1-oxobutan-2-yl)carbamate [(S)-55] 
Lithium aluminum hydride (342 mg, 9 mmol) was added at 0°C to a 
solution of (54) (2.0 g, 7.2 mmol) in dry THF (20 mL) and the reaction 
mixture was stirred for 2 h at r.t. The mixture was carefully quenched with 
water at 0°C, diluted with diethyl ether (75 mL) and treated sequentially 
with 3 N hydrochloric acid (3×20 mL), aqueous sodium hydrogen carbonate 
(3×20 mL), and saturated with brine (3×20 mL). The organic layer was 
dried over sodium sulfate and the solvent was evaporated to yield the crude 
 Hemiasterlin: cexperimental section 
61 
aldehyde (1.2 g, 5.58 mmol, 92% yield), that was used without any 
purification.  
1H NMR (CDCl3, 200 MHz): δ 0.86 (d, 3H, J = 7 Hz), 0.95 (d, 3H, J = 6.8 
Hz), 1.44 (s, 9H), 2.25 (m, 1H), 2.74 (s, 3H), 4.65 (m, 1H), 9.63 (s, 1H). 
Rf  (Hexane/EtOAc 6/1): 0.4 
 
(S, E)-ethyl 4-(tert-butoxycarbonyl(methyl)amino)-2,5-dimethylhex-2-
enoate [(S)-58]. 
To a solution of aldehyde 55 (840 mg, 3.9 mmol) in dry CH2Cl 2 (10 mL) 
under an argon atmosphere at room temperature was added 
(carbethoxyethylidene)triphenylphosphorane (2.8 g, 7.8 mmol) and it was 
refluxed 5 h. The reaction mixture was concentrated in vacuo and the crude 
was triturated with Hexane several times ( 20 ml x5). The combined organic 
extracts were concentrated in vacuo to afford the required E-2-alkenoate as 
a yellow oil (0.940 g, 3.14 mmol, 81%).  
1 H-NMR (200 MHz, CDCl3 ) 0.74 (d, J=6 Hz, 3H ), 0.79 (d, J=6 Hz, 3H ), 
1.17 (t, J=0.7 Hz, 3H), 1.34 (s, 9H
 
), 1.72 (m, 1H), 1.78 (s, 3H), 2.60 (bs, 
3H), 4.08 (q, J=7 Hz, 2H), 4.15-4.20 (m, 0.5H), 4.21-4.32 (m, 0.5H), 6.54 
(d, J=8 Hz, 1H). 13C NMR (CDCl3, 400 MHz): δ 13.2, 14.2, 19.5, 59.6, 60.7, 
79.7, 132.0, 138.8, 155.7, 168.0 
Rf  (Hexane /EtOAc 6/1): 0.5 
 
Hylide of ethylic ester of 2-(triphenylphosponium)propionic acid (57).  
To a solution of triphenylphosphine (60.5 g, 0.23 mol) in toluene (100 ml), 
ethyl 2-bromopropanoate 56 (30 ml, 0.23 mol) was added. 
The suspension was stirred for 48 h at r.t. After that the mixture was filtered 
on Gooch and a white solid was obtained (71.3 g, 0.16 mol, 70%). The solid 
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(19.5 g, 44 mmol) was solved in 75 ml of water and to this solution, a 
saturated solution of NaOH was added until pH 9. 
The mixture was left stirring until the formation of a precipitate, that was 
filtered and the solid was triturated with water (10 ml x3). The yellow solid 
was concentrated in vacuo, solved in AcOEt and crystallized from 
petroleum ether to afford a yellow solid (10.4 g, 28.7 mmol, 65%) 
1H NMR (CDCl3, 200 MHz): δ 0.44 (t, 3H, J = 7.0 Hz), 1.6 (d, 3H, J = 7.0 
Hz), 3.7 (q, 2H, J = 7.2 Hz), 7.53 (m, 15H). 13C NMR (CDCl3. 400 MHz): δ 
12.8, 14.2, 57.4, 76.5, 128.5, 132.0, 133.6, 168.0. 
 
(S, E)-6-ethoxy-N, 2,5-trimethyl-6-oxohex-4-en-3-aminium 2,2,2-
trifluroacetate [(S)-59] 
[(S)-58] (641 mg, 2.1 mmol) solved in 2.2. ml of CH2Cl2 was treated with 
TFA/CH2Cl2 (0.1 mmol/1 mL) at room temperature for 2 h. Removal of the 
solvent in vacuo, followed by repeated rinsing of the residual material with 
methanol (3×5 mL) and evaporation of the remaining traces of solvent 
afforded the TFA salt of the amino acid ester in quantitative yield, that was 
used in next step without any purification. 
1H NMR (CDCl3, 200 MHz): δ 0.98 (d, 3H, J = 6.4 Hz), 1.01 (d, 3H, J = 6.2 
Hz), 1.31 (t, 3H, J = 7 Hz), 1.93 (d, 3H, J = 1.2 Hz), 2.2 (m, 1H), 2.59 (t, 
3H, J = 5.2 Hz), 3.8 (m, 1H), 4.23 (q, 2H, J = 7 Hz), 6.65 (dd, 1H, J = 1.2 
Hz, J = 9.2 Hz), 8.9 (s, 1H); 9.1 (s,1H) 
13C NMR (CDCl3, 400 MHz): δ 13.4, 14.0, 17.1, 19.0, 31.4, 31.6, 61.6, 
63.1, 130.9, 136.7, 166.6. IR (KBr): ν = 2974, 1715, 1669, 1173, 1130. 
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General procedure 1: pivaloyl chloride-mediated amide bond 
formation [(S)(S)-62a,b] 
To a cold (-78°C) solution of carboxylic acid (1.1 eq) in dry THF (1 
ml/mmol) of amino acid ester) under an argon atmosphere was added 
DIPEA (1.5 eq) and pivaloyl chloride (1.2 eq). The resulting mixture was 
warmed to 0°C for 1 h and then re-cooled to -78°C. 
DIPEA (2.2 eq) was added to the reaction flask followed by the addition, 
via syringes, of the TFA salt of the amino acid ester (1 eq) in dry THF (0.5 
ml/mmol of amino acid ester) at -78°C. 
Stirring was continued for 1 h and then quenched by the addition of H2O. 
The mixture was allowed to warm to r.t. and extracted three times with 
diethyl ether. The combined organic layer was dried over sodium sulphate 
and concentrated in vacuo. The crude oil was purified by silica gel column 
chromatography using a EtOAc/petroleum ether mixture as the mobile 
phase. 
 
(S,E)-ethyl 4-((S)-2-(tert-butoxycarbonylamino)-N, 3,3-
trimethylbutanaido)-2,5-dimethylhex-2-enoate 62a 
It was obtained following the general procedure 1: (70%, colorless oil) 
1H NMR (CDCl3, 400 MHz): δ 0.88 (d, 6H, J = 2.4 Hz), 0.9 (d, 6H, J = 1.6 
Hz), 1.29 (t, 3H, J = 7.2 Hz), 1.41 (s, 9H), 1.87 (d, 3H, J = 1.2 Hz), 2.85 (m, 
1H), 2.94 (s, 3H), 3.1 (m, 1H), 4.19 (q, 2H, J = 7.2 Hz), 4.35 (dd, 1H, J = 
6.8 Hz, J = 9.2 Hz), 5.04 (dd, 1H, J = 9.2 Hz, J = 10.8 Hz), 6.63 (dd, 1H, J 
= 1.2 Hz, J = 9.2 Hz), 7.5 (m, 1H) 
13C NMR (CDCl3, 400 MHz): δ 13.7, 14.3, 17.6, 18.8, 19.5, 28.3, 30.0, 
30.4, 31.0, 55.5, 56.4, 60.9, 79.5, 133.9, 138.4, 156.1, 167.8, 172.6. Rf  
(Hexane /EtOAc 2/1): 0.85 
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(S,E)-ethyl 4-((S)-2-(tert-butoxycarbonylamino)-N, 3-
dimethylbutanaido)-2,5-dimethylhex-2-enoate 62b  
It was obtained following the general procedure 1: (62%, colorless oil) 
1H NMR (CDCl3, 400 MHz): δ 0.88 (d, 6H, J = 2.4 Hz), 0.9 (d, 6H, J = 1.6 
Hz), 1.29 (t, 3H, J = 7.2 Hz), 1.41 (s, 9H), 1.87 (d, 3H, J = 1.2 Hz), 2.85 (m, 
1H), 2.94 (s, 3H), 3.1 (m, 1H), 4.19 (q, 2H, J = 7.2 Hz), 4.35 (dd, 1H, J = 
6.8 Hz, J = 9.2 Hz), 5.04 (dd, 1H, J = 9.2 Hz, J = 10.8 Hz), 6.63 (dd, 1H, J 
= 1.2 Hz, J = 9.2 Hz), 7.5 (m, 1H) 
13C NMR (CDCl3, 400 MHz): δ 13.7, 14.3, 17.6, 18.8, 19.5, 28.3, 30.0, 
30.4, 31.0, 55.5, 56.4, 60.9, 79.5, 133.9, 138.4, 156.1, 167.8, 172.6. Rf  
(Hexane/EtOAc 2/1): 0.75 
 
General procedure 2: Trifluoacetic acid mediated cleavage of N-Boc 
group of dipeptides [(S)(S)-63a,b] 
N-Boc-dipeptide (1.0 equiv.) was treated with TFA/CH2Cl2 (0.1 mmol/1 
mL) at room temperature for 2 h. Removal of the solvent in vacuo, followed 
by repeated rinsing of the residual material with CH2Cl2 (3×5 mL) and 
evaporation of the remaining traces of solvent afforded the TFA salt of the 
amino acid ester in quantitative yield. TFA salts were used without further 
purification. 
 
Dipeptide [(S)(S)-63a] 
It was obtained following the general procedure 2: (85%, colorless oil) 
1H NMR (DMSO-d6, 400 MHz): δ 0.95 (d, 3H, J = 7.6 Hz), 0.98 (s, 9H), 
1.00 (d, 3H, J = 6.0 Hz), 1.21 (t, 3H, J = 7.2 Hz), 1.82 (d, 3H, J = 1.6 Hz), 
2.05 (m, 1H), 2.93 (s, 3H), 4.14 (q, 2H, J = 7.2 Hz), 4.21 (m, 1H), 4.93 (t, 
1H, J = 10.0 Hz), 6.67 (dd, 1H, J = 1.6 Hz, J = 10.8 Hz), 7.5 (m, 3H). 13C 
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NMR (DMSO-d6, 400 MHz): δ 13.9, 16.5, 18.8, 19.2, 25.9, 32.9, 34.1, 52.3, 
56.5, 60.9, 127.0, 137.9, 167.9, 169.0 
 
Dipeptide [(S)(S)-63b] 
It was obtained following the general procedure 2: (85%, colorless oil) 
1H NMR (DMSO-d6, 400 MHz): δ 0.82 (d, 6H, J = 6.8 Hz), 0.85 (d, 6H, J = 
6.8 Hz), 1.22 (t, 3H, J = 7.2 Hz), 1.80 (d, 3H, J = 1.6 Hz), 2.05 (m, 1H), 
2.10 (m, 1H), 2.89 (s, 3H), 4.13 (q, 2H, J = 7.2 Hz), 4.23 (m, 1H), 4.83 (dd, 
1H, J = 10.2 Hz, J = 10.0 Hz), 6.67 (dd, 1H, J = 1.4 Hz, J = 9.6 Hz), 8.08 
(m, 3H). 13C NMR (DMSO-d6, 400 MHz): δ 13.3, 13.9, 16.4, 17.7, 18.8, 
28.5, 30.2, 31.1, 54.2, 56.9, 60.8, 133.1, 137.9, 166.7, 168.3 
 
(R,S)(S)(S) 2-bromopropanoyl-dipeptide ethyl ester  
[(R,S)(S)(S)-65a]: To a solution of dipeptide ethyl ester 63a (0,96 mmol, 
273 mg) and Et3N (0.96 mmol, 0.13 mL) in anhydrous CH2Cl2 (5 mL) was 
dropped at 0° C, (R,S)-2-bromopropanoyl bromide 64 (0.96 mmol, 0.1 mL) 
dissolved in CH2Cl2 (3 mL). The mixture was allowed to warm at r.t. and 
stirred overnight. The resulting solution was diluted with CH2Cl2 (30 mL) 
and washed 3 times x 5 mL, in the order, with citric acid (10%), NaHCO3 
(5%), brine and dried over Na2SO4. Evaporation of organic phase to 
constant weight gave the bromo acyl-peptide 65a as a diastereomeric 
mixture of an oil (267 mg, 69%). Rf (Hexane/EtOAc 4/1): 0.35 and 0.25. 
Column chromatography of (R,S)(S)(S)-65a (Hexane/EtOAc 3/1) allowed 
us to obtain the single diastereoisomers (S)(S)(S)-65a and (R)(S)(S)-65a. 
Absolute configurations were assigned by indipendent syntheses of the two 
single diastereoisomers by reaction of (S)- or (R)-2-bromopropanoic acid 
(67) with (S)(S)-63a (see in next context). 
Hemiasterlin: cexperimental section  
 
66 
For (S)(S)(S)-65a: Rf (Hexane/AcOEt 4/1) 0.25. 
1H NMR (CDCl3, 400 MHz): d 0.78 (d, 3H, J = 6.4), 0.85 (d, 3H, J = 6.4 
Hz), 0.96 (s, 9H), 1.27 (t, 3H, J = 7.2 Hz), 1.82 (d, 3H, J = 6.8 Hz), 1.81-
1.88 (m, 1H), 1.89 (d, 3H, J = 1.6 Hz), 2.96 (s, 3H); 4.17 (q, 2H, J = 7.2 
Hz), 4.37 (q, 1H, J = 6.8 Hz), 4.77 (d, 1H, J = 9.6 Hz), 5.07 (dd, 1H, J = 9.6 
and 9.8 Hz), 6.61 (dd, 1H, J = 1.6 and 9.8 Hz), 6.89 (d, 1H, J = 9.6 Hz). 
13C NMR (CDCl3, 400 MHz): d 13.8, 14.2, 18.7, 19.4, 22.8, 26.4, 30.0, 
31.1, 36.1, 44.2, 55.2, 56.2, 61.0, 132.8, 138.2, 167.8, 169.1, 171.0. 
For (R)(S)(S)-65a: Rf (Hexane/EtOAc 4/1) 0.35. 
1H NMR: (CDCl3, 400 MHz): d 0.80 (d, 3H, J = 6.8 Hz), 0.87 (d, 3H, J = 
6.8 Hz), 0.97 (s, 9H), 1.29 (t, 3H, J = 7.2 Hz), 1.82 (d, 3H, J = 7.2 Hz), 
1.82-1.90 (m, 1H), 1.90 (d, 3H, J = 1.6 Hz), 2.97 (s, 3H), 4.19 (q, 2H, J = 
7.2 Hz), 4.40 (q, 1H, J = 7.2 Hz), 4.76 (d, 1H, J = 9.4 Hz), 5.10 (dd, 1H, J = 
7.3 and 7.1 Hz), 6.63 (dd, 1H, J = 1.6 and 7.3 Hz), 6.93 (d, 1H, J = 9.4 Hz). 
13C NMR (CDCl3, 400 MHz): d 13.3, 14.3, 18.7, 19.5, 23.0, 26.5, 30.1, 
31.1, 35.6, 44.6, 55.5, 56.1, 60.9, 132.9, 138.3, 167.8, 169.3, 171.0 
 
(S)-2-bromopropionic acid [(S)-67]. 
To a solution of (L)-alanine 66 (3 g, 34 mmol) in H2SO4 2.5 N (140 ml), 
KBr (14, 119 mmol) was added. At 0°C, NaNO2 (3.7 g, 54 mmol) was 
added portionwise. The mixture was stirred at r.t. for 3 h. 
The yellow solution was extracted with ethylic ether (3x15 ml)and the 
organic phase was washed with Na2S2O3 (3x75 ml), brine (3x75 ml). The 
organic phase was dried over Na2SO4 to afford a colorless oil ( 2.9 g, 18.95 
mmol, 56%). 
1H NMR (CD3OD, 200 MHz): δ 1.92 (d, 3H), 4.48 (q, 1H). 13C NMR 
(CD3OD, 200 MHz): δ 21.1, 42.3, 171.0 
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[α]20D = -30.4 
The same procedure was followed to get the other enantiomer (R)-2-
bromopionic acid [(R)-67], starting from (D)-alanine 66 (3 g, 34 mmol). 
The product is a colorless oil (2.6 g, 17 mmol, 50%). 
1H NMR (CD3OD, 200 MHz): δ 1.92 (d, 3H), 4.48 (q, 1H). 13C NMR 
(CD3OD, 200 MHz): δ 21.3, 42.5, 171.2 
[α]20D = +30.4 
 
General procedure 3: diastereoselective synthesis of Bromopropanoyl-
dipeptide ethyl ester. 
To a cold (-78°C) stirred solution of (S)-2-bromopionic acid (1.1 equiv.) in 
dry THF (1 mL/mmol) under argon atmosphere was added DIEA (1.5 
equiv.) and trimethylacetyl chloride (1.2 equiv.). The resulting mixture was 
warmed to 0°C for 1 h and then re-cooled to -78° C. DIEA (1.5 equiv.) and 
dipeptide ester (S)(S)-63a or b (1 equiv.) dissolved in dry THF (1 mL/mol) 
were added via syringes. Stirring was continued for 1 h and H2O (30 mL). 
The mixture was allowed to warm to room temperature, and extracted with 
diethyl ether (3 x 30 mL) was added. The combined organic extracts were 
washed with brine (30mL), dried and concentrated.  
[(S)(S)(S)-65a] Oil (62%). Rf (hexane/AcOEt 4/1) 0.25. See above for 
spectroscopy data. 
Following the same procedure, [(R)(S)(S)-65a] was obtained as an oil 
(62%). Rf (hexane/AcOEt 4/1) 0.25. See above for spectroscopy data. 
 
2-Bromopropanoyl-dipeptide ethyl ester [(R,S)(S)(S)-65b]  
It was obtained from dipeptide ethyl ester [(S)(S)-63b] and (R,S)-2-
bomopropanoyl bromide 64, following the general procedure 3. The product 
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was obtained as colorless oil (85%). Rf (Hexane/AcOEt 2:1): 0.5 and 0.53. 
Due to the difficulty to separate the diastereomeric mixture by 
chromatography, (S)(S)(S)-65b and (R)(S)(S)-65b were obtained by 
independent syntheses following the general procedure 4. 
 
2-Bromopropanoyl-dipeptide ethyl ester [(S)(S)(S)-65b]. 
According to general procedure 4, it was obtained from dipeptide ethyl ester 
(S)(S)-63b and (S)-2-bromopropanoic acid [(S)-67] 
1H NMR (CDCl3, 400 MHz): d 0.83 (d, 3H, J = 6.4 Hz), 0.84 (d, 3H, J = 6.4 
Hz), 0.86 (d, 3H, J = 6.8 Hz), 0.93 (d, 3H, J = 6.8 Hz), 1.31 (t, 3H, J = 7.2 
Hz), 1.82-1.88 (m, 1H), 1.86 (d, 3H, J = 7.0 Hz), 1.89 (d, 3H, J = 1.6 Hz), 
1.96-2.06 (m, 1H), 2.94 (s, 3H), 4.2 (q, 2H, J = 7.2 Hz), 4.40 (q, 1H, J = 7.0 
Hz), 4.74 (dd, 1H, J = 8.6 and 9.0 Hz), 5.04 (dd, 1H, J = 9.2 and 10.5 Hz), 
6.64 (dd, 1H, J = 1.6 and 9.2 Hz), 6.98 (d, 1H, J = 8.6 Hz). 13C NMR 
(CDCl3, 400 MHz):  d 13.7, 14.2, 17.1, 18.8, 19.4, 19.6, 22.7, 26.5, 29.8, 
30.3, 31.5, 44.1, 54.2, 56.6, 60.9, 132.9, 137.9, 167.7, 169.3, 171.3. 
Rf (Hexane/AcOEt 2:1): 0.5 
 
2-Bromopropanoyl-dipeptide ethyl ester [(R)(S)(S)-65b]. 
It was obtained from dipeptide ethyl ester [(S)(S)-63b] and (R)-2-
bromopropanoic acid [(R)-67], according to general procedure 3. 
1H NMR (CDCl3, 400 MHz): d 0.85 (d, 3H, J = 6.4 Hz), 0.87-0.93 (m, 9H), 
1.28 (t, 3H, J = 7.6 Hz), 1.84 (d, 3H, J = 6.8 Hz), 1.89 (d, 3H, J = 1.6 Hz), 
2.95 (s, 3H), 4.20 (q, 2H, J = 7.6 Hz), 4.19 (q, 1H, J = 6.8 Hz), 4.68 (dd, 
1H, J = 6.4 and 8.8 Hz), 5.05 (dd, 1H, J = 9.6 and 10.8 Hz), 6.63 (dd, 1H, J 
= 1.6 and 9.6 Hz), 6.99 (br d, 1H).  
 Hemiasterlin: cexperimental section 
69 
13C NMR (CDCl3, 400 MHz): d 13.7, 14.3, 17.6, 18.9, 19.5, 19.6, 22.9, 
29.9, 30.4, 31.5, 44.44, 54.7, 56.7, 61.0, 132.0, 138.1, 167.8, 169.4, 171.4. 
Rf (Hexane/EtOAc 2/1) 0.53 
 
General Procedure 4: reduction of tertiary alcohol 
To a suspension of Mg (2 eq) in 10 ml of dry ethylic ether, methyl iodide 
(2.2 eq) was added dropwise and stirred for several minutes while carefully 
observing the mixture for signs of reaction. When the reaction has started 
the solvent began to reflux vigorously. Once the addition is complete, a 
solution of ketone (1 eq) in 15 ml of ethylic ether was added dropwise and 
the mixture was stirred at r.t. for 2 h. 
The mixture was quenched with NH4Cl (3 ml) until pH 6-7 and extracted 
with ethylic ether (3x 15 ml). The organic phase was dried over sodium 
sulfate, concentrated in vacuo to give the desired product. 
 
2-(naphthalen-2-yl)propan-2-ol 69d 
The product is a yellow solid, 93%.  
1H NMR (CDCl3, 400 MHz): d 1.68 (s, 6H), 7.38 (m, 2H), 7.10 (dd, 1H), 
7.80 (m, 3H), 7.88 (dd, 1H). 13C NMR (CDCl3, 400 MHz): d 31.7, 72.8, 
122.44, 123.6, 125.8, 126.1, 127.5, 128.0, 128.2, 132.3, 133.2, 146.5.  
Rf (Hexane/AcOEt 4:1) 0.3 
 
2-(4-bromophenyl)propan-2-ol 69e 
The product is an oil, 91%. 
1H NMR (CDCl3, 400 MHz): δ 1.56 (s, 6H), 1.79 (s, 1H), 7.35 (d, 2H, J = 
8.8 Hz), 7.45 (d, 2H, J = 8.8 Hz). 13C NMR (CDCl3, 400 MHz): δ 31.8, 
72.4, 120.6, 126.4, 131.3, 148.2.  
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Rf (petroleum ether/diethyl ether 1:1) 0.5 
 
General procedure 5: synthesis of the azide 70a, 70d, 70e from the 
corresponding alcohols 69a, 69d, 69e. 
A solution of alcohol (1 eq), and NaN3 (2 eq) in CHCl3 (1 ml/1 mmol) was 
cooled at -5°C. At this temperature, a mixture of CHCl3 and trifluroacetic 
acid (5 eq) was added portionwise, paying attention to the temperature 
increase. The mixture was left stirring at r.t. for 24 h, after that it was 
quenched with NH4OH until pH 9. 
The organic phase was washed with water, dried over Na2SO4 and 
concentrated in vacuo to give the product as an oil. 
 
(2-azidopropan-2-yl)benzene 70a  
The product is a colourless oil, 60%. 
1H NMR (CDCl3, 200 MHz): δ 1.64 (s, 6H), 7.37 (m, 5H). 13C NMR 
(CDCl3, 400 MHz): δ 30.4, 63.0, 125.9, 126.1, 128.4, 138.3.  
Rf (Hexane/ AcOEt 1:1): 0.85 
 
2-(2-azidopropan-2-yl)naphthalene 70d  
The product is a yellow oil, 86%.  
1H NMR (CDCl3, 200 MHz): δ 1.74 (s, 6H), 7.54 (m, 2H), 7.85 (m, 5H). 
13C NMR (CDCl3, 400 MHz): d 31.7, 74.0, 122.44, 123.6, 125.8, 126.1, 
127.5, 128.0, 128.2, 132.3, 133.2, 146.5. Rf (Hexane/ AcOEt 4:1) 0.4 
 
1-(2-azidopropan-2-yl)-4-bromobenzene 70e 
The product is an oil, 85%. 
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1H NMR (CDCl3, 200 MHz): δ 1.56 (s, 1H), 1.61 (s, 6H),  7.31 (d, 2H, J = 
8.8 Hz), 7.48 (d, 2H, J = 8.8 Hz). 13C NMR (CDCl3, 400 MHz): δ 28.4, 
63.4, 121.5, 127.1, 131.7. Rf (Hexane/AcOEt 4:1) 0.8 
 
General procedure 6: reduction of  azide 70a, 70d, 70e, to the 
corresponding amine 71a, 71d, 71e. 
To a solution of amine in EtOAc, it was added portionwise C/Pd previously 
suspended in EtOAc. The suspension hydrogenated for 6 h, at r.t., at 50 psi. 
The reaction mixture was filtered on celite and rinsed with EtOAc. The 
solvent was concentrated in vacuo to afford the desired product. 
 
2-phenylpropan-2-amine (71a) 
The product is an oil , 85% . 
1H NMR (CDCl3, 200 MHz): δ 1.51 (s, 6H), 2.09 (s, 2H), 7.37 (m, 5H). 13C 
NMR (CDCl3, 400 MHz): δ 34.6, 55.5, 125.9, 126.1, 128.4, 144.6 
Rf (Hexane/EOAc 1:1): 0.15 
 
2-( naphathalen-2-yl)propan-2-amine (71d) 
The crude is a colourless oil, 14%, after distillation from the yellow crude. 
1H NMR (CDCl3, 200 MHz): δ 1.60 (s, 6H), 7.37 (m, 2H), 7.67 (dd, 1H), 
7.83 (m, 3 H), 13C NMR (CDCl3, 400 MHz): d 34.6, 55.9, 125.1, 126.0, 
127.0, 127.3, 127.5, 127.6, 128.2, 131.8, 133.7, 135.2.  
Rf (Hexane/EtOAc 1:1) 0.18 
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2-( 4-bromophenyl)propan-2-amine (71e) 
The product is an oil , 85% 
1H NMR (CDCl3, 200 MHz): δ 1.45 (s, 6H), 7.41 (m, 4H). 13C NMR 
(CDCl3, 400 MHz) : δ 34.6, 55.5, 120.3, 124.9, 125.5, 143.6 
 
1-methyl-1H-indole-3-carbonitrile (73) 
To a suspension of KOH (158 mg, 2.8 mmol) in DMSO (5 ml), indole 72 
(200 mg, 1.4 mmol) and methyl iodide (104.6 µl, 1.68 mmol) were added. 
The reaction mixture was left stirring at r.t. for 2 h. 
After addition of water, the mixture was extracted with EtOAc (3x 20 ml), 
washed with brine (5 ml), dried over Na2SO4 and concentrated to get a red 
oil that was purified by flash chromatography (EtOAc: petroleum ether 1:2). 
It was obtained (174 mg, 1.1 mmol, 80%) of a pale red oil. 
1H NMR (CDCl3, 200 MHz): δ 3.85 (s, 3H), 7.33 (m, 3H), 7.57 (s, 1H), 
7.76 (dd, 1H). 13C NMR (CDCl3, 400 MHz): δ 29.8, 33.7, 110.4, 120.0, 
122.23, 123.9, 135.6. Rf (Hexane/EtOAc 1:2) 0.7 
MS, m/z (ES+): 157 [M+H] 
 
(1-methyl-1H-indol-3-yl)methanamine 71f 
The product was obtained according the general procedure 6 starting from 
73.  
The product was a yellow oil 85%. 
1H NMR (CDCl3, 200 MHz): δ 3.69 (s, 3H), 4.24 (s, 2H), 6.35 (s, 1H), 7.02 
(m, 1H), 7.37 (m, 1H), 7.51-7.56 (m, 2H). 13C NMR (CDCl3, 400 MHz): δ 
42.5, 34.0, 109.6, 112.5, 118.8, 119.8, 121.7, 126.5, 127.7, 137.5. Check  
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General procedure 7: nucleophilic substitution reaction Ag2O 
catalyzed. 
To a suspension of Ag2O (2eq) in dry toluene (2.5 mL/eq), [(S)(S)(S)-65a] 
(1eq) and amine 71a-f (3eq) were added. The mixture was refluxed for 2½ h 
under argon atmosphere filtered over celite. Evaporation of the solvent  
gave the crude product as a yellow oil that was purified by column 
chromatography to afford the desired product. 
 
• Amine 71a 
Tripeptide ethyl ester [(S)(S)(S)-75a] 
It was obtained following the general procedure 6, after purification by flash 
chromatography (toluene/AcOEt 3.5:3) to afford the product as solid, 90%, 
Rf (toluene/EtOAc 3.5: 3) 0.3.  
By comparison with TLC and NMR of the diastereomeric mixture obtained 
from [(R,S)(S)(S)-65a], we confirmed the optical purity.  
MS (m/z) MALDI: 502 (M+H+), 524 (M+ Na+), 540 (M+K+). 
1H NMR (CDCl3, 400 MHz): d 0.79 (d, 3H, J = 6.8 Hz), 0.87 (d, 3H, J = 6.8 
Hz), 0.97 (s, 9H), 1.21 (s, 3H), 1.32 (t, 3H, J = 7.2 Hz), 1.40 (d, 3H, J = 6.8 
Hz), 1.52 (s, 3H), 1.87-1.91 (m, 1H), 1.90 (d, 3H, J = 0.8 Hz), 2.90-3.01 (br, 
2H), 3.01 (s, 3H), 4.17-4.22 (m, 3H), 4.79 (d, 1H, J = 9.6 Hz), 5.08 (dd, 1H, 
J = 10 and 10.2 Hz), 6.63 (dd, 1H, J = 9.6 and 0.8 Hz), 7.19-7.49 (m, 5H). 
13C NMR d 13.9, 14.3, 18.8, 19.5, 21.3, 26.5, 27.3, 30.0, 31.2, 32.2, 35.4, 
54.7, 56.3, 61.0, 68.2, 124.6, 126.6, 128.4, 132.8, 138.2, 150.1, 167.8, 
171.8, 174.6. 
 
 
 
Hemiasterlin: cexperimental section  
 
74 
Tripeptide ethyl ester [(R)(S)(S)-75a] 
It was obtained following the general procedure 7, starting from bromoacyl-
dipeptide [(R)(S)(S)-65a]leu. 
Rf (Toluene/AcOEt 3.5:3) 0.25. 
MS, (m/z) MALDI: 502 (M+H+), 524 (M+ Na+), 540 (M+K+) 
1H NMR (CDCl3, 400 MHz): d 0.77 (d, 3H, J = 6.4 Hz), 0.86 (d, 3H, J = 6.4 
Hz), 1.00 (s, 9H), 1.06 (d, 3H, J = 6.8 Hz), 1.30 (t, 3H, J = 7.2 Hz), 1.42 (s, 
3H), 1.47 (s, 3H), 1.8 (br, 1H), 1.82-1.89 (m, 1H), 1.91 (d, 3H, J = 1.6 Hz), 
2.95 (q, 1H, J = 6.8 Hz), 2.98 (s, 3H), 4.19 (q, 2H, J = 7.2 Hz), 4.75 (d, 1H, 
J = 10.0 Hz), 5.11 (dd, 1H, J =9.6 and 9.8 Hz), 6.62 (dd, 1H, J = 10 and 1.6 
Hz), 7.20-7.42 (m, 5H), 8.14 (d, 1H, J = 10.0 Hz). 13C NMR (CDCl3, 400 
MHz): d 13.9, 14.3, 18.7, 19.5, 21.4, 26.6, 27.0, 30.1, 31.0, 31.1, 31.7, 35.2, 
52.9, 54.6, 55.9, 56.6, 60.9, 125.6, 126.7, 128.3, 132.8, 138.6, 147.2, 167.8, 
171.8, 176.2. 
 
• Reaction with amine 71b 
Tripeptide ethyl ester [(R)(R,S)(S)(S)-75b]  
It was obtained as colourless oil (55%), following the general procedure 7. 
Rf (AcOEt/petroleum ether 1:2) 0.26. 
It is a diastereomeric mixture, thus spectroscopic data are not reported, as 
they are all multiplets. 
MS, m/z (ES+): 488 [M+H] 
 
• Reaction with amine 71c 
Tripeptide ethyl ester [(S)(S)(S)-75c] 
It was obtained as a solid (79%) from (S)(S)(S)-65leu, following the general 
procedure 7. 
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Rf (Hexane/AcOEt 1:8) 0.3. MS, m/z (ES+): 474 [M+H], 496 [M+Na]. 
1H NMR (CDCl3, 400 MHz): d 0.83 (d, 3H, J = 6.5 Hz), 0.85-0.90 (m, 9H), 
1.11 (d, 3H, J = 7.2 Hz), 1.35 (t, 3H, J = 7.1 Hz), 1.49 (s, 3H), 1.55 (s, 3H), 
1.80 (br s, 1H), 1.92 (d, 3H, J = 1.4 Hz), 1.99-2.18 (m, 2H), 4.21 (q, 2H, J = 
7.1 Hz), 4.28 (q, 1H, J = 7.2 Hz), 4.76 (dd, 1H, J = 7.2 and 9.8 Hz), 5.17 
(dd, 1H, J = 9.7 and 10.5 Hz), 6.33 (dd, 1H, J = 1.4 and 9.2 Hz), 7.22-7.40 
(m, 5H), 8.14 (d, 1H, J = 9.6 Hz). 13C NMR (CDCl3, 400 MHz): d 14.9, 
15,4, 16.6, 17.7, 18.4, 19.5, 19.7, 21.0, 21.4, 31.3, 31.9, 32.3, 53.1, 54.9, 
56.9, 57.9, 61.3, 127.6, 127.9, 129.0, 132.3, 138.5, 138.7, 167.6, 172.7, 
175.9. 
 
Tripeptide ethyl ester [(R)(S)(S)-75c] 
It was obtained as a solid (76%) from (R)(S)(S)-65leu according to general 
procedure 7. 
Rf (Hexane/EtOAc 1:8) 0.3; MS, m/z (ES+): 474 [M+H], 496 [M+Na]. 
1H NMR (CDCl3, 400 MHz): d 0.80 (d, 3H, J = 6.4 Hz), 0.87-0.93 (m, 9H), 
1.09 (d, 3H, J = 7.2 Hz), 1.31 (t, 3H, J = 7.2 Hz), 1.46 (s, 3H), 1.50 (s, 3H), 
1.80 (br s, 1H), 1.91 (d, 3H, J = 1.6 Hz), 1.93-2.11 (m, 2H), 4.20 (q, 2H, J = 
7.2 Hz), 4.25 (q, 1H, J = 7.2 Hz), 4.66 (dd, 1H, J = 7.2 and 9.6 Hz), 5.07 
(dd, 1H, J = 9.6 and 10.8 Hz), 6.34 (dd, 1H, J = 1.6 and 9.2 Hz), 7.21-7.42 
(m, 5H), 8.01 (d, 1H, J = 9.6 Hz). 13C NMR (CDCl3, 400 MHz): d 14.5, 
15,1, 16.9, 17.9, 18.6, 19.8, 19.9, 20.6, 20.4, 31.1, 31.4, 31.7, 52.9, 54.7, 
56.0, 57.8, 61.2, 127.4, 128.8, 128.9, 132.1, 138.2, 138.5, 167.9, 172.9, 
175.5. 
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• Reaction with amine 71d 
Tripeptide ethyl ester [(R,S)(S)(S)-75d] 
It was obtained from (R,S)(S)(S)-65leu, as yellow oil (80%) according to 
general procedure 7. 
Rf (AcOEt/Hexane 1:1) 0.4 
1H NMR (CDCl3, 400 MHz): δ 0.78 (d, 3H, J = 6.8 Hz), 0.82 (d, 3H, J = 6.8 
Hz), 0.96 (s, 9H), 1.20 (m, 3H), 1.48 (m, 3H) 1.57 (s, 3H), 1.90-2.04 (m, 
4H), 2.8-3.00 (m, 4H), 4.16 (q, 2H, J = 6.8 Hz), 4.75 (dd, 1H, J = 3.2-7.2 
Hz),5.07-5.14 (m, 1H), 6.65 (d, 1H, J = 9.6 Hz), 7.08-7.82 (m, 7H), 8.23 (d, 
1H).  13C NMR (CDCl3, 400 MHz): δ 14.0, 14.3, 18.9, 19.5, 21.7, 21.8, 
25.5, 25.8, 26.5, 27.1, 29.8, 29.9, 31.2, 31.6, 32.1, 35.7, 53.3, 53.9, 55.9, 
56.5, 56.7, 60.9, 122.5, 125.5, 126.6, 127.5, 128.3, 131.3, 132.7, 138.7, 
138.8, 146.7, 147.6, 167.8, 171.2, 173.09, 175.9, 176.2, 186.80. 
 
• Reaction with amine 71e 
Tripeptide ethyl ester [(S)(S)(S)-75e] 
It was obtained from [(R,S)(S)(S)-65a] as yellow oil (41 %) according to 
general procedure 7. 
1H NMR (CDCl3, 400 MHz): δ 0.77 (d, 3H, J = 6.8 Hz), 0.87 (d, 3H, J = 6.8 
Hz), 0.96 (s, 9H), 1.18 (d, 3H, J = 6.8 Hz), 1.29 (t, 3H, J = 7.2 Hz) 1.34 (s, 
3H), 1.35 (s, 3H), 1.85-1.94 (m, 1H), 1.86-1.95 (m, 1H), 3.00 (s, 3H), 4.18 
(q, 1H, J = 6.8 Hz), 4.75 (dd, 1H, J = 3.2-7.2 Hz),5.07-5.14 (m, 1H), 6.65 
(d, 1H, J = 9.6 Hz), 7.25-7.43 (m, 4H), 8.23 (d, 1H, J = 14 Hz).  13C NMR 
(CDCl3, 400 MHz): δ 14.0, 14.3, 18.9, 19.5, 21.7, 21.8, 25.5, 25.8, 26.5, 
27.1, 29.8, 29.9, 31.2, 31.6, 32.1, 35.7, 53.3, 53.9, 55.9, 56.5, 56.7, 60.9, 
12.5, 125.5, 126.6, 127.5, 128.3, 131.3, 132.7, 138.7, 138.8, 146.7, 147.6, 
167.8, 171.2, 175.9, 176.2 . 
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Tripeptide ethyl ester [(R)(S)(S)-75e] 
It was obtained from [(R,S)(S)(S)-65a] as white solid (80%), according to 
general procedure 7. 
1H NMR (CDCl3, 400 MHz): δ 0.77 (d, 3H, J = 6.4 Hz), 0.87 (d, 3H, J = 6.4 
Hz), 0.99 (s, 9H), 1.09 (d, 3H, J = 6.8 Hz), 1.31 (t, 3H, J = 7.2 Hz), 1.41 (s, 
3H), 1.45 (s, 3H), 1.85-1.94 (m, 1H), 1.92 (s, 3H), 2.89-2.96 (m, 1H), 2.99 
(s, 3H), 4.20 (q, 2H, J = 7.2 Hz), 4.76 (d, 1H, J = 10 Hz), 5.11 (t, 1H, J = 10 
Hz), 6.63 (d, 1H, J = 9.2 Hz), 7.30 (d, 2H, J = 8.4 Hz), 7.44 (d, 2H, J = 8.8 
Hz), 7.99 (d, 1H, J = 10 Hz). 
13C NMR (CDCl3, 400 MHz): δ 13.9, 14.3, 18.7, 19.5, 21.6, 26.6, 26.8, 
27.1, 29.8, 30.1, 31.1, 31.5, 35.3, 53.0, 54.7, 55.9, 56.5, 60.9, 120.7, 127.6, 
131.4, 138.6, 167.8, 171.8, 175.9 
MS, m/z (ES+): 580 (M+H), 582 (M+2) 
 
Tripeptide ethyl ester [(R,S)(S)(S)-75f] 
It was obtained from [(R,S)(S)(S)-65a] as an oil (80%) according to general 
procedure 7. 
1H NMR(CDCl3, 400 MHz) : δ 0.5-1 (m, 6H), 0.97 (s, 9H), 1.00 (s, 9H), 
1.18 (d, 3H), 1.22 (d, 2H), 1.20-1.35 (m, 3H), 1.50-1.70 (m 1H), 1.78-2.00 
(m, 1H), 1.91 (s, 3H), 1.93 (s, 1H), 3.01 (s, 3H), 3.03 (s, 3H), 3.25-3.35 (m, 
1H), 3.76 (s, 3H), 3.85-4.02 (m, 1H), 6.60-6.70 (m, 1H), 7.03 (s, 1H), 7.10-
7.30 (m, 3H), 7.60-7.70 (m, 1H), 7.98 (d, 1H), 8.00 (d, 1H). 
13C NMR (CDCl3, 400 MHz): δ 13.8, 13.9, 14.3, 17.6, 18.7, 18.8, 19.5, 
19.8, 20.3, 20.8, 23.9, 26.6, 29.8, 30.2, 31.2, 32.7, 35.1, 35.4, 43.1, 43.8, 
54.2, 54.3, 55.9, 57.9, 60.9, 109.3, 112.8, 112.9, 118.9, 119.0, 119.2, 121.7, 
121.9, 127.4, 127.9, 132.8, 138.8, 167.9, 171.7, 175.0, 175.1. 
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2-Hydroxypropanoyl-dipeptide ethyl ester [(S)(S)(S)-77g] 
It was obtained as solid (98%) according general procedure 7.  
Rf (Hexane/AcOEt 1:1) 0.28. MS, m/z (ES+): 384 (M+H). 
1H NMR (CDCl3, 400 MHz): d 0.79 (d, 3H, J = 6.8 Hz), 0.87 (d, 3H, J = 6.8 
Hz), 0.97 (s, 9H), 1.32 (t, 3H, J = 7.2 Hz), 1.40 (d, 3H, J = 6.8 Hz), 1.83-
1.94 (m, 1H), 1.90 (d, 3H, J = 0.8 Hz), 2.88 (br s, 1H), 3.01 (s, 1H), 4.18-
4.22 (m, 3H), 4.79 (d, 1H, J = 9.6 Hz), 5.08 (dd, 1H, J = 10.0 and 10.2 Hz), 
6.63 (dd, 1h, J = 10.0 and 0.8 Hz), 7.21 (d, 1H, J = 9.6 Hz). 13C NMR 
(CDCl3, 400 MHz): d 13.9, 14.3, 18.8, 19.5, 21.3, 26.5, 30.0, 31.2, 35.4, 
54.7, 56.3, 61.0, 68.3, 132.8, 138.2, 167.8, 171.8, 174.6. 
 
2-Hydroxypropanoyl-dipeptide ethyl ester [(R)(S)(S)-77g] 
It was obtained as for [(S)(S)(S)-77g] but starting from bromoacyl-dipeptide 
[(R)(S)(S)-65]. 
Rf (Hexane/AcOEt 1:1) 0.5, (toluene/EtOAc) 0.4. MS, m/z (ES+): 384 
(M+H). 
1H NMR (CDCl3, 400 MHz): d 0.78 (d, 3H, J = 6.4 Hz), 0.86 (d, 3H, J = 6.4 
Hz), 0.97 (s, 9H), 1.30 (t, 3H, J = 7.2 Hz), 1.38 (d, 3H, J = 6.4 Hz), 1.87-
1.92 (m, 1H), 1.89 (d, 3H, J = 1.2 Hz), 3:00 (s, 3H), 3.70 (br, 1H), 4.19 (q, 
2H, J = 7.2 Hz), 4.26 (q, 1H, J = 6.4 Hz), 4.81 (d, 1H, J = 9.6 Hz), 5.07 (dd, 
1H, J = 10.8 and 9.6 Hz), 6.62 (dd, 1H, J = 1.2 and 9.6 Hz), 7.20 (d, 1H, J = 
9.6 Hz). 13C NMR (CDCl3, 400 MHz): d 13.9, 14.2, 18.7, 19.5, 21.3, 26.5, 
30.1, 31.2, 35.4, 54.6, 56.2, 61.0, 68.2, 132.9, 138.3, 167.8, 171.8, 174.4. 
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Tripeptide ethyl ester [(R,S)(S)(S)-77h] 
It was obtained as oil (98%), following the general procedure 7, purified by 
flash chromatography (Hexan/AcOEt 1:2) starting from [(R,S)(S)(S)-65a] e 
cyclohexylamine. 
Rf (Hexan/AcOEt 1:2) 0.2; MS, m/z (MALDI): 488 (M+ Na+) 
1H NMR (CDCl3, 400 MHz): d 0.78 (d, 3H, J = 6.4 Hz), 0.86 (d, 3H, J = 
6.4), 0.97 (s, 9H), 1.11-2.11 (m, 4H), 1.30 (t, 3H, J = 7.2 Hz), 1.38 (d, 3H, J 
= 6.4 Hz), 1.3-1.6 (m, 4H), 1.5-1.6 (m, 2H), 1.6 (m, 1H), 1.86 (s, 3H), 1.90 
(m, 1H), 2.10 (m, 1H), 2.90 (s, 3H), 3.21 (m, 1H), 4.18 (q, 2H), 4.8 (m, 1H), 
5.10 (m, 1H), 6.60 (m, 1H), 8.10 (m, 1H).13C NMR (CDCl3, 400 MHz): d 
13.1, 14.2, 20.0, 23.7, 25.7, 26.0, 29.7, 33.2, 33.9, 35.5, 56.6, 61.7, 64.9, 
126.8, 137.3, 162.3, 171.0, 171.9 
 
General procedure 8: hydrolysis of ethylic ester at C-terminus. 
To a solution of tripeptide ethyl ester  (60 mg, 0.12 mmol) in MeOH (2 mL) 
and H2O (1 mL), LiOH monohydrate (50 mg, 1.2 mmol) was added and the 
reaction mixture stirred for 3 h at r. t. The mixture was acidified with TFA 
and then extracted with AcOEt (3 x 5 mL). The combined extracts were 
dried over anhydrous Na2SO4 and concentrated in vacuo to give the product 
as trifluoroacetate salt. The crude product was then purified by trituration 
with Et2O (3 x 3mL).  
 
Tripeptide trifluoroacetate salt [(S)(S)(S)-76a] 
The crude product was purified by trituration with Et2O (3 x 3mL), to afford 
a solid (86%). Rt: 19.81 MS, m/z (ES+): 474 (M+H) 
1H NMR (CD3OD, 400 MHz): 0.77 (d, 3H, J = 6.4 Hz), 0.86 (d, 3H, J = 6.4 
Hz), 0.9 (s, 9H), (d, 3H, J = 7.2 Hz), 1.75 (s, 3H), 1.80 (s, 3H), 1.84 (d, 3H, 
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J = 0.6 Hz), 1.90-2.03 (m, 1H), 2.62 (d, 2H, J = 15.6 Hz), 3.03 (s, 3H), 3.80 
(q, 1H, J = 7.2 Hz), 4.58 (s, 1H), 4.95 (dd, 1H, J = 10 and 9.6 Hz), 6.65 (dd, 
1H, J = 9.6 and 0.6 Hz), 7.42-7.56 (m, 5H). 13C NMR (CD3OD, 400 MHz)  
d 13.4, 15.1, 18.6, 19.3, 19.5, 19.6, 26.0, 26.2, 28.7, 30.8, 34.7, 42.8, 52.1, 
54.4, 55.8, 64.8, 72.1, 125.8, 127.6, 128.5, 131.2, 131.8, 138.3, 168.5, 
171.2, 174.8. 
 
Tripeptide trifluoroacetate salt [(R)(S)(S)-76a] 
It was obtained following the general procedure 8. 
Rt: 21.02. MS, m/z (ES+): 475 (M+H) 
1H NMR (CD3OD, 400 MHz) d 0.89 (d, 3H, J = 6.8 Hz), 0.92 (d, 3H, J = 
6.4 Hz), 0.96 (s, 9H), 1.39 (d, 3H, J = 6.8 Hz), 1.63 (s, 3H), 1.75 (s, 3H), 
1.89 (d, 3H, J = 0.8 Hz), 2.01-2.10 (m, 1H), 3.09 (s, 3H), 3.78 (q, 1h, J = 
6.8 Hz), 4.73 (s, 1H), 5.01 (dd, 1H, J = 9.8 and 9.4 Hz), 6.90 (dd ,1H, J = 
0.8 and 9.0 Hz), 7.42-7.57 (m, 5H). 
13C NMR(CD3OD, 400 MHz): d 14.2, 18.9, 19.4, 19.9, 26.2, 26.8, 27.1, 
31.1, 31.9, 35.6, 53.9, 57.9, 58.2, 64.4, 127.6, 130.6, 130.7, 134.0, 139.6, 
139.9, 168.6, 171.0, 172.9. 
 
Tripeptide trifluoroacetate salt [(R)(R,S)(S)(S)-76b] 
It was obtained following the general procedure 8. 
Rt: 11.66. MS, m/z (ES+): 460 (M+H) 
1H NMR (CD3OD, 400 MHz) d 0.89 (d, 3H, J = 6.8 Hz), 0.92 (d, 3H, J = 
6.4 Hz), 0.96 (s, 9H), 1.39 (d, 3H, J = 6.8 Hz), 1.63 (m, 3H), 1.77 (s, 3H), 
1.94 (d, 1H, J = 0.8 Hz), 2.01-2.10 (m, 1H), 3.09 (s, 3H), 3.78 (q, 1H), 4.73 
(m, 1H), 5.01 (d, 1H, J = 9.8), 6.90 (dd ,1H, J = 0.8 and 9.0 Hz), 7.42-7.57 
(m, 5H). 
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13C NMR(CD3OD, 400 MHz): d 14.2, 18.9, 19.4, 19.9, 26.2, 26.8, 27.1, 
31.1, 31.9, 35.6, 53.9, 57.9, 58.2, 64.4, 127.6, 130.6, 130.7, 134.0, 139.6, 
139.9,161.44 168.6, 171.0, 172.9. 
 
Tripeptide trifluoroacetate salt [(S)(S)(S)-76c] 
It was obtained according general procedure 8 after purification by 
preparative HPLC to get a solid (84%). 
Rt: 12.26. MS, m/z (ES+): 446 [M+H], 468 [M+Na]. 
1H NMR (CD3OD, 400 MHz): d 0.81 (d, 3H, J = 6.4 Hz), 0.89 (d, 3H, J = 
6.5 Hz), 1.01 (s, 9H), 1.44 (d, 2H, J = 6.8 Hz), 1.89 (dd, 3H, J = 1.4 and 6.9 
Hz), 1.95-2.10 (m, 1H), 3.13 (s, 3H), 3.95-4.20 (m, 3H), 4.76 (s, 1H), 5.04 
(dd, 1H, J = 10 and 9.8 Hz), 6.74 (dd, 1H, J = 9.6 and 6.9 Hz), 7.46 (s, 5H). 
13C NMR (CD3OD, 400 MHz): d 14.1, 16.8, 19.8, 26.7, 27.0, 30.9, 31.8, 
35.6, 51.0, 56.2, 57.8, 58.0, 130.4, 131.1, 131.2, 132.2, 133.9, 170.1, 170.9, 
172.7. 
 
Tripeptide trifluoroacetate salt [(R)(S)(S)-76c] 
It was obtained following the general procedure 8 after purification by 
preparative HPLC as solid (84%). 
Rt: 12.12. MS, m/z (ES+): 446 [M+H], 468 [M+Na]. 
1H NMR(CD3OD, 400 MHz): d 0.81 (d, 3H, J = 6.4 Hz), 0.90 (d, 3H, J = 
6.5 Hz), 1.00 (s, 9H), 1.44 (d, 2H, J = 6.8 Hz), 1.88 (dd, 3H, J = 1.6 and 6.8 
Hz), 1.95-2.10 (m, 1H), 3.09 (s, 3H), 4.83 (s, 1H), 5.09 (dd, 1H,  J = 10 and 
9.8 Hz), 6.72 (dd, 1H, J = 9.5 and 7.0 Hz), 7.46 (s, 5H). 13C NMR (CD3OD, 
400 MHz): d 14.1, 17.3, 19.2, 26.7, 26.9, 31.0, 31.7, 35.9, 50.8, 56.6, 57.4, 
58.2, 130.5, 130.8, 131.0, 132.1, 140.0, 170.2, 170.9, 172.8. 
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Tripeptide TFA salt [(R,S)(S)(S)-76d] 
It was obtained according to the general procedure 8 as white solid (70%). 
1H NMR (CD3OD, 400 MHz): δ 0.78 (d, 3H, J = 6.8 Hz), 0.82 (d, 3H, J = 
6.8 Hz), 0.96 (s, 9H), 1.20 (m, 3H), 1.57 (s, 3H), 1.90-2.04 (m, 4H), 2.8-
3.00 (m, 4H), 4.75 (dd, 1H, J = 3.2-7.2 Hz), 5.07-5.14 (m, 1H), 6.65 (d, 1H, 
J = 9.6 Hz), 7.08-7.82 (m, 7H), 8.23 (d, 1H).  13C NMR (CD3OD, 400 
MHz): δ 14.0, 14.3, 18.9, 19.5, 21.7, 21.8, 25.5, 25.8, 26.5, 27.1, 29.8, 29.9, 
31.2, 31.6, 32.1, 35.7, 53.3, 53.9, 55.9, 56.5, 56.7, 60.9, 122.5, 125.5, 126.6, 
127.5, 128.3, 131.3, 132.7, 138.7, 138.8, 146.7, 147.6, 167.8, 171.2, 173.09, 
175.9, 176.2, 186.80. 
 
Tripeptide TFA salt [(S)(S)(S)-76e] 
It was obtained following the general procedure 8.( 95%) 
1H NMR (CD3OD, 400 MHz): δ 0.77 (d, 3H, J = 6.8 Hz), 0.86 (d, 3H, J = 
6.8 Hz), 0.90 (s, 9H), 1.32 (d, 3H, J = 7.2 Hz), 1.73 (s, 3H), 1.77 (s, 3H), 
1.85 (s, 3H), 1.91-2.01 (m, 1H), 3.02 (s, 3H), 3.79 (q, 1H, J = 7.2 Hz), 4.50 
(s, 1H), 4.98 (t, 1H, J = 10 Hz), 6.71 (d, 1H, J = 9.6 Hz), 7.47 (d, 2H, J = 8.8 
Hz), 7.61 (d, 2H, J = 8.8 Hz). 13C NMR (CD3OD, 400 MHz): δ 14.1, 18.9, 
19.2, 19.8, 25.9, 26.6, 26.9, 30.9, 31.7, 35.4, 53.6, 57.6, 58.1, 63.4, 124.6, 
129.8, 133.3, 133.8, 139.8, 170.8, 171.1, 172.7. 
 
Tripeptide TFA salt [(R)(S)(S)-76e] 
It was obtained according to procedure 8 (95%) 
1H NMR (CD3OD, 400 MHz): δ 0.88-0.97 (m, 6H,), 1.01 (s, 9H), 1.38 (d, 
3H, J = 6.8 Hz), 1.51 (s, 3H), 1.67 (s, 3H), 1.95 (s, 3H), 1.98-2.01 (m, 1H), 
3.13 (s, 3H), 3.70 (q, 1H, J = 7.2 Hz), 4.96 (t, 1H, J = 4.4 Hz), 6.73 (dd, 1H, 
J = 1.3-4.1 Hz), 7.41 (d, 2H, J = 6.8 Hz), 7.61 (d, 2H, J = 6.8 Hz). 13C NMR 
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(CD3OD, 400 MHz): δ 14.1, 18.8, 18.9, 19.9, 20.1, 24.3, 26.9, 28.3, 30.7, 
31.8, 35.8, 53.9, 57.6, 59.6, 63.8, 124.5, 129.2, 132.9, 133.6, 138.9, 139.3, 
170.8, 171.1, 172.9. 
 
Tripeptide TFA salt [(R,S)(S)(S)-76f] 
It was obtained following general procedure 8 (95%) 
1H NMR (CD3OD, 400 MHz): δ 0.82 (d, 6H, J = 6.6 Hz), 0.89 (d, 6H, J = 
6.5 Hz), 1.01 (s, 9H), 1.04 (s, 9H), 1.43 (d, 3H, J = 7 Hz), 1.51 (d, 3H, J = 7 
Hz), 1.87 (d, 3H, J = 1.5 Hz), 1.91 (d, 3H, 1,5), 1.95-2.08 (m, 1H), 3.09 (s, 
3H), 3.16 (s, 1H), 3.85 (s, 3H), 3.98-4.05 (m, 1H), 4.09 (q, 1H, J = 7 Hz), 
4.18 (d, 1H, J = 13 Hz), 4.31 (d, 1H, J = 13 Hz), 4.79 (s, 1H), 4.82 (s, 1H), 
5.04 (t, 1H, J = 10 Hz), 5.10 (t, 1H, J = 10 Hz), 6.72-6.79 (m, 1H), 7.15-
7.20 (m, 1H), 7.24-7.29 (m, 1H), 7.37 (s, 1H), 7.40 (s, 1H), 7.43 (d, 1H, J = 
8 Hz), 7.45 (d, 1H, J = 8 Hz), 7.69-7.74 (m, 1H) 
13C NMR (CD3OD, 400 MHz): δ 14.3, 14.7, 17.2, 17.6, 19.5, 20.0, 22.4, 
24.4, 27.1, 27.2, 28.2, 31.1, 31.2, 32.0, 32.1, 33.3, 35.8, 36.1, 42.2, 55.5, 
55.6, 57.7, 58.1, 58.2, 58.5, 61.7, 104.5, 104.6, 111.1, 111.2, 119.6, 119.7, 
121.5, 123.8, 128.7, 132.4, 132.7, 133.9, 134.1, 138.8, 140.0, 170.5, 171.0, 
173.0, 173.2. 
 
2-Hydroxypropanoyl-dipeptide [(S)(S)(S)-78g] 
It was obtained following the general procedure 8 (94%). 
Rt: 15.3; MS, m/z (ES+): 357 (M+H). 
1H NMR (DMSO-D6): d 0.70 (d, 3H, J = 6.8 Hz), 0.79 (d, 3H, J = 6.8 Hz), 
0.89 (s, 9H), 1.21 (d, 3H, J = 6.8 Hz), 1.77 (d, 3H, J = 0.8 Hz), 1.82-1.98 
(m, 1H), 2.93 (s, 3H), 3.98 (q, 1H, J = 6.8 Hz), 4.69 (d, 1H, J = 10.0 Hz), 
4.92 (dd, 1H, J = 10.0 and 10.3 Hz), 5.40 (br s, 1H), 6.62 (dd, 1h, J = 10.0 
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and 0.8 Hz), 7.44 (d, 1H, J = 9.6 Hz). 13C NMR (DMSO-D6): d 13.9, 18.5, 
19.3, 21.6, 26.0, 28.8, 42.6, 53.1, 55.6, 67.0, 72.3, 131.8, 138.2, 168.5, 
171.2, 174.5.  
 
2-Hydroxypropanoyl-dipeptide [(R)(S)(S)-78g] 
It was obtained according to procedure 8 (90%). 
Rt: 14.7; MS, m/z (ES+): 357 (M+H). 
1H NMR (DMSO-D6): d 0.73 (d, 3H, J = 6.7 Hz), 0.81 (d, 3H, J = 6.8 Hz), 
0.93 (s, 9H), 1.18 (d, 3H, J = 6.9 Hz), 1.71 (d, 3H, J = 0.7 Hz), 1.86-2.01 
(m, 1H), 2.95 (s, 3H), 4.04 (q, 1H, J = 6.8 Hz), 4.62 (d, 1H, J = 10.1 Hz), 
4.99 (dd, 1H, J = 10.1 and 10.4 Hz), 5.42 (br s, 1H), 6.66 (dd, 1h, J = 10.4 
and 0.7 Hz), 7.51 (d, 1H, J = 10.1 Hz). 13C NMR (DMSO-D6): d 13.7, 19.1, 
19.2, 21.9, 26.3, 28.0, 42.4, 53.5, 55.9, 66.8, 72.5, 131.9, 138.2, 168.4, 
171.5, 174.7. 
 
Tripeptide TFA salt [(R,S)(S)(S)-79h] 
It was obtained according to general procedure 8.(white solid, 60%) 
1H NMR (CD3OD, 400 MHz): d 0.78 (d, 3H, J = 6.4 Hz), 0.86 (d, 3H, J = 
6.4), 0.97 (s, 9H), 1.11-2.11 (m, 4H), 1.38 (d, 3H, J = 6.4 Hz), 1.3-1.6 (m, 
4H), 1.5-1.6 (m, 2H), 1.6 (m, 1H), 1.86 (s, 3H), 1.90 (m, 1H), 2.10 (m, 1H), 
2.90 (s, 3H), 3.21 (m, 1H), 4.8 (m, 1H), 5.10 (m, 1H), 6.60 (m, 1H), 8.10 
(m, 1H).13C NMR (CD3OD, 400 MHz): d, 20.0, 23.7, 25.7, 26.0, 29.7, 33.2, 
33.9, 35.5, 56.6, 61.7, 64.9, 126.8, 137.3, 162.3, 171.0, 171.9 
 
Tripeptide ethyl ester valine derivative [(S)(S)(S)-80a] 
It was obtained according to general procedure 8 (white solid, 64%). 
MS, m/z (ES+): 439 [M+H], 460 [M+Na]. 
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1H NMR (CDCl3, 400 MHz) 0.81 (d, 3H, J = 6.4 Hz), 0.89 (d, 3H, J = 6.5 
Hz), 1.01 (s, 9H), 1.44 (d, 2H, J = 6.8 Hz), 1.89 (dd, 3H, J = 1.4 and 6.9 
Hz), 1.95-2.10 (m, 1H), 3.13 (s, 3H), 3.95-4.20 (m, 3H), 4.76 (s, 1H), 5.04 
(dd, 1H, J = 10 and 9.8 Hz), 6.74 (dd, 1H, J = 9.6 and 6.9 Hz), 7.46 (s, 5H). 
13C NMR (CDCl3, 400 MHz) 14.1, 16.8, 19.8, 26.7, 27.0, 30.9, 31.8, 35.6, 
51.0, 56.2, 57.8, 58.0, 130.4, 131.1, 131.2, 132.2, 133.9, 170.1, 170.9, 
172.7. 
 
Tripeptide ethyl ester [(R)(S)(S)-80a] 
It was obtained following the general procedure 7 after purification by 
column chromatography (Hexane/AcOEt 1/1) to get a solid (92%). 
Rf (Hexane/AcOEt 1/3) 0.36 
1NMR (CDCl3, 400 MHz): d 0.82 (d, 3H), 0.89 (d, 9H, J = 6.4 Hz), 1.17 (d, 
3H, J = 7.2 Hz), 1.31 (t, 3H, J = 6.8), 1.38 (s, 3H), 1.40 (s, 3H), 1.63 (br, 
1H), 1.88-1.95 (m, 1H), 1.91 (d, 3H, J = 0.8 Hz), 1.97-2.08 (m, 1H), 2.90 
(q, 1H, J = 7.2 Hz), 2.97 (s, 3H), 4.20 (q, 2H, J = 6.8 Hz), 4.68 (dd, 1H, J = 
7.2 and 9.2 Hz), 5.08 (dd, 1H, J = 10.0 and 6.0 Hz), 6.65 (dd, 1H, J = 0.8 
and 9.2 Hz), 7.13-7.38 (m, 5H), 8.18 (d, 1H, J = 9.2 Hz). 13C NMR (CDCl3, 
400 MHz): d 13.8, 14.3, 17.7, 18.9, 19.5, 19.6, 21.9, 25.6, 30.0, 30.6, 31.7, 
32.0, 53.2, 53.5, 56.3, 56.8, 60.9, 103.7, 125.6, 126.6, 128.3, 138.6, 147.5, 
167.9, 171.8, 176.6. 
 
Tripeptide ethyl ester [(S)(S)(S)-80c]  
It was obtained following the general procedure 7 as a solid (89%). 
Rf (CH2Cl2/MeOH/Toluene 17/2/2.5) 0.3. MS, m/z (ES+): 460 [M+H], 482 
[M+Na]. 
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1H NMR (CDCl3, 400 MHz): d 0.80 (d, 3H, J = 6.8 Hz), 0.86-0.95 (m, 9H), 
1.28 (t, 3H, J = 7.1 Hz), 1.43 (d, 3H, J = 6.9 Hz), 1.80 (br s, 1H), 1.90-1.96 
(m, 4H), 1.99-2.11 (m, 1H), 2.98 (s, 3H), 3.24 (q, 1H, J = 6.9 Hz), 3.59-3.69 
(m, 2H), 4.22 (q, 2H, J = 7.0 Hz), 4.78 (dd, 1H, J = 9.6 and 10.3 Hz), 5.02 
(dd, 1H, J = 9.6 and 7.0 Hz), 6.62 (dd, 1H, J = 1.2 and 7.0 Hz), 7.31-7.33 
(m, 5H), 7.75 (d, 1H, J = 9.6 Hz). 13C NMR (CDCl3, 400 MHz):  d 14.3, 
17.5, 18.8, 19.0, 19.5, 19.6, 20.2, 29.9, 30.4, 31.3, 52.6, 53.7, 56.6, 57.7, 
61.0, 127.3, 128.6, 128.8, 132.9, 138.1, 138.3, 167.8, 172.1, 175.1. 
 
Tripeptide ethyl ester [(R)(S)(S)-80c]  
It was obtained following the general procedures 8 as white solid (81%). 
Rf (CH2Cl2/MeOH/Toluene 17/2/2.5) 0.3. MS, m/z (ES+): 460 [M+H], 482 
[M+Na]. 
1H NMR (CDCl3, 400 MHz): d 0.82 (d, 3H, J = 6.8 Hz), 0.85-0.95 (m, 9H), 
1.27 (t, 3H, J = 7.0 Hz), 1.41 (d, 3H, J = 6.9 Hz), 1.84 (br s, 1H), 1.92-1.98 
(m, 4H), 2.00-2.15 (m, 1H), 2.97 (s, 3H), 3.22 (q, 1H, J = 6.9 Hz), 3.48-3.59 
(m, 2H), 4.20 (q, 2H, J = 7.0 Hz), 4.80 (dd, 1H, J = 9.7 and 10.4 Hz), 5.05 
(dd, 1H, J = 9.6 and 7.0 Hz ), 6.62 (dd, 1H, J = 1.2 and 7.1), 7.30-7.33 (m, 
5H), 7.75 (d, 1H, J = 9.7 Hz). 13C NMR (CDCl3, 400 MHz): d 13.7, 14.2, 
17.5, 17.8, 18.8, 19.4, 19.6, 20.2, 21.4, 29.9, 30.4, 31.1, 31.3, 52.6, 53.4, 
53.7, 56.3, 56.6, 57.7, 57.9, 61.0, 68.3, 127.3, 128.1, 128.4, 128.6, 132.9, 
138.1, 138.4, 138.5, 167.8, 172.0. 
 
Tripeptide trifluroacetate salt [(S)(S)(S)-81a] 
It was obtained following the general procedure 8 as white solid (92%). 
Rt: 16.28. MS, m/z (ES+): 488 [M+H]. 
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1H NMR (CD3OD, 400 MHz): d 0.79 (d, 3H, J = 6.0 Hz), 0.83-0.88 (m, 
6H), 1.33 (d, 3H, J = 7.2 Hz), 1.76 (s, 3H), 1.80 (s, 3H), 1.84 (d, 3H, J = 
1.2Hz), 1.83-1.99 (m, 2H), 3.00 (s, 3H), 3.68 (q, 1H, J = 7.2Hz), 4.35 (dd, 
1H, J = 9.3 and 9.9 Hz), 4.96 (dd, 1H, J = 10.1 and 9.6 Hz), 6.71 (dd, 1H, J 
= 9.9 and 1.2 Hz), 7.43-7.58 (m, 5H). 13C NMR (CD3OD): d 13.8, 15.6, 
18.8, 18.9, 19.0, 19.7, 25.0, 29.4, 30.1, 30.6, 43.1, 52.2, 54.9, 56.5, 65.4, 
72.9, 126.8, 129.2, 132.4, 138.6, 169.0, 171.3, 171.7, 175.0. 
 
Tripeptide trifluoroacetate salt [(R)(S)(S)-81a] 
It was obtained following the general procedure 8 as white solid (95%). 
Rt: 21.0, MS, m/z (ES+): 342, 459 [M+H]. 
1H NMR (CD3OD, 400 MHz) d 0.88-0.93 (m, 12H), 1.39 (d, 3H, J = 7.2 
Hz), 1.65 (s, 3H), 1.76 (s, 3H), 1.88 (d, 3H, J = 1.6 Hz), 1.92-2.10 (m, 2H), 
3.07 (s, 3H), 3.66 (q, 1H, J = 7.2 Hz), 4.53 (d, 1H, J = 7.6 Hz), 4.99 (dd, 
1H, J = 10.4 and 10.0 Hz), 6.76 (dd, 1H, J = 1.6 and 9.2 Hz), 7.45-7.59 (m, 
5H). 13C NMR (CD3OD, 400 MHz): d 12.5, 17.0, 17.7, 17.9, 18.3, 23.0, 
27.0, 29.4, 29.8, 30.2, 52.7, 55.3, 57.4, 63.0, 110.0, 125.8, 129.0, 129.1, 
132.3, 138.0, 138.0, 161.0, 169.3, 171.8. 
 
Tripeptide trifluoroacetate salt [(S)(S)(S)-81c] 
It was obtained following the general procedure 8 after purification by 
preparative HPLC as solid (87%). 
Rt: 16.06, MS, m/z (ES+): 432 [M+H] 
1H NMR (CD3OD, 400 MHz) d 0.83 (d, 3H, J = 6.4 Hz), 0.89-1.00 (m, 9H), 
1.46 (d, 3H, J = 6.8 Hz), 1.86 (d, 3H, J = 1.6 Hz), 1.90-1.98 (m, 2H), 3.12 
(s, 3H), 3.95-4.15 (m, 3H), 4.60 (d, 1H, J = 8.1Hz), 5.01 (dd, 1h, J = 10.4 
and 9.6 Hz), 6.75 (dd, 1H, J = 1.6 and 9.6 Hz), 7.46 (s, 5H). 13C NMR 
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(CD3OD, 400 MHz) d 14.0, 17.8, 18.9, 19.4, 19.5, 20.5, 21.4, 30.0, 30.5, 
31.0, 52.6, 53.5, 56.3, 57.9, 68.4, 128.1, 128.4, 128.8, 132.9, 138.0, 138.4, 
167.8, 172.0, 174.5. 
 
Tripeptide trifluoroacetate salt [(R)(S)(S)-81c] 
It was obtained by hydrolysis of the relative ester after purification by 
preparative HPLC to afford a solid (85%). 
Rt: 16.45. MS, m/z (ES+): 432 [M+H] 
1H NMR (CD3OD, 400 MHz): d  0.89 (d, 3H, J = 6.5 Hz), 0.91-1.02 (m, 
9H), 1.53 (d, 3H, J = 6.8 Hz), 1.88 (d, 3H, J = 1.6 Hz), 1.98-2.05 (m, 2H), 
3.09 (s, 3H), 3.91-4.10 (m, 3H), 4.56 (d, 1H, J = 8 Hz), 5.04 (dd, 1h, J = 
10.4 and 9.5 Hz), 6.75 (dd, 1H, J = 1.6 and 9.5 Hz), 7.45 (s, 5H).13C NMR 
(CD3OD, 400 MHz) d 14.1, 16.7, 18.9, 19.3, 19.5, 19.8, 30.9, 31.2, 31.4, 
50.8, 56.4, 56.9, 58.6, 130.3, 130.8, 131.1, 132.1, 133.8, 139.5, 169.9, 
170.8, 173.8. 
 
2-Hydroxypropanoyl-dipeptide ethyl ester [(S)(S)(S)-82g] 
It was obtained following the general procedure 7 as solid (97%).  
Rf (hexane/AcOEt 1/3) 0.61. 
1H NMR (DMSO-d6, 400 MHz): d 0.79 (d, 3H, J = 6.8 Hz), 0.86-0.92 (m, 
6H), 1.29 (t, 3H, J = 76.8 Hz), 1.46 (d, 3H, J = 7.2 Hz), 1.83-1.88 (m, 1H), 
1.86 (d, 1H, J = 0.7 Hz), 1.88-2.07 (m, 1H), 2.91 (s, 3H), 2.95 (br s, 1H), 
4.19 /q, 2H, J = 7.2 Hz), 4.78 (dd, 1H, J = 9.6 and 7.3 Hz), 5.02 (dd, 1H, J = 
10.1 and 6.7 Hz), 5.18 (q, 1H, J = 7.2 Hz), 6.62 (dd, 1H, J = 0.7 and 9.6 
Hz), 6.68 (d, 1H, J = 10.1 Hz). 13C NMR (DMSO-d6, 400 MHz): d 13.8, 
14.3, 17.3, 17.6, 18.0, 19.4, 19.6, 27.1, 30.0, 31.6, 53.3, 56.4, 60.1, 70.4, 
133.0, 138.3, 167.7, 171.4, 177.0. 
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2-Hydroxypropanoyl-dipeptide ethyl ester [(R)(S)(S)-82g] 
It was obtained following the general procedure 7 as white solid (88%).  
Rf (Hexane/AcOEt 1/3) 0.42; (hexane/AcOEt 1/2) 0.2. 
1H NMR: (CD3OD, 400 Mhz) d 0.81 (d, 3H, J = 6.8 Hz), 0.88-0.92 (m, 9H), 
1.30 (t, 3H, J = 7.6 Hz), 1.40 (d, 3H, J = 7.2 Hz), 1.72 (br s, 1H), 1.85-1.98 
(m, 1H), 1.88 (d, 3H, J = 1.6 Hz), 1.98-2.01 (m, 1H), 2.97 (s, 3H), 4.20 (q, 
2H, J = 7.6 Hz), 4.26 (q, 1H, J = 7.2 Hz), 4.73 (dd, 1H, J = 6.8 and 8.8 Hz), 
5.02 (dd, 1H, J = 10 and 9.9 Hz), 6.63 (dd, 1H, J = 1.6 and 8.8Hz), 7.08 (d, 
1H, J = 9.2Hz). 13C NMR (CD3OD, 400 MHz) d 13.7, 14.3, 17.7, 18.8, 
19.4, 19.6, 21.4, 30.0, 31.1, 31.2, 53.9, 56.6, 61.0, 68.2, 133.0, 138.1, 167.8, 
172.1, 174.5. 
 
2-Hydroxypropanoyl-dipeptide [(S)(S)(S)-83g] 
It was obtained following the general procedure 8 as white solid (90%). 
1H NMR (CD3OD, 400 MHz): d 0.71 (d, 3H, J = 6.4 Hz), 0.77-0.86 (m, 
9H), 1.15 (d, 3H, J = 6.4 Hz), 1.76 (d, 3H, J = 1.2 Hz), 1.90-2.03 (m, 2H), 
2.92 (s, 3H), 3.97 (q, 1H, J = 6.4 Hz), 4.54 (dd, 1H, J = 6.8 and 9.0 Hz), 
4.85 (dd, 1H, J = 9.8 and 9.5 Hz), 5.2 (br, 2H), 6.61 (dd, 1H, J = 1.2 and 9.3 
Hz), 7.45 (d, 1H, J = 8.3 Hz). 13C NMR d 13.2, 17.6, 18.4, 18.6, 18.9, 19.0, 
21.2, 28.8, 30.2, 52.7, 67.0, 113.8, 138.3, 168.4, 171.0, 174.0. 
 
2-Hydroxypropanoyl-dipeptide [(R)(S)(S)-83g] 
It was obtained following the general procedure 8 as solid (87%). 
1H NMR (CD3OD, 400 MHz) d 0.72 (d, 3H, J = 6.4 Hz), 0.79-0.82 (m, 9H), 
1.20 (d, 3H, J = 6.4 Hz), 1.75 (d, 3H, J = 1.2 Hz), 1.91-2.06 (m, 2H), 2.91 
(s, 3H), 4.02 (q, 1H, J = 6.4 Hz), 4.52 (dd, 1H, J = 6.9 and 9.0 Hz), 4.87 
(dd, 1H, J = 9.9 and 9.6 Hz), 5.8 (br, 2H), 6.62 (dd, 1H, J = 1.2 and 9.3 Hz), 
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7.58 (d, 1H, J = 8.2 Hz). 13C NMR (CD3OD, 400 MHz): d 13.2, 17.4, 18.5, 
18.7, 18.9, 19.2, 20.9, 28.9, 30.1, 52.9, 56.0, 56.1, 66.9, 113.9, 138.1, 168.4, 
171.1, 174.0.  
 
(S)-2-bromo-3-phenylpropanoic acid [(S)-90] 
It was prepared following the same procedure for [(S)-67] as solid 60%. 
1H NMR (CD3OD, 200 MHz): δ  3.18-3.30 (dd, 1H, J = 8, J = 10 Hz), 3.42-
3.54 (dd, 1H, J = 7.2, J = 10 Hz), 4.43 (t, 1H, J = 7.4 Hz), 7.18-7.38 (m, 
5H) 
13C NMR(CD3OD, 400 MHz): δ 39.1, 53.1, 125.9, 127.7, 128.6, 139.4, 
171.0 
 
(R)-2-bromo-3-phenylpropanoic acid [(R)-89] 
It was obtained following the same procedure for [(S)-67] as solid 60%. 
1H NMR (CD3OD, 200 MHz): δ 3.19-3.30 (dd, 1H, J = 8, J = 10 Hz), 3.42-
3.53 (dd, 1H, J = 7.2, J = 10 Hz), 4.43 (t, 1H, J = 7.4 Hz), 7.19-7.39 (m, 
5H) 
13C NMR (CD3OD, 200 MHz): δ 39.2, 53.2, 127.8, 126.0, 128.7, 139.5, 
171.1 
 
Bromoacyl-dipeptide [(S)(S)(S)-91] 
It was obtained following the general procedure 3, after chromatography 
purification. as an oil, 60% (Hexan/AcOEt 5/1): Rf = 0.2 
1H NMR (CDCl3, 400 MHz): δ 0.71 (d, 3H, J = 6.4 Hz), 0.86 (d, 3H, J = 6.4 
Hz), 0.94 (s, 9H), 1.30 (t, 3H, J = 7.2 Hz), 1.81-1.92 (m, 1H), 1.89 (s, 3H), 
2.94 (s,3H), 3.19-3.57 (dd, 2H, J = 8, 6.4 Hz), 4.19 (q, 2H, J = 7.2 Hz), 4.44 
(t, 1H, J = 6.4 Hz), 4.78 (d, 1H, J = 9.6 Hz), 5.06 (t, 1H, J = 9.6 Hz), 6.62 
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(d, 1H, 5.2 Hz), 6.84 (d, 1H, J = 9.2 Hz), 7.19-7.31 (m, 5H). 13C NMR 
(CDCl3, 400 MHz): δ 13.9, 14.3, 18.8, 19.5, 26.5, 30.0, 31.1, 36.2, 41.3, 
50.2, 55.3, 56.2, 60.9, 127.2, 128.6, 129.3, 132.9, 137.1, 138.2, 167.8, 
167.9, 171.0. 
 
Bromoacyl-dipeptide [(R)(S)(S)-91] 
It was obtained following the general procedure 3, affording the product as 
oil (60%) 
1H NMR (CDCl3, 400 MHz): δ 0.82 (d, 3H, J = 6.5 Hz), 0.86 (s, 9H), 0.88 
(d, 3H, J = 6.5 Hz), 1.30 (t, 3H, J = 7.2 Hz), 1.89 (s, 3H), 1.85-1.95 (m, 
1H), 2.97 (s, 3H), 3.13-3.54 (dd, 2H, J = 7.2-7.6 Hz), 4.19 (q, 2H, J = 7.2 
Hz), 4.39 (t, 1H, J = 7.2 Hz, 4.77 (d, 1H, J = 9.6 Hz), 5.09 (t, 1H, J = 5.6 
Hz), 6.63 (d, 1H, J = 9.2 Hz), 6.80 (d, 1H, J = 9.2 Hz), 7.19-7.32 (m, 5H). 
13C NMR (CDCl3, 400 MHz): δ 13.8, 14.3, 18.9, 19.5, 26.4, 30.0, 31.1, 
35.6, 41.7, 50.0, 55.4, 56.2, 60.9, 127.3, 128.6, 129.3, 132.9, 137.1, 138.3, 
167.8, 168.1, 171.1 
 
Tripeptide ethyl ester[(S)(S)(S)-92] 
It was obtained following the general procedure 7, Rf (Hexan/AcOEt 3/1) 
0.20 as solid (85%) 
1H NMR (CDCl3, 400 MHz): δ 0.81 (d, 3H, J = 6.8 Hz), 0.88 (d, 3H, J = 6.4 
Hz), 0.98 (s, 9H), 1.19 (t, 3H), 1.29 (s, 6H), 1.93 (s, 3H), 1.85-1.95 (m, 1H), 
2.55 (dd, 1H, J = 4, J = 9.2 Hz), 2.99 (dd, 1H, J = 4, J = 10 Hz), 3.05 (s, 
3H), 3.13 (dd, 1H, J = 4, J = 5.6 Hz), 4.21 (q, 2H, J = 7.2 Hz), 4.80 (d, 1H, 
J = 9.6 Hz), 5.13 (t, 1H, J = 10 Hz), 6.67 (d, 1H, J = 9.6 Hz), 7.01 (m, 4H), 
7.11 (m, 3H), 7.21 (m, 3H), 8.31 (d, 1H, J = 9.6 Hz). 13C NMR (CDCl3, 400 
MHz): δ 14.1, 14.3, 19.0, 19.5, 25.2, 26.6, 29.8, 29.9, 31.3, 35.6, 40.6, 54.2, 
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56.0, 56.2, 59.0, 60.9, 125.4, 126.3, 126.9, 128.2, 128.8, 129.4, 132.6, 
137.2, 138.8, 146.9, 167.9, 171.1, 175.4 
 
Tripeptide ethyl ester [(R)(S)(S)-92] 
It was obtained following the general procedure 8, as solid 85%. 
1H NMR (CDCl3, 400 MHz): δ 0.80 (d, 3H, J = 6.4 Hz), 0.87 (d, 3H, J = 6.4 
Hz), 0.99 (s, 9H), 1.26 (t, 3H), 1.30 (s, 6H), 1.82-1.95 (m, 1H), 1.93 (s, 3H), 
2.49 (q, 1H, J = 4, J = 9.6 Hz), 2.89 (dd, 1H, J = 4, J = 9.6 Hz), 3.02 (s, 
3H), 3.20 (dd, 1H, J = 4.4, J = 5.2 Hz), 4.20 (q, 2H, J = 7.2 Hz), 4.79 (d, 
1H, J = 10 Hz), 5.13 (t, 1H, J = 10 Hz), 6.64 (d, 1H, J = 8 Hz), 6.94-7.26 
(m, 10H), 7.95 (d, 1H, J = 9.6 Hz). 13C NMR (CDCl3, 400 MHz): δ 13.9, 
14.3, 18.9, 19.5, 26.5, 26.7, 30.0, 31.1, 31.2, 35.4, 40.354.9, 55.9, 56.1, 
58.8, 60.9, 125.4, 126.4, 126.8, 128.2, 128.8, 129.4, 132.7, 137.2, 138.5, 
146.9, 167.9, 171.7, 175.6 
 
Tripeptide TFA salt [(S)(S)(S)-93] 
It was obtained following general procedure 8, as a solid (95%). 
1H NMR (CD3OD, 400 MHz): δ 0.83 (s, 9H), 0.88 (d, 3H, J = 6.4 Hz), 0.93 
(d, 3H, J = 6.4 Hz), 0.94-1.01 (m, 1H), 1.68 (s, 3H), 1.77 (s, 3H), 1.87 (s, 
3H), 1.85-2.00 (m, 1H), 3.00 (s, 3H), 2.91-3.01 (m, 1H), 3.45-3.52 (m, 1H), 
4.72 (d, 1H, J = 8.4 Hz), 5.00 (t, 1H, J = 10 Hz), 6.48 (d, 1H, J = 10 Hz), 
6.55 (d, 1H, J = 9.2 Hz 6.67 (d, 1H, J = 6.8Hz), 6.74 (d, 1H, J = 8.8 Hz), 
6.83 (m, 2H). 7.15-7.25 (m, 3H), 7.33-7.37 (m, 3H), 7.41-7.46 (m, 2H). 13C 
NMR (CD3OD, 400 MHz): δ 13.7, 18.9, 19.3, 19.6, 20.4, 24.4, 26.4, 26.6, 
27.8, 29.8, 31.6, 35.3, 37.8, 56.2, 57.1, 58.9, 62.3, 63.1, 126.2, 126.4, 127.8, 
128.8, 128.9, 129.1, 129.2, 129.5, 131.9, 134.5, 138.8, 139.9, 162.0, 169.2, 
170.9. 
 Hemiasterlin: cexperimental section 
93 
Tripeptide TFA salt [(R)(S)(S)-93] 
It was obtained following the general procedure 8, as solid (95%) 
1H NMR (CD3OD, 400 MHz): δ 0.61 (s, 9H), 0.85 (d, 3H, J = 6.4 Hz), 0.90 
(d, 3H, J = 6.4 Hz), 0.95-1.02 (m, 1H Hz), 1.58 (s, 3H), 1.84 (s, 3H), 1.87 
(s, 3H), 1.88-2.01 (m, 1H), 3.01 (s, 3H), 2.94-3.03 (m, 1H), 3.11-3.19 (m, 
1H), 3.55-3.61 (dd, 1H, J = 4.8 Hz), 4.61 (d, 1H, J = 8.4 Hz), 5.05 (t, 1H, J 
= 10 Hz), 6.43 (m, 1H), 6.74 (d, 1H, J = 10 Hz), 6.78-6.81 (m, 2H), 7.13-
7.21 (m, 3H), 7.37-7.47 (m, 3H), 7.57-7.61 (m, 2H). 13C NMR (CD3OD, 
400 MHz): δ 13.7, 19.0, 19.4, 26.1, 26.5, 28.6, 29.7, 31.3, 34.8, 37.8, 56.7, 
57.2, 58.7, 63.3, 126.4, 127.9, 129.0, 129.3, 129.5, 129.6, 132.0, 134.3, 
138.1, 139.4, 161.7, 170.9, 171.3 
 
 
(S)-ethyl (3-(2-(tert-butoxycarbonylamino)-3,3-
dimethylbutanamido)benzoate [(S)-85] 
It was obtained following the general procedure 1 as oil (73%) after 
purification (Hexan/AcOEt 2:1). 
Rf (Hexan/AcOEt 2:1) 0.5, m/z (ES+): 432 [M+H] 
 
1H NMR (CDCl3, 400 MHz): δ 0.79 (s, 9 H), 1.32-1.43 (m, 9H), 4.36 (q, 
2H, J = 7.2 Hz), 5.2 (d, 1H), 7.23 (s, 1H), 7.7 ( m, 2H), 7.9 (m, 1H),  8.03 
(s, 1H), 8.13 (d, J = 2 Hz, 1 H) 
13C NMR (CDCl3, 400 MHz): δ 13.8, 25.8, 28.4, 45.1, 60.8, 66.8, 79.5, 
119.5, 124.1, 127.4, 133.7, 137.1, 156.0, 164.1, 172.0, 185.6. 
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(S)-ethyl 3-(2-amino-3,3-dimethylbutanamido)benzoate [(S)-85a] 
It was obtained following the general procedure 2 as oil ( 90%). 
1H NMR (CDCl3, 400 MHz): δ 0.98 (s, 9 H), 1.29 (t, 3H, J = 7.2 Hz), 4.36 
(q, 2H, J = 7.2 Hz), 5.2 (s, 1H), 7.23 (s, 1H), 7.7 (dd, 1H), 7.9 (dd, 1H), 8.03 
(d, 1H), 8.13 (d, J = 2 Hz, 1 H), 9.02 (bs, 2H). 
13C NMR (CDCl3, 400 MHz): δ 13.8, 25.8, 28.4, 45.1, 60.8, 73.2, 119.5, 
124.1, 127.4, 133.7, 138.1, 144.7, 164.1, 172.0, 185.6. 
 
 [(R,S)(S)-86] bromo-acyl-peptide. 
It was obtained following the general procedure 3 as oil (80%) after 
purification (Hexan/AcOEt 2:1) 0.48 
1H NMR (CDCl3, 400 MHz): δ 0.98 (s, 9 H), 1.29 (t, 3H, J = 7.2 Hz), 1.97 
(d, 3H), 4.36 (q, 2H, J = 7.2 Hz), 5.2 (s, 1H), 7.23 (s, 1H), 7.54 (dd, 1H), 
7.8-8.3 (m, 2H), 8.03 (s, 1H), 8.3 (d, J = 2 Hz, 1 H) 
13C NMR (CDCl3, 400 MHz): δ 14.1, 22.0, 25.8, 35.2, 45.6, 60.9, 64.6, 
120.6, 125.5, 128.8, 130.3, 141.4, 165.9, 172.0, 175.4.  
 
[(R,S)(S)-87] tripeptide  
It was obtained following the general procedure 7 as oil (78%) 
1H NMR (CDCl3, 400 MHz): δ 0.94 (s, 9H), 1.27-1.29 (m, 9H), 2.0 (s, 1H), 
3.74 (m, 1H), 4.30 (q, 2H), 4.51 (s, 1H), 7.23-7.37 (m, 6H), 7.54 (d, 1H), 
7.82 (m, 1H), 8.03 (s, 1H), 8.29 (d, 1H). 
13C NMR (CDCl3, 400 MHz): δ 14.1, 24.0, 25.8, 32.0, 35.2, 56.8, 60.9, 
65.3, 120.6, 125.9, 126.1, 128.4, 130.3, 141.4, 144.6, 165.9, 171.7 
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[(R,S)(S)-88] Tripeptide salt. 
It was obtained following the general procedure 8 as white solid (55%). 
1H NMR (CD3OD, 400 MHz): δ 0.97 (s, 9H), 1.42 (d, 1H), 1.73 (s, 3H), 
1.73 (s, 3H), 3.9 (m, 1H), 7.2 (t, 1H), 7.2 (t, 2H), 7.48-7.52 (m, 3H), 7.82 
(m, 2H), 8.31 (d, 1H). 
13C NMR (CD3OD, 400 MHz): δ 18.97, 25.8, 35.2, 54.5, 56.9, 65.3, 120.6, 
125.9, 126.1, 128.4, 130.3, 130.6, 133, 138.8, 140.0, 165.9, 170.3, 170.7 
m/z (ES+): 440 [M+H] 
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9. Microtubules depolymerization inducing agents 
 
9.1.  Epothilones 
Epothilones are a family of macrocyclic poliketides, isolated from the 
culture broth of the myxobacterial strain Sorangium cellulosum SoCe90, 
which was found in soil samples collected along the Zambezi River in 
Africa.1 
This class is represented by the natural epothilones A and B, discovered as 
antifungal agents by Höfle and Reichenbach. 
They became interesting when Bollag et al. in 1995 reported that they had 
the same mechanism of action of paclitaxel, stabilizing the tubulin polymers 
and causing apoptotic cell death.2 
 
 
Figure IX-1. Structure of Epothilones A and B. 
 
Despite the structural difference between taxol and epothilones, it was 
observed a competitive pattern of inhibition by epothilone A and B on the 
binding of paclitaxel to polymer formed with purified tubulin.  
Epothilone B was the most effective compound in inducing assembly of 
tubulin polymers, while the potency of Epo A was similar to that of 
paclitaxel.3  
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The epothilones seem to have different potential advantage in comparison to 
Taxol®. 
First of all, epothilones have a simpler structure, that is adapt to be easily 
manipulated both in total synthesis and in the synthesis of analogues for 
structure-activity relationship (SAR) studies. This wasn’t possible for taxol 
because of its complex structure.4 
Even more interestingly, epothilones A and B retain their activity also in 
PgP-overexpressing taxol-resistant cancer cells-lines.5  
Taxol was scarcely soluble, it was administered together with vehicles such 
as Cremophor EL (polythoxylated castor oil), which is responsible of 
cardiac problems and cause severe hypersensitivity responses.3  
Whereas, epothilones have a higher water solubility, which suggest the 
possibility of an easier formulation.  
Several research groups have started a synthetic exploration, which led 
quickly to the total synthesis of epothilones A and B.6-9 
Resolution of the trickiest key step of the synthetic route allowed 
extensively SAR studies, in order to find analogs with a better 
pharmacological profile. 
 
Table IX-1. Inhibition of human carcinomas cell lines by taxol, EPO A, Epo B. 
Cell lines  IC50 [nM] 
 Taxol  Epo A  Epo B 
HCT-116 (colon) 2.79 2.51 0.32 
PC-3M (prostate) 4.77 4.27  0.52 
A549 (lung) 3.19 2.67 0.23 
MCF-7 (breast) 1.8 1.49 0.18 
NCI-ADR[a,b] 9105 27.5 2.92 
KB-31 (cervix) 2.31  2.1 0.19 
KB-8511[b,c] 533 1.9 0.19 
[a]Multi-drug resistant cell-lines. [B] Multiple resistance 
mechanisms/MDR. [C] P-gp overexpression/MDR. 
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In this last years, a huge number of different epothilones have been 
synthesized, and tested in several cancer cell lines.3 
The previous table (Table IX-1) shows human carcinoma cell growth 
inhibition data of the Epo A and B in comparison with taxol. 
 
9.2. Structure and SAR of epothilones  
The epothilones chemical structure is characterized by a poliketide core 
featuring a 16-membered lactone, a ketone at position 5, and an aromatic 
side chain attached at C15 of the core ring. The compounds were termed 
“epothilones” by Reichenbach and Höfle to reflect their structural features, 
which includes an epoxide moiety, a thiazole-containing side chain, and a 
single keto(ne) function.3 
So far, six natural epothilones have been discovered (Epo A-F) that have 
been considered as starting point for further structural modifications.  
Both the importance of the macrolactone ring substitution pattern and 
stereochemistry for biological activity have been extensively investigated in 
the context of SAR studies, as well as many modifications of the side 
chain.3 
 
 
Figure IX-2. Structures of Epothilones C, D, E, F. 
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9.2.1. C12-C13 modifications 
The epoxide moiety at C12-C13 of the macrolactone ring was object of 
wide interest for SAR study and analyzing deoxyepothilones (Epo C and 
D), it was found that their biological activity is similar to that of the parent 
compounds. 
Efforts have been made to explore the effect of modifications at position 
(C26)10; some of the smaller substituents (ethyl, halomethyl) produced 
activities comparable with epothilones B, while large or polar groups 
proved to be detrimental.11 
Moreover, Epo C and D microtubules stabilization efficiency and the potent 
human cancer cell growth inhibition don’t depend on the presence of an 
epoxide moiety, conversely to previous beliefs about its important role as 
hydrogen-bond acceptor in the binding to tubulin.12 
Since the most active epoxide derivatives have a trans geometry, several 
analogs were synthesized bearing small rings such as a cyclopropane fused 
at the C12-C13 bond with the macrocyclic core.  
The new compounds are equipotent with the epoxide-derived natural 
product (for example, IC50 values against cell line HCT-116 are 1.4 nM for 
7 and 0.7 nM for 8, compared with 4.4 nM and 0.8 nM for Epo A and Epo 
B, respectively).3 
This result suggests that the contribution of the epoxide moiety is mainly 
conformational-type and serve to stabilize the proper bioactive 
conformation of the macrolactone ring.13 
The activity of the trans- cyclopropane derivatives of Epo A and its analogs 
makes them promising compounds. 
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Figure IX-3. Cyclopropane analogs of Epothilone A and B.  
 
9.2.2. Side chain modifications 
The aromatic side chain is the most obvious site for structural modifications 
of epothilones, because it doesn’t involve the macrocycle believed crucial 
for the activity. 
The thiazole ring in Epo A-D and in cyclopropanated Epo A and B has been 
replaced by other heterocycles or simple phenyl groups, and the synthesis of 
C16-desmethyl Epo B.3  
Modifications have been also involve the methyl group on the thiazole, 
while small substituents such as hydroxymethyl14, aminomethyl, 
fluoromethyl, methylthio15, or ethyl are well tolerated, bulkier substituents 
cause a significant loss in potency.16 Moreover, the natural stereochemistry 
at C-15 is preferred.17 
The atom of sulphur was found not necessary for biological activity as well 
as the presence of a five-membered heterocycle at C-16, while six-rings 
members are well tolerated such as pyridine.17 
Based on this SAR data, Epo D analogs provided with a benzoheterocycle 
(9, 10) were prepared, whose cellular activity is higher in those with the 
nitrogen in natural position.18 
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Figure IX-4. Analogs of Epo D bearing a benzoheterocyclic side chain, and 
pyridine Epo B analogs. 
 
The benzoheterocyclic analogs derives from the observations that in the 
bioactive conformation of epothilones, the torsion angle about C16-C17-
C18-N portion of the molecule is 180° and the consequent inclusion of this 
part in a rigid structure, as the bicyclic side chain should be tolerated.19 
 
9.2.3.  C1-C5 and C6-C11 fragment modifications.  
This part of the macrocycle has been investigated in order to understand the 
importance of the hydroxy group at C-3 (11) and its stereochemistry, that 
can’ t be inverted, because of the lack of activity.20 
 
 
Figure IX-5. C3-deoxy-Epo B. 
 
SAR investigations established that changes of stereochemistry or 
substitution pattern at C8 or simultaneous inversion of the stereochemistry 
at both C6 and C7 lead to a lack of biological activity.17 
Generally, C6-C11 fragment is unchanged, apart an interesting derivative 
(12) that is in phase III of clinical trial (ZK-EPO).22 
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Figure IX-6. Structure of C-6 allylated Epo B derivative, ZK-EPO. 
 
This C-6 allylated compound has been considered as a model for our project 
on benzothiazole analog synthesis. 
 
9.2.4.  Epothilones in clinical trials  
Among all epothilones analogs, only a small numbers of derivative are in 
clinical trials. 
At the moment the most advanced of these compounds is the lactam analog 
of Epo B, Ixabepilone, which received FDA approval for the treatment of 
metastatic breast cancer in 2007 and marked under the trade name Ixempra 
®, by Bristol Mayer Squibb.3 
Clinical evaluation of this drug is going for a large number of prostate, 
pancreatic and ovarian cancer. 
Epothilone B (patupilone), developed by Novartis is at an advanced stage of 
clinical trials against ovarian cancer cells (phase III). 
Epothilone D has entered clinical trials supported by Kosan –Roche (Kos-
862) but when it was at II phase, the company chose to interest to an 
unsaturated epothilones D analog (Kos-1584), which is in phase I of 
investigation for breast cancer.3 
Sagopilone, (ZK-EPO) is a fully synthetic epothilones analog developed by 
Bayer-Schering pharma, and is currently undergoing in phase II clinical 
trials for a number of malignancies, including prostate, ovarian, and lung 
cancer and melanoma.22  
  
 Epothilones: introduction 
107 
 
 
 
 
 
 
 
 
 
Chapter 10 
Scopes and aims
 
Epothilones: scopes and aims  
 
108 
10. Project aims 
 
10.1.  Synthetic approaches to an epothilone B analogue provided 
with tumor targeting moiety. 
 
Conventional cytotoxic therapies of cancer often suffer from a lack of 
specificity, as they present low therapeutic index and considerable toxicity 
to healthy organs. 
A new approach to overcome this disadvantage is the selective delivery of 
drugs to the tumor site by their conjugation to an antibody (carrier) 
molecule specific for a tumor-associated molecular marker, as the tumor 
vasculature expresses markers, attractive targets for a site-specific 
pharmacodelivery through blood flow.23 
Recent research in this field, has demonstrated that the construction of in 
vivo active conjugates between tumor specific antibodies and cytotoxic 
agents requires the latter to have in vitro potency in the sub-nM range. 
 
Thanks to SAR information we know that not all modifications are 
compatible with the retention of cytotoxic activity of epothilones .3, 10-21 
Moreover, aware of the clinical trials progresses of ZK-EPO (12), the group 
of Prof. Altmann, in which I spent a period of 9 months as visiting Ph. D. 
student, has designed a benzothiazole analog of Epo B. 
It is provided with a functional “handle” (Fig. X-1, red chain)for antibody 
conjugation, in which the natural 12,13-epoxide moiety has been replaced 
by a cyclopropane ring. 
This modification eliminates potential problems of chemical and/or 
metabolic stability linked to the epoxide functionality; indeed, the 
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cyclopropane doesn’t lead to any loss of antiproliferative activity.3 The 
replacement of thiazole with benzothiazole leads to enhanced in vitro 
activity, the most important requirement for the construction of antibody-
drug conjugates (ADCs). 
In fact, ZK-EPO shows a mean IC50 value below 1 nM in antiproliferative 
test on different human tumor cell lines.22  
It is reported to be more active than parental compound Epo B against a 
variety of drug sensitive cancer cells and to overcome the problem linked to 
resistance P-gp-mediated in some kind of tumor.22 
 
Figure X-1. From Epo B, through ZK-EPO to target compound 13. 
 
It was thought to introduce a hydroxyethyl side chain at position 2 of the 
heterocyclic core, that is expected to be tolerated. Indeed, benzothiazole-
base epothilones analogs with substituents different from methyl group in 
this position have never been investigated. 
It is important to notice that the handle is not bulky, since we don’t know 
anything about the effect of additional volume. 
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Although the final compound 13, shows 3 hydroxyl groups, only the 
primary alcohol will be used for the linkage, given that the other two are 
quite hindered. 
In the following scheme is represented the structure of the conjugate 
between the carrier and the epothilone linked together by means of an 
opportune linker; in this context it hasn’t been explained the nature of this 
linker, as the scope of my project is strictly limited to the synthesis of the 
intermediate 15. 
 
  
 
 
Figure X-2. Scheme of antibody tumor targeting as therapeutic approach. 
 
10.2. Retrosynthetic analysis 
The inclusion of C16-C18 olefin double bond in a six-membered aromatic 
ring which also incorporated C17, C19 and C22 of the original epothilones 
structure, led to a coplanar arrangement between these two moieties 
reducing the conformationally entropy of the heterocycle side chain.  
A highly convergent strategy was followed that allowed us to introduce 
structural modification at every position of the 16-membered ring 
macrocycle. 7, 10, 24, 
The introduction of the hydroxyethyl side chain at position 2 of the 
benzothiazole mandated the synthesis of the heterocycle to occur at the very 
beginning of the synthetic route.  
Moreover, Charette cyclopropanation25 of the C12-C13 double bond, 
requiring the presence of an allylic alcohol 22 to occur, took place before 
macrocycle Heterocyclic 
core 
Linker antibody 
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ring closure metathesis reaction (RCM) in the west-northern part of the 
molecule.26  
It was observed, that the cyclopropanation on C-12 desmethyl analog is 
highly stereoselective, providing the desired cyclopropane as single isomer, 
but the presence of an additional methyl group C2 at the double bond, 
caused the decrease of the selectivity.26 
A ratio of both possible products in the range of 15:1 is considered 
acceptable to go toward the target  molecule 13. 
 
 
Scheme X-1 Retrosynthetic analysis of 13: disconnections into two building 
blocks. 
 
Worst situation would lead us to give up with the synthesis of 13; in this 
context is the meaning of my project.  
Two crucial disconnections of the macrocyclic core allowed 14 and 15 to be 
traced back to two primary building blocks (scheme X-1). 
Building block 16, which contains the heterocycle provided with the side 
chain, will be coupled with 15 through a Yamaguchi esterification after 
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selective deprotection of the secondary alcohol at C15 and hydrolysis of 
methyl ester at C1.20 
The synthesis is accomplished with the cleavage of the two silyl ethers on 
O3 and O7 and of the side chain protecting group.26 
As we need the primary alcohol at the very end of the synthetic route, for 
the linkage with antibodies, we decided to employ a different protecting 
group from the others at C3 and C7. 
Building block 16 with its three stereocenters at C6, C7 and C8 might be 
accessed by a stereoselective aldol reaction of the known Schinzer ketone24, 
27
 21 and a chiral aldehyde28 20 as the key step: this was followed by a 
series of functional group manipulation to provide carboxylic acid in 57% 
overall yield from aldol product (scheme X-2). The synthesis of building 
block 16, was performed in prof. Altmann research group. 29 
 
Scheme X-2. Retrosynthetic analysis of building block 16. 
 
The allylic alcohol 22 is the result of Still-Gennari olefination on the 
aldehyde 23. 
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Apart the cyclopropanation, other key steps have characterized the 
achievement of 15. 
First of all, the synthesis of the heterocyclic core 22 bearing the 
hydroxyethyl side chain, was required to be high yielding and possibly 
adapt to be scaled-up (g-quantities). 
All attempts to get the benzoheterocycle functionalized 22, 30 have been 
made starting from only one precursor, 4-chloro-3-nitro benzoic acid 24. 
The introduction of the chiral centre at C15 of 22, was a challenge and it 
was planned as an enantioselective reaction of the achiral aldehyde; on 
purpose several methods were available. 
At first, we tried with asymmetric allylation reactions,31, 32 but because of 
the lack of selectivity, Evans chiral auxiliaries were employed in a 
stereoselective aldol reaction (scheme X-3). 
 
 
Scheme X-3. Retrosynthetic analysis of building block 15. 
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11. Results and discussion 
11.1 Synthesis of heterocyclic core 
11.1.1  First synthetic approach 
The synthesis of the benzothiazole core provided with hydroxyethyl side 
chain at position 2 started from commercially available 4-chloro-3-nitro-
benzoic acid 25.22 The heterocycle 26 was obtained heating together 25 and 
sodium sulfide nonahydrate, followed by quick addition of mixed acetic 
formic anhydride in a nucleophilic aromatic substitution reaction of chlorine 
ion. 
This reaction was performed to 60% yield (1 gram scale) working under 
argon atmosphere, because in situ prepared mixed anhydride was found 
easily hydrolysable.  
After protection of the acid moiety as methyl ester 27, none of the 
formylation attempts at position 2, afforded the aldehyde 28 that would 
have afforded monosubstituted olefin 29, by hydroboration.33 
 
 
Scheme XI-1. Reagents and conditions: (i) Na2S nonahydrate, acetic formic 
anhydride, CH3COOH, 120°C, 60%; (ii) H2SO4, MeOH, 65°C, 98%; (iii) THF, n-
BuLi 1.6 M in hexan, -78°C, 1h, DMF, -78°C to r.t. or (iv) THF, n-BuLi 1.6 M in 
hexane, -78°C to -50°C, 27, -78°C. 
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Direct formylation of 27 was tried following two general procedures 34a,b 
that differ each other in both addition order and number of equivalents of 
reagents, but was unsuccessfully (Scheme XI-1). 
 
11.1.2. Second synthetic approach  
This approach was based on the direct oxidation of the methyl group of 2-
methylbenzo[d]thiazole-5-carboxylate 31.34, 35 
 
 
Scheme XI-2. Reagents and conditions: (i) Na2S nonahydrate, CH3COOH, acetic 
anhydride, 120°C, 2h, 60%; (ii) H2SO4, MeOH, reflux, overnight, 98% ; (iii) SeO2, 
CH3COOH, reflux, 4 h, 50%; (iv) base, CH3PPh3Br, THF; (v) (1) 9-BBN 0.5 M 
THF, 0°C to r.t. overnight, (2) H2O, NaOH 4N, 30% H2O2; (vi) (1) BH3·  SCH3, 
THF, -10°C to 0°C, 2h; (2) 2M NaOH, H2O2 30% 
 
Intermediate 31 has been obtained following the procedure described in the 
scheme XI-1, employing acetic anhydride in place of mixed acetic formic 
anhydride.  
It is worth noting that on large scale (from 5 to 15 grams) the yield 
decreases detrimentally, probably because of the formation of a slurry 
mixture in which the product is trapped, during the work up. 
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Indeed, a by-product due to nitro group reduction, 3-amino-4-chlorobenzoic 
acid represented 50% of the crude product, difficult to separate in the 
chromatography purification. 
The aldehyde 28 was reacted with non-stabilized ylide, prepared treating the 
methyl triphenylphosphonium salt with a strong base under inert conditions. 
We noticed that even changing kind of base (LiHMDS, NaH, and n-
BuLi)36,28 the yield of Wittig reaction was always around 20-50%, despite 
the complete consumption of starting material. 
The best outcome (yield 50 %) was related to a quick filtration of the crude 
on a small pad of silica gel, in order to avoid possible degradation of the 
product. 
The evidence of its instability was confirmed by literature data, that 
described the low yield (36%) of the of 2-vinylbenzo[d]thiazole.37 
However, the negative outcome of the next hydroboration step, using both 
BH3·SMe2 and 9-BBN, have made us to give up further olefination reaction 
trials (scheme XI-2).36, 38 
 
11.1.3.  Third synthetic approach 
The third attempt was based on the direct elongation of the methyl group, 
heating together, at 165°C in an oil bath, 31 and paraformaldehyde in a 
sealed microwave vial.39 
Although the desired product was achieved in low yield (18%), the bright 
side of this reaction was the complete recovery of unreacted starting 
material by chromatography. 
Thus, at this stage of the synthetic route, substantial amount of compound 
30 derived from as series of parallel reactions on 1 gram scale of 31. 
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It was observed that higher amount of starting material 31 was detrimental 
also in term of isolation of the product, because of a “glue” formation 
difficult to solve with common chromatographic solvent and consequently 
to purify. 
Whereas a base-(LDA) mediated reaction of 31 with paraformaldehyde 
failed completely in affording the hydroxyethyl derivative (scheme XI-3).40 
 
 
 
Scheme XI-3. Reagents and conditions: (i) (HCHO)n, 165°C, 3h, 18% (ii) (1) 
LDA, THF; (2) DMF, (3) MeOH, acetic acid, NaBH4; (iii) (1) LDA 2M THF, (2) 
(HCHO)n, THF. 
 
11.1.4.  Fourth synthetic approach 
The fourth synthetic approach was devised on the condensation of benzoic 
acid 3-amino-4-mercapto methyl ester 32 with in situ prepared 
propionaldehyde by oxidation with PCC of the correspondent 1,3-
propanediol 36. 41  
As, the isolation of the intermediate 32 from the melted mixture between 25 
and sodium sulfide was hardous, it was employed in the next reaction 
without any characterization (scheme XI-4). 42 
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Scheme XI-4. Reagents and conditions: (i) Na2S nonahydrate, 120°C, 2h; (ii) 
H2SO4, MeOH, reflux, overnight, 98%; (iii) Na2S nonahydrate, 120°C, 2h, slow 
addition of MeOH, solution A: 1,3-propandiol 36, PCC, DDQ 
 
11.1.5.  Fifth synthetic approach 
The 1,3-propanediol 36, was also the starting material of the fifth synthetic 
approach, in which opportunely monoprotected 3-hydroxypropanoic acid 
37a-b was coupled with methyl 3-amino-4-chlorobenzoate 39 to afford the 
correspondent amide 40a-b.  
 
Scheme XI-5. Reagents and conditions: (i) SnCl2, MeOH, reflux, 1h, 90%; (ii) 
NaH 60% min. oil, THF, 0° C, BnBr, TBAI, r.t., 2h, 90% or (iii) NaH 60% min. oil, 
THF, 0°C, 1h, p-CH3OBnCl, TBAI, 0°C to r.t. 2h, 25% (iv) Jones reagent 1.26 M, 
acetone, 0°C; (a) 76%, (b) 36%; (v) SOCl2, DMA, 0°C, r.t. overnight, (a)79%, (b) 
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11.1.6.  Choice of the best protecting group 
Since we need hydroxyethyl moiety at the very end of the synthetic route, 
for the linkage with antibodies, we decided to distinguish alcohols in the 
molecule, choosing PMB for primary alcohol, and TBS for secondary 
alcohol, at the future C15 position of the epothilones macrocycle. 22,26 
We have also chosen TBS, with the aim not to change the reactivity of this 
molecule portion, before the key step of Charette cyclopropanation, which 
is known to work with TBS protected alcohol, as reported in literaure.26 
Unfortunately, in the new synthetic route, PMB monoprotected propandiol 
37b was found incompatible with Jones oxidation conditions to get 38b, 
since it is removed in oxidative environment by DDQ; moreover, the yield 
of thiation reaction was very low (18%).43 
Otherwise, before trying this new approach (schemes XI-3 and XI-6), 
alcohol 30b obtained as shown in the scheme XI-3, was protected with 
PMB via imidate in moderate yield (56-60 %).44 
Intermediate 30b, was used to explore the whole synthetic route until the 
cyclopropanation step. 
 
 
Scheme XI-6. Reagents and conditions: (i) PMB imidate, PPTS, DCM, r.t., 24 h, 
60%  
 
11.1.6.1. Benzyl side chain protection 
A good alternative was the benzyl protecting group 30a, that could be 
removed at the end of the synthetic route. 
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We will have to verify if its cleavage conditions keep intact the 
cyclopropane from the ring opening. 
The amide 40a was changed into the thioamide 41a with Lawesson’s 
reagent that is a mild and convenient thionating agent for ketones. 
 
 
Scheme XI-7. Reagents and conditions: (i) Lawesson’s reagent , dioxane, reflux, 2 
h, 81%, (ii) NaH 60%, NMP,160°C, 1h, 72% 
 
Thus, only the benzyl protected derivatives afforded the desired heterocycle 
30a in good yield 72% and in large amount (scheme XI-7).45 
Reaction time longer than one’s due, gave the unsubstituted olefin at the 
side chain, main product against our expectations, instead of 30a.42 
An excess of cheap 1,3-propandiol has been required to afford the 
monoprotected alcohol 37a, as the main product over dibenzylated 
derivative, obtained following other procedures, in which equimolar 
amounts of diol and benzyl bromide were used.46 
The acid 38a was coupled with the correspondent aromatic amine 39 in 
presence of condensing agents like CDI (entry 2, table XI-1) or EDCI (entry 
1, table XI-1).47, 48 
High yields were obtained when the acid was activated as acyl- derivative 
and dimethylacetamide was employed instead of dichloromethane (entry 5, 
table XI-1).42,49 
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Entry Acid (eq) Amine (eq) Conditions 
1 1 1 EDCI, 1-HOBT, DMAP, DMF 
2 1 1 CDI, THF 
3 1 1 Oxalyl chloride, DCM 
4 1.1 1 Oxalyl chloride, TEA, DMF (drops) DCM 
5 1 1 SOCl2, DMA 
Table XI-1. Conditions of coupling reaction.  
 
11.2.  Synthesis of the homoallylic alcohol. 
Intermediates 30a-b have been reduced and the correspondent primary 
alcohols 42a-b were oxidized to aldehydes 24a,b by Swern oxidation.50 
Our main goal was the enantioselective allylation of the aldehyde 30b 
followed by ozonolysis, that would have furnished the precursor for 
Charette cyclopropanation, after a sequence of Still-Gennari 
olefination/reduction of the α,β-unsaturated ester. 26 
The aldehyde 24b was allylated following Keck conditions, that might have 
achieved high level of enantioselectivity, employing catalytic amount of a 
chiral Lewis acid, prepared by addition of trifluoromethanesulfonic acid to a 
mixture of (S)-binaphtol and titanium tetraisopropoxide.31 
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Scheme XI-8. Reagents and conditions: (i) DIBAL-H 1M DMC,DCM, -78°C; 1½ 
h, 72% (ii) DMSO, oxalyl chloride, TEA, -78°C to r.t., 87%; (iii) allyltri-n-
butylstannane, (S)-BINOL, Ti(OiPr)4, CF3SO3H, DCM, -78°C, 60 h, 52%; (iv) (1) 
solution A: C3H5MgBr, (-)-IPc2BCl, Et2O, -78°C to r.t., slow addition of solution A, 
-100°C, 54%; (2) Ethanolamine, MeOH; (v) Triethylborane, 1M hexane, CF3SO3H, 
DIPEA, DCM, 2h,-78°C 
 
Unfortunately, the enantioselectivity of this reaction was limited, giving the 
product 43 as a racemic mixture. 
For this reason, Brown (-)-β-allyldiisopinocamphenylborane has been 
employed as chiral ligand to install the asymmetric centre at C15 (scheme 
X-8).32 
Better results, only in terms of selectivity (ee 75%, in favour of the desired 
enantiomer), were obtained from Brown allylation, because the low yield 
was always variable from trial to trial. 
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However, the moderate value of enantiomeric excess, measured by Mosher 
ester analysis, wasn’t satisfactory in the perspective to arrive at 
cyclopropanation, possibly with only one enantiomer, given that the 
selectivity of this key step is unpredictable on this substrate.51 
The ee of 43 decreased from 75% to 50% when dichloromethane was used 
as reaction solvent under alternative Brown’s conditions (other solvent were 
allowed, such as dichloromethane, THF, chloroform, in place of the diethyl 
ether).32 
The low solubility of 30b in ethylic ether was thought to be related to the 
lipophilic nature of protecting group (PMB). Thus, a more polar one was 
chosen for the hydroxyethyl moiety (30).52 
TBS-protecting group was easier to install than PMB, but it wasn’t resistant 
to Swern oxidation condition, because of HCl produced during the reaction, 
that cleaved the protection of this primary alcohol. 
 
11.2.1.  Diastereoselective aldol reaction 
We tried to obtain the product as mixture of diastereoisomers easily 
separable, through a stereoselective aldol reaction. 
Our first approach made use of the boron enolate of the acetylated 
Oppolzer’s camphor sultam, a chiral auxiliary. 
Its reductive cleavage (45), after silylation of the alcohol, would have afford 
the aldehyde 23 ready to be used for the following Still- Gennari olefination 
(scheme XI-8).53  
After several unsuccessful attempts in term of yield, we decided to exploit 
Evans oxazolidinone chemistry. 
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They are a class of oxazolidinones substituted at 4 and 5 position and thanks 
to their steric hindrance, they direct any aldol reaction to the α position of 
the carbonyl of the substrate (scheme XI-10).54  
Structurally different oxazolidinones were acetylated with the aim to find 
the best combination Lewis acid/chiral auxiliary that could ensure high 
level of diastereoselectivity or lead to a mixture of separable 
distereoisomers, (table XI-2).55 
 
11.2.1.1.  Evans aldol reaction  
The potentiality of the aldol reaction is the highly stereoselective C-C bond 
formation. 
This reaction proceeds via enolate, using a Lewis acid and a weak base as 
di-n-butylborontriflate/ DIPEA 36 or DIPEA /TiCl4.37  
For example, the reaction of an achiral aldehyde with (Z)-boron enolate of 
N-acyloxazolidinone gives the syn aldol product, while (E)-enolate afford 
the anti product, as confirmed by Zimmermann-Traxler six-membered 
transition state characterized by a chair-conformation (scheme XI-9).  
Unfortunately, the selectivity was about 1:1 and the two possible 
diastereoisomers were neither separable by flash chromatography, nor as 
C15-OTBS ethers (table XI-2, entry 1-4). 
The negative result was expected, as boron enolate doesn’t give high level 
of selectivity with simple N-acetyloxazolidinones. 
 In the perspective of the synthetic route exploration, our main aim was to 
collect enough desired distereoisomer to go straight to cyclopropanation 
step. The stereochemistry of aldol products was confirmed comparing the 
spectroscopic and analytic data of the product obtained from two different 
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reaction conditions, employing the two enantiomers of the same 
oxazolidinone (table XI-2, entry 1, 2). 
 
 
Scheme XI-9. Reagents and conditions: (i) DIPEA, Bu2BOtf, DCM, 0°C; (ii) 
(1) R''CHO, DCM, -78°C to r.t., (2) oxidative work-up. 
A strong base like LDA in which lithium cation is replaced with zinc, 
furnished by ZnCl2, provided control of stereochemistry.22 
 
Table XI-2. Aldol reaction of 24b with Evans chiral auxiliaries. 
Evans auxiliary Conditions Outcome 
 
di-n-BuOTf, DIPEA, 
DCM 
A 
53% (3:2 mixture),  
separable as TBS protected 
O N
O
Ph
O
 
TiCl4, DIPEA, DCM 
B 
54% (1:1 mixture) 
 
di-n-BuOTf, DIPEA, 
DCM 
C 
54% (3:7 mixture, 85% brsm) 
not separable neither as TBS 
protected 
 
di-n-BuOTf, DIPEA, 
DCM No product 
 
LDA, ZnCl2 0.5 M in 
THF, THF 
64% (5:1 mixture, 85% brsm) 
separable as TBS protected 
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Thus, zinc enolate of a N-acetylated (1R, 2S)-(-)-norephedrine derivative 46 
allowed us to obtain a 5:1 diastereomeric mixture (47) in 64% yield. 
The two diastereoisomers have been separated by flash chromatography as 
TBS protected 48 (scheme XI-10).  
Every mixture of diastereoisomers and their silylated derivatives has been 
analyzed by HPLC just to determine the ratio of two components, instead of 
Mosher ester analysis.  
 
11.3.  Toward the synthesis of the cyclopropane key 
intermediate 15. 
Among Evans auxiliary removal methods, the most convenient was the 
reductive cleavage with LiBH459 because the corresponding primary alcohol 
might be easily oxidized to aldehyde 23, but migration of TBS protecting 
group from new chiral centre to primary alcohol was observed.  
Thus, 48 was esterified in refluxing EtOH with freshly distilled Ti(OEt)4 to 
give 49, subsequently reduced to aldehyde 23. 
The storage of the aldehyde 23 led to formation of a completely conjugated 
π-electron system, the more stable α,β-unsaturated aldehyde via TBS-OH 
elimination.22  
After a filtration on a small plug of silica, the aldehyde 23 was used for 
Still-Gennari olefination which is Z-selective, as confirmed by NOESY 
experiment on intermediate 50.60 
The reduction of 50 with DIBAL-H, gave the allylic alcohol 15 which was 
reacted with an excess of Et2Zn/CH2I2 in presence of Charette ligand 51, to 
give the desired product as a mixture of diasteroisomers in good yield.25 
The dr was in the range of 15:1 in favour of the right diastereoismer as 
confirmed by 1H NMR.22, 25  
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Scheme XI-10. Reagents and conditions: (i) LDA, ZnCl2 0.5 M THF, THF, -70°C, 
2½ h, 64%; (ii) TBS-Cl, imidazole, DMF, r.t.,overnight, 90%; (iii) Ti(OEt)4, EtOH, 
78°C, 98%; (iv) DIBAL-H 1.2 M toluene, DCM, -78°C, 30';(v) KHMDS, 18-crown-
6, (CF3CH2O)P(O)C(CH3)CO2Et, -78°C, 30', 54%; (vi) DIBAL-H 1M DCM, DCM, 
-78°C, 1 ½ h; (vii) Et2Zn, CH2I2, DCM, Charette ligand, 0°C to r.t.,1½ h 
 
Charette cyclopropanation is a stereoselective method to facilitate the 
access to enantioenriched cyclopropanes, and is based on haloalkylzinc, 
widely used in Simmons-Smith reaction, that gave very low selectivity. 
The cyclopropanation might be explosive because of the exotermicity of the 
formation of Zn(CH2I)2, for this reason it is carried out on scale lower than 
8 mmol. This methodology is specific for allylic alcohol, through a 
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transition state, in which it is thought that the bulkier butyl substituent on 
the dioxaborolane adopts the less congested pseudoequtorial position and 
the allylic alkoxide the more stable pseudoaxial position. This allows the 
complex to act as a bidentate ligand. 
The zinc reagent should then be complexed simultaneously by both the 
highly basic carbonyl amide of the dioxaborolane ligand and the oxygen 
atom of the allylic alkoxide.  
The most suitable conformation for the methylene delivery is that in which 
the allylic chain is in its most stable conformation. This model correctly 
predicts the absolute configuration for the cyclopropanation of all the allylic 
alcohols. 
 
Figure XI-1. Transition state of  Charette cyclopropanation reaction. 
 
11.4 Conclusions 
This experience of Ph.D. visiting student has been accomplished with the 
achievement of the result, that was to arrive to the key step 15. 
The synthetic route to obtain the heterocyclic core in high yield was 
designed that allowed to go straight to cyclopropanated intermediate. 
The positive outcome both in term of yield, both in term of selectivity are 
promising in the perspective to arrive at the very end of the synthetic route. 
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Chapter 12 
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12 Experimental procedures 
 
12.1.  General Informations 
All solvents used for reactions were purchased as anhydrous grade from 
Fluka (puriss.; dried over molecular sieves; H2O < 0.005%) and used 
without further purification. Solvents for extractions, flash column 
chromatography (FC) and thin layer chromatography (TLC) were purchased 
as commercial grade and distilled prior to use. All non-aqueous reactions 
were performed under an argon atmosphere using flame-dried glassware 
and standard syringe/septa techniques. All other commercially available 
reagents were used without further purification, unless otherwise noted. In 
general, reactions were magnetically stirred and monitored by TLC 
performed on Merck TLC aluminum sheets (silica gel 60 F254). Spots were 
visualized with UV light (λ = 254 nm) or through staining with 
Ce2(SO4)3/phosphomolybdic acid/H2SO4 or KMnO4/K2CO3.  
Melting points were obtained in open capillary tubes using a Büchi melting 
point apparatus B-540 and are uncorrected. 1H- and 13C-NMR spectra were 
recorded in CDCl3 (unless otherwise noted) on a Bruker AV-400 400 MHz 
at room temperature. Chemical shifts (δ) are reported in ppm and are 
referenced to added tetramethyl silane as an internal standard (otherwise to 
chloroform; δ 7.26 ppm for 1H, δ 77.16 ppm for 13C). All 13C-NMR 
spectra were measured with complete proton decoupling. Data for NMR 
spectra are reported as follows: s = singlet, d = doublet, t = triplet, q = 
quartet, m = multiplet, br = broad signal, J = coupling constant in Hz.  
Infrared spectra (IR) were recorded on a Jasco FT/IR-6200 instrument. 
Resonance frequencies are given as wavenumbers in cm-1. Data for IR 
spectra are reported as follows: w = weak, m = medium, s = strong, br = 
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broad signal. Optical rotations were measured on a Jasco P-1020 
polarimeter. Mass spectra were recorded by the ETH Zürich MS service; 
HRMS (ESI) spectra were obtained on a Varian IonSpec spectrometer. 
 
Synthesis of benzo[d]thiazole-5-carboxylic acid (26). 
An equimolar mixture of formic acid (1 g, 21.7 mmol) and acetic anhydride 
(2.22 g, 21.7 mmol) were heated up to 65 °C for 15 minutes. After cooling 
down to 0 °C, this solution was used in the following reaction without any 
purification. 
A mixture of 4-chloro-3-nitrobenzoic acid (548 mg, 2.72 mmol) and sodium 
sulphide nonahydrate (1.96 g, 8.15 mmol) was heated at 120°C for 30 min, 
and then cooled to 0°C in an ice bath. Mixed anhydride (718 mg, 8.15 
mmol) was added rapidly dropwise, followed by dropwise addition of acetic 
acid (256.4 µl, 4.07 mmol). The resulting mixture was refluxed for 4 h, then 
allowed to cool to room temperature and stirred overnight.  
The mixture was distributed in water (5 ml) and AcOEt (20 ml), and the 
precipitated sulphur was removed by filtration on celite, the organic phase 
was washed with brine (5 ml), dried over magnesium sulphate, and 
concentrated in vacuo to give a yellow solid in 60 % of yield (292 mg, 1.63 
mmol).  
For spectroscopic data of compound 26 and the corresponding methyl 
benzo[d]thiazole-5-carboxylate 13 see:  
Walker, D. P.; Bioorg. Med. Chem. 2006, 14(24), 8219-8248  
Vel’tman, R. P.; Zhurnal Obshchei Khimii 1996, 26, 3388-91. 
 
 
 
  Epothilones: experimental section 
133 
Synthesis of methyl 2-methylbenzo[d]thiazole-5-carboxylate (31). 
3-nitro-4-chloro-benzoic acid (25g, 0.124 mol) and sodium sulphide 
nonahydrate (89.37 g, 0.372 mol) were heated until melting (bath 
temperature 120°C, caution: reaction is highly exothermic). 
After 30 min, the heating bath was removed, cooled to 0°C in an ice bath 
and acetic anhydride (35.15 ml, 0.37 mol) (caution: after adding 50% of 
acetic anhydride, a highly exothermic reaction started) followed  by acetic 
acid (11.7 ml, 0.186 mol) were added rapidly, dropwise. 
The resulting mixture was refluxed for 2 h, then allowed to cool to room 
temperature and stirred overnight.  
The mixture was distributed in water (50 ml) and AcOEt (200 ml), and 
stirring was continued for 30 minutes. The suspension was filtered through 
celite to remove sulfur, the aqueous layer was washed with ethyl acetate and 
the combined organic layers were washed with brine (10 ml), dried over 
MgSO4 and concentrated in vacuo to give 10 g of yellow powder. 
The filter was washed several times with EtOH, and concentrated to give a 
further batch that was combined with the first one and purified by flash 
chromatography (AcOEt and 1% of acetic acid) to afford 5 g of 2-
methylbenzo[d]thiazole-5-carboxylic acid (21%). 
A solution of 2-methylbenzo[d]thiazole-5-carboxylic acid (5 g, 0.026 mol) 
in 30 ml of MeOH was cooled to 0° C, then SOCl2 was carefully added 
(4.75 ml, 0.065 mol) dropwise. 
The mixture was heated to 70° C for two hours, and concentrated under 
reduced pressure. To the mixture were added 5 ml of water and 15 ml of 
ethylic ether (3 x 15 ml). The organic phase was washed with Na2CO3 sat. 
and with brine. Finally it was dried over Mg2SO4 and evaporated. The crude 
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was purified by fc (Hexane/AcOEt 12:1) to get 3 g of 31 as yellow solid 
(55%). 
1H NMR (400 MHz, CDCl3): δ 8.61 (s, 1H), 8.03 (dd, J = 8.5, 1.6 Hz, 1H), 
7.87 (d, J = 8.5 Hz, 1H), 3.97 (s, 3H), 2.87 (s, 3H); 13C NMR (400 MHz, 
CDCl3): δ 168.5, 167.1, 153.5, 140.8, 128.5, 125.6, 124.1, 121.4, 52.6, 20.4; 
IR (film, CHCl3): 2954 (w), 2902 (w), 1715 (s), 1431 (m), 1300 (s), 1240 
(m), 1090 (s), 904 (m), 758 (m); Rf 0.4 (Hexane/Ethylic ether: 1:1); M.p.: 
96-98°C; MS (ESI): 208.0423 [M + H]+ 
 
Synthesis of methyl 2-formylbenzo[d]thiazole-5-carboxylate (28). 
A solution of methyl-benzothiazole (500 mg, 2.41 mmol) and SeO2 (1.07 
mg, 9.65 mmol) in 12 ml of AcOH was refluxed for 4 h. 
The mixture was filtered through celite to remove the dark precipitate and 
the filtrate was concentrated. The residue was neutralized with aq. saturated 
NaHCO3 solution (4 ml) and extracted with AcOEt (12 ml x 3). The 
combined organic extracts were dried on Mg2SO4 and evaporated to give 
after purification by fc (AcOEt/Hexane 1:11) 303 mg of white solid (57%). 
1H NMR (400 MHz, CDCl3): δ 10. 17 (s, 1H), 8.94 (dd, J = 1.7, 0.5 Hz, 
1H), 8.22 (dd, J = 8.5, 1.8 Hz, 1H), 8.05 (dd, J =8.5 Hz, 0.5 Hz, 1H), 4.00 
(s, 1H); 13C NMR (400 MHz, CDCl3): δ 185.4, 166.8, 166.3, 153.5, 140.8, 
129.97, 128.8, 127.6, 122.8; IR (film, CHCl3): 2957 (w), 2921 (w), 1720 
(s), 1685 (s), 1488 (w), 1314 (m), 1206 (m), 754 (m); Rf 0.59 
(Hexane/AcOEt 5:1); M.p.: 137°C (decomposition); MS (ESI): m/z = 
220.0425 
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Synthesis of methyl 2-vinylbenzo[d]thiazole-5-carboxylate (29) 
To a methyltriphenylphosponium bromide (30 mg, 0.085 mmol) in 1.5 ml 
of THF was added LiHMDS 1M in THF (85 µl, 0.085 mmol) at 0°C and it 
was left stirring for 30 min at that temperature. Then the aldehyde 14 (15 
mg, 0.068 mmol) dissolved in 0.5 ml of THF was added and the reaction 
mixture was left stirring for 1 h at 0°C. The reaction was cautiously 
quenched by addition of NH4Cl, water and afterwards diluted with ethylic 
ether. The phases were separated and the aqueous phase was extracted with 
ethylic ether, the combined ethereal layers were dried over MgSO4, 
concentrated under reduced pressure and purified by fc to afford (8 mg, 
0.036 mmol) of desired product (54%). 
1H NMR (400 MHz, CDCl3): δ 8.66 (s, 1H), 8.06 (dd, J = 8.5, 1.7 Hz, 1H), 
7.89 (d, J = 8.5 Hz, 1H), 7.05 (dd, J = 17.9, 11 Hz, 1H), 6.22 (d, J = 17.7 
Hz, 1H), 5.82 (d, J = 10.2 Hz, 1H), 3.98 (s, 3H); 13C NMR (400 MHz, 
CDCl3): δ 168. 5, 166.9, 153.72, 139.3, 131.4, 128.8, 126.4, 124.90, 124.3, 
121.6, 52.6; IR (film CHCl3): 2949, 1741, 1454, 1433, 1304, 1208, 1091, 
756; Rf: (Hexane/AcOEt 4:1) 0.48; M.p.: 81.4°C; MS (ESI): m/z = 
220.0417 [M+H]+ 
 
Synthesis of Methyl 2-(2-hydroxyethyl)benzo[d]thiazole-5-carboxylate 
(30). 
Methyl 2-methylbenzo[d]thiazole-5-carboxylate (1.00 g, 0.05 mol) and 
paraformaldehyde (291.36 mg, 0.010 mol) were heated together in a sealed 
microwave vial at 165°C in an oil bath for 6 hours. After cooling to room 
temperature, the reaction mixture was carefully transferred in a 
chromatography column and purified by fc (AcOEt/Hexane 1:1) to give 196 
mg (0.83 mmol, 17%) of yellow solid. 
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1H NMR (400 MHz, CDCl3): δ 8.63 (d, J= 1.4 Hz, 1H), 8.05 (dd, J= 8.4, 
1.6 Hz, 1H), 7.90 (d, J= 8.4 Hz, 1H), 4.15 (q, J= 5.8 Hz, 2H), 3.97 (s, 3H), 
3.35 (t, J= 5.7, 2H), 3.20 (t, J= 6.0 Hz, 1H)  
13C NMR (400 MHz, CDCl3): δ 171.1, 167.0, 153.0, 139.8, 128.6, 125.9, 
124.3, 121.6, 61.1, 52.6, 36.9; IR (CHCl3, film): 3382 (br, 3600-3000), 
1718 (s), 1432 (m), 1418 (w), 1301 (s), 1287 (m), 1219 (m), 1094 (m), 888 
(m), 702 (m); Rf 0.5 (AcOEt/Hexane 5:1); M.p.: 101-103°C; MS (ESI): m/z 
= 238.0528 [M + H]+ 
 
Synthesis of Methyl 2-(2-(4-methoxybenzyloxy)ethyl)benzo[d]thiazole-
5-carboxylate (30b) 
To a solution of 4-methoxybenzyl alcohol (1.5 g, 10.86 mmol) in 10 ml of 
ethylic ether was added at r.t. NaH 60% (40.4 mg). The resulting suspension 
was allowed to stir until the solid has dissolved and the gas evolution had 
ceased (approximately 1h). 
Then the mixture was cooled to 0 °C and trichloroacetonitrile (1.09 ml, 
10.86 mmol) was added over 15 min dropwise. The mixture was stirred at 
0°C for another 5 min and at r.t. for 20 min. 
It was then transferred to a separatory funnel, washed with saturated 
NaHCO3-solution (3 ml) and brine, dried over MgSO4, and concentrated in 
vacuo to yield the crude 4-methoxybenzyl trichloroacetimidate as yellow oil 
(2.92 g, 95%). To 2.19 g of imidate in 8 ml of DCM were added methyl 2-
(2-hydroxyethyl)benzo[d]thiazole-5-carboxylate (832 mg, 3.5 mmol) and 
the pyridinium p-toluenesulphonate (35 mg, 0.14 mmol) 
The mixture was stirred at room temperature overnight, then washed with 
saturated NaHCO3-solution (4 ml), brine (4 ml), dried MgSO4, and 
concentrated in vacuo. 
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The crude was purified by flash chromatography (AcOEt/Hexane 1:1) to 
give 640 mg of pale yellow solid (51%). 
1H NMR (400 MHz, CDCl3): δ 8.65 (d, J= 1.5 Hz, 1H), 8.04 (dd, J= 8.4, 
1.5 Hz, 1H); 7.89 (dd, J= 8.4, 1.5 Hz, 1H), 7.26 ( d, J= 8.0 Hz, 2H), 6.86 (d, 
J= 8.0 Hz, 2H), 4.52 (s, 2H), 3.97 (s, 3H), 3.92 (t, J= 6.2 Hz, 2H), 3.8 (s, 
3H), 3.42 (t, J= 6.3 Hz, 2H); 13C NMR (400 MHz, CDCl3): δ 170. 7, 167.2, 
159.4, 153.0, 140.6, 130.1, 129.5, 128.4, 125.6, 124.3, 121.5, 114, 73.1, 
68.1, 55.4, 52.4, 35.2; IR: 1718 (s), 1609 (w), 1512 (m), 1433 (w), 1298 (s), 
1245 (s), 1093 (m), 1033 (w), 909 (m), 757(m) 
Rf 0.2 (AcOEt/Hexane 1:3); M.p.: 58 °C; MS (ESI): m/z = 358.1108 [M + 
H]+ 
 
Synthesis of (2-(2-(4-methoxybenzyloxy)ethyl)benzo[d]thiazol-5-
yl)methanol (42b). 
To a solution of methyl 2-(2-(4-methoxybenzyloxy)ethyl)benzo[d]thiazole-
5-carboxylate (621.6 mg, 1.74 mmol) in 7 ml of DCM was added DIBAL-H 
1M in DCM (4.35 ml, 4.35 mmol) at -78°C under argon. After 1h, Et2O (3 
ml) was added and the mixture was allowed to warm to r.t. After the 
addition of further ethylic ether (3 ml) and Rochelle salt, the mixture was 
stirred until the solution become clear. The mixture was concentrated and 
the crude was suspended in DCM (15 ml) and washed with water (3x 3ml).  
The organic phase was dried over MgSO4, and concentrated in vacuo. The 
crude was purified by fc (AcOEt/Hexane 1:1) to give (335.6 mg, 1.02 
mmol) of yellow solid 59%. 
1H NMR (400 MHz, CDCl3): δ 7.86 (dd, J= 1.9, 0.8 Hz, 1H), 7.75 (d, J= 
8.3 Hz, 1H), 7.31 (dd, J= 8.3, 1.6 Hz, 1H), 7.18 (d, J= 8.8 Hz, 2H), 6.78 (d, 
J= 8.8 Hz, 2H), 6.78 (d, J= 8.8 Hz, 2H), 4.75 (d, J= 5.2 Hz, 2H), 4.44 (s, 
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2H), 3.82 (t, J= 6.44 Hz, 2H), 3.72 (s, 3H), 3.32 (t, J= 6.4 Hz, 2H), 1.96 (t, 
J= 6.4 Hz, 1H); 13C NMR (400 MHz, CDCl3): δ 169.9, 159.5, 153.4, 
139.42, 134.82, 130.13, 129.5, 124.2, 121.7, 121.0, 113.98, 73.1, 68.4, 65.4, 
55.5, 35.2; IR: 3314 (br, 3500-3100), 2920 (m), 2858 (m), 1611 (m), 1508 
(s), 1366 (m), 1304 (w), 1175 (m), 1154 (m), 1245 (s), 1090 (s), 1033 (s), 
813 (s), 584 (m); Rf 0.14 (AcOEt/Hexane 1:1); M.p.: 84-85°C; MS (ESI): 
m/z = 330 .1160  
 
Synthesis of (2-(2-(4-methoxybenzyloxy)ethyl)benzo[d]thiazole-5-
carbaldehyde (24b). 
DMSO (289.4 ml, 4.075 mmol) was added to a solution of oxalyl 
chloride(131.3 ml, 1.528 mmol) in DCM (3.5 ml) at -78°C. After 5 min 
alcohol (335.6 mg, 1.02 mmol) in DCM (2.5 ml) was added. Stirring was 
continued at -78°C for an additional 15 min, whereupon TEA (495.6 µl, 
3.56 mmol) was added. The ice bath was removed and the reaction was 
stirred at r.t. for additional 2.5 h. The reaction was quenched by addition of 
NH4Cl (3 ml). The aqueous phase was extracted with DCM (10 ml x 3), the 
combined organic phases were washed with brine and dried over MgSO4. 
The yellow crude was purified by chromatography on silica gel 
(AcOEt/Hexane 1:3→ AcOEt/Hexane 1:1) to give mg 280 (84%) as yellow 
solid. 
1H NMR (400 MHz, CDCl3): δ 10.13 (s, 1H), 8.42 (dd, J= 1.6, 0.6 Hz, 1H), 
7.99 (d, J= 8.3, 1H), 7.90 (dd, J= 8.3, 1.6 Hz, 1H), 7.26 (d, J= 8.8, Hz, 2H), 
6.87 (d, J= 8.8 Hz, 2H), 4.53 (s, 1H), 3.92 (t, J= 6.2 Hz, 2H), 3.8 (s, 3H), 
3.43 (t, J= 6.2 Hz, 2H); 13C NMR (400 MHz, CDCl3): δ 191.8, 171.3, 
159.52, 153.22, 142.22, 135.06, 130.0, 129.55, 125.6, 124.3, 122.3, 114.0, 
73.12, 68.01, 55.43, 35.29; IR (film, CHCl3): 1691 (s), 1602 (m), 1511 (s), 
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1282 (m), 1244 (s), 1093 (m), 1062 (w), 1033 (m), 813 8m); M.p.: 83.6-
84.6°C; Rf 0.67 (AcOEt/Hexane 3:1); MS (ESI): m/z = 328.0987 [M+ H]+ 
 
Synthesis of methyl 4-chloro-3-nitrobenzoate (34). 
Concentrated sulphuric acid (200 µl) was cautiously added to a chilled 
(0°C) solution of 4-chloro-3-nitrobenzoic acid (1 g, 5 mmol) in methanol 
(10 ml) and the resulting mixture heated under reflux for 16 h. The reaction 
mixture was evaporated do dryness, solved in AcOEt (9 ml) and washed 
with sat. NaHCO3 (3 ml), dried over MgSO4 and concentrated under reduced 
pressure to afford the title compound as white solid 950 mg (88%). 
Rf 0.7 (AcOEt/Hexane 1:1); IR (film, CHCl3): 1729 (w), 904, 45 (s), 723. 
66 (s). 
1H, 13C NMR, M.p. are described in: Joensson, D., Warrington, B.H., & 
Ladlow, M. (2004) Journal of Combinatorial Chemistry, 6, 584-595.  
 
Synthesis of Methyl 3-amino-4-chlorobenzoate (39). 
To a solution of methyl 4-chloro-3-nitrobenzoate (1.66 g, 8 mmol) in 
MeOH 65 ml was added anhydrous SnCl2 (14.6 g, 77 mmol) and the 
resulting reaction mixture was refluxed for 1 h. The reaction mixture was 
cooled to 0°C followed by dropwise addition of a saturated solution of 
NaHCO3 to pH = 8. 
The reaction mixture was filtered and the filtrate was extracted with AcOEt 
(3x 30 ml). The combined organic extracted were dried over MgSO4, filtered 
and concentrated under reduced pressure to obtain a orange crude that was 
purified (AcOEt/Hexane 1:2) to get 1.34 g (90%) of pale yellow solid. 
1H-NMR (400 MHz, CDCl3): δ 7.4 (d, J= 1.89 Hz, 1H), 7.3 (dd, J= 8.4, 
1.89 Hz, 1H), 7.23 (d, J= 8.4 Hz, 1H), 4.12 (bs, 1H), 3.85 (s, 3H); 13C NMR 
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(400 MHz, CDCl3): δ 166.6, 142.8, 129.63, 129.42, 119.87, 116.56, 53.1; 
IR (film, CHCl3): 1701 (m), 1253 (s), 1097 (m), 755 (s); Rf 0.7 
(AcOEt/Hexane 1:1); M.p.: 82-83°C; MS (ESI): m/z = 186.0318 [M+ H]+ 
 
Synthesis of methyl-3-(3-(benzyloxy)propanamido)-4-chlorobenzoate 
(40a). 
3-(benzyloxy)propanoic acid (615 mg, 3.41 mmol) in 20 ml DMA was 
treated with thionyl chloride (250 µl, 3.41 mmol) at 0°C. The mixture was 
stirred for 30 min, and then methyl 3-amino-4-chlorobenzoate (633.5 mg, 
3.41 mmol) was added. The resulting suspension was stirred overnight and 
then quenched with 5 ml of NaHCO3. The reaction mixture was extracted 
with AcOEt (10 ml x 3), washed with brine, dried over MgSO4 and 
concentrated under reduced pressure. The crude was purified by fc 
(Et2O/Hexane 1:2) to get 1.09 gr (90 %) of white solid. 
1H-NMR (400 MHz, CDCl3): δ 8.93 (d, J= 1.9 Hz, 1H), 8.86 (s, 1H), 7.60 
(dd, J= 8.3, 2 Hz, 1H), 7.30 (d, J= 8.3 Hz, 1H), 7.29-7.19 (m, 5H), 4.56 (s, 
1H), 3.80 ( s, 3H), 3.75 (t, J= 5.4 Hz, 2H), 2.66 (t, J= 5.4 Hz, 2H); 13C-
NMR (400 MHz, CDCl3) δ 137.1, 135.2, 129.7, 129.0, 128.5, 128.1, 128, 
125.5, 122.7, 73.9, 66.0, 52.4, 38.6; IR (film, CHCl3): 3306 (w), 2950, 2867 
(w), 1723 (s), 1697 8M9, 1584 (m), 1531 (m), 1416 (m), 1293 (s), 1293 (s), 
1106 (s), 760 (m); Rf 0.16 (Hexane/AcOEt 5:1); M.p.: 78°C; MS (ESI): 
m/z = 348 .0991 [M + H]+ 
 
Synthesis of methyl-3-(3-(benzyloxy)propanethioamido)-4-
chlorobenzoate (41). 
To a solution of methyl-3-(3-(benzyloxy)propanamido)-4-chlorobenzoate 
(1g, 3 mmol) in dioxane (18 ml) was added Lawesson’s reagent (1.28 g, 3 
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mmol) and the reaction mixture was refluxed for 3 h. The solvent was 
evaporated and the crude was directly purified by fc (two columns, 
AcOEt/Hexane 1:6) to obtain 881.8 mg (81%) of yellow oil. 
1H NMR (400 MHz; CDCl3): δ10.23 (s, 1H), 9.13 (d, J= 2.6 Hz, 1H), 7.8 
(dd, J= 8.4, 2.0 Hz, 1H), 7.49 (d, J= 8.4 Hz, 1H), 7.38-7.27 (m, 5H), 4.64 ( 
s, 2H), 3.92 (s, 3H), 3.9 (t, J= 5.5 Hz, 2H), 3.26 (t, J= 5.5 Hz, 2H); 13C 
NMR (400 MHz, CDCl3): δ 203.7, 165.8, 137.0, 136.0, 132.1, 129.6, 129.1, 
128.6, 128.2, 128.1, 128.0, 126.9, 73.8, 68.2, 52.5, 48.7; Rf 0.5 
(Hexane/AcOEt 2:1); IR (film, CHCl3): 3260(w), 3030, 2950 (w), 1723 (s), 
1436 (w), 1376 (s), 1302 (s), 1248 (s), 1108 (s), 760 (m), 747 (m); MS 
(ESI): m/z = 364.0761 [M + H] +  
 
Synthesis of methyl-2-(2-(benzyloxy)ethyl)benzo[d]thiazole-5-
carboxylate (30a). 
To a solution of 26a in NMP (20 ml) was added portionwise NaH 60 % min 
oil (185 mg). The reaction was refluxed for 1h at 160°C. The reaction 
mixture was poured into a flask with water and crushed ice. 
The organic phase was extracted with AcOEt (3x 50 ml) and washed with 
brine. The combined organic phases were dried over MgSO4, concentrated 
to get an orange oil  as crude that was directly purified by fc 
(AcOEt/Hexane 1:5) to get 1 g (63%) of pale yellow solid. 
1H NMR (400 MHz, CDCl3): δ 8.65 (d, J= 1.3 Hz, 1H), 8.04 (dd, J= 8.3, 
1.7 Hz, 1H), 7.89 (d, J = 8.3 Hz, 1H), 7.36-7.26 (m, 5H), 4.6 (s, 2H), 3.96 
(s, 3H), 3.94 (t, J= 6.3 Hz, 2H), 3.44 (t, J= 6.3 Hz, 2H), 13C NMR (400 
MHz, CDCl3): δ 170.5, 167.1, 153.8, 140.5, 138.0, 128.5, 127.8, 127.8, 
125.5, 124.3, 121.4, 73.5, 68.6, 52.4, 35.5; IR (film, CDCl3): 2949.6 (w), 
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1716 (s), 1299 (s), 1284 (s), 1209 (s), 1091 (s), 758 (s), 698 (s); Rf 0.74 
(Hexane/AcOEt: 2:1); M.p.: 45-46°C; MS (ESI): m/z = 328.0999 [M + H] + 
 
Synthesis of (2-(2-benzyloxy)ethyl)benzo[d]thiazol-5-yl)methanol (28a). 
To a solution of 42a (1g, 4 mmol) in 16 ml of DCM was added slowly 7.5 
ml of DIBAL-H 1.2 M in toluene at -78°C. The mixture was stirred for 1 ¼ 
h and after the addition of 10 ml of ethylic ether, the reaction was allowed 
to reach r.t. 
360 µl of water, 360 µl of NaOH 15%, 900 µl of water were added 
following this order, after stirring for 15 min at r.t., a small amount of 
MgSO4 was added and it was left stirring for 15 min at r.t. The mixture was 
filtrated, the filtrate was transferred in a funnel and the organic phase was 
extracted with Et2O, dried over MgSO4, concentrated to get a yellow oil as 
crude. 
The crude was purified by fc (AcOEt/Hexane 1: 2.5→1:2→1:1→2:1) to get 
773.5 mg (72%) of yellow oil. 
1H NMR (400 MHz, CDCl3): δ 7.9 (dd, J= 2.2, 0.9 Hz, 1H), 7.82 (d, J= 8.4 
Hz, 1H), 7.38 (dd, J= 8.2, 1.6 Hz, 1H), 7.36-7.26 (m, 5H), 4.8 (s, 2H), 4.6 
(s,. 2H), 3.93 (t, J= 6.2 Hz, 2H), 3.42 (t, J= 6.2 Hz, 2H); 13C NMR (400 
MHz, CDCl3): δ 169.7, 153.5, 139.4, 138.2, 135, 129, 128, 124.2, 121.7, 
121.0, 73.4, 68.7, 65.4, 35.1; IR (film, CHCl3): 3344 (bs, w), 2856 (w), 
1099 (m), 884 (m), (747 (m), 697 (s); Rf 0.1 (Hexane/AcOEt 2:1); MS 
(ESI): m/z = 300.1055 [M + H]+ 
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Synthesis of the 2-(2-(benzyloxy)ethyl)benzo[d]thiazole-5-carbaldehyde 
(24a). 
To a cooled solution (-78°C) of oxalyl chloride (332.8 µl, 3.875 mmol) in 9 
ml of DCM was added DMSO (734 µl, 9.7 mmol) as a solution in DCM 
(2.5 ml), over a period of 5 min. 
After 10 min of stirring at -78°C the alcohol (725 mg, 2.42 mmol) solved in 
10 ml of DCM was added over 5 min and stirring was continued for 15 min. 
1.18 ml of TEA was added to the mixture, the cold bath was removed and it 
was allowed to stir at r.t. for 2.5 h. After the addition of 4 ml of NH4Cl (3 
ml), the aqueous phase was extracted with DCM (10 ml x 3), the combined 
organic phases were washed with brine and dried over MgSO4. The yellow 
crude was purified by fc (AcOEt/Hexane 1:3) to give mg 280 (84%)  to get 
the product as yellow solid. 
1H NMR (400 MHz, CDCl3): δ 10.15 (s, 1H), 8.42, (dd, J= 1.7, 0.5 Hz, 
1H), 7.99 (d, J=8.5 Hz, 1H), 7.90 (dd, 8.3, 1.5 Hz, 2H), 7.34- 7.26 (m, 5H), 
4.6 (s, 2H), 3.9 (t, J= 6.2 Hz, 2H), 3.46 (t, J= 6.2 Hz, 2H); 13C NMR (400 
MHZ, CDCl3): δ 191.94, 171.12, 153.33, 142.27, 137.95, 134.93, 128.53, 
127.94, 127.87, 125.5, 124.27, 122.33, 73, 48, 68.37, 35.28; IR (film, 
CHCl3): 2860 (W); 1695 (s), 1598.7 (w), 1103.08 (w). 
 
Aldol reaction of 24b with 3-acetyl-4-benzyloxazolidin-2-one  
 
Procedure with di-n-butylborontriflate/DIPEA(table X-2, entry 1) 
To (S)-3-acetyl-4-benzyloxazolidin-2-one43 (0.151 mmol, 33.1 mg) in 1.5 
ml of DCM, di-n-butylboron triflate 1M in DCM  (0.151 ml, 0.15 mmol) 
and DIPEA (35 µl, 0.202 mmol) were added at 0°C. The pale yellow 
solution was cooled to -78°C and the aldehyde 29b (33 mg, 0.101 mmol) in 
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1 ml of DCM was added dropwise. The solution was stirred for 30 min at -
78°C and then slowly warmed to 0°C (in 25 min). It was then stirred for 2 
hours at 0°C. Phospate buffer solution (1 ml) and (1ml) MeOH/ 30% H2O2 
solution (2:1) were added and the resulting two layers were stirred for 1 h at 
0°C.  
Sat. aq. NH4Cl solution (3 ml) and AcOEt were added. The layers were 
separated and the aq. layer was extracted with AcOEt (3x 10 ml). The 
combined organic layers were washed with brine (2 ml), dried over MgSO4 
and concentrated under reduced pressure. Purification by fc (AcOEt/Hexane 
1:1) to separate the starting material from the product, afforded as white 
solid (29.5 mg, 53%, dr = 3:2). 
1H NMR (400 MHz, CDCl3): data for major isomer: (S)-4-benzyl-3-((S)-3-
hydroxy-3-(2-(2-(4-methoxybenzyloxy)benzo[d]thiazol-5-
yl)propanoyl)oxazolidin-2-one: δ 8.03 (t, J= 3.1, 1.7 Hz, 1H), 7.85 (d, J= 
8.3 HZ, 1H), 7.47 (dt, J= 8.3, 3.1, 1.5 Hz, 1H), 7.38-7.16 (m, 9H), 6.87 (d, 
2H), 5.4 (m, 1H), 4.72 (m, 1H), 4.52 (s, 2H), 4.26 (m, 2H), 3.9 (t, J= 6.4 
Hz, 2H), 3.8 (s, 3H), 3.53-3.26 (m, 5H); IR: 3385 (bs), 2915 (w), 1777 (s), 
1698 (m), 1512 (m), 1388 (m), 1245 (s); Rf  0.35, 0.30 both 
diastereoisomers (Hexane/AcOEt 1:1); M.p.: 99-100°C; Rt: 8.77 (38.79%), 
9.24 (61.21%) Method 50-60%; MS (ESI): m/z = 547.1893 [M + H]+ 
 
Procedure with TiCl4, DIPEA (table X, entry 2) 
TiCl4 1M in DCM (84 µl, 0.084 mmol) was added dropwise to a solution 
0.2 M of (R)-3-acetyl-4-benzyloxazolidin-2-one43 (16.7 mg, 0.076 mmol) in 
0.5 ml of DCM at -78°C under argon giving a yellow slurry. After 2 min, 
DIPEA (16 µl, 0.092 mmol) was added dropwise, and the resulting deep red 
solution was stirred at -78°C under argon for 1.5 h. After the dropwise 
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addition of aldehyde (30 mg, 0.092 mmol) in 0.8 ml of DCM, stirring was 
continued at -78°C for 2h and for 1 h at -20°C.  
The reaction was quenched with 1.2 ml of NH4Cl and extracted with Et2O 
(3x 5 ml). The combined organic layers were washed with brine, dried over 
MgSO4 and concentrate. The crude was purified by fc (Hexane/AcOEt 1:1) 
to afford the product as white solid (27 mg, 54%). 
The dr in this case hasn’t been calculated as the mixture was not separable. 
 
Synthesis of corresponding OTBS-derivative. 
In a mass vial to (S)-4-benzyl-3-((S),(R)-3-hydroxy-3-(2-(2-(4-
methoxybenzyloxy)benzo[d]thiazol-5-yl)propanoyl)oxazolidin-2-one (8.8 
mg, 0.016 mmol) (dr = 1:1), in 15 µl of DMF, imidazole (2.41 mg, 0.035 
mmol) and TBS-Cl (2.7 mg, 0.018 mmol) were added and the mixture was 
stirred at r.t. overnight 
1H NMR (400 MHz, CDCl3): data for major isomer (S)-4-benzyl-3-((S)-3-
(tert-butyldimethylsilyloxy)-3-(2-
(methoxybenzyloxy)ethyl)benzo[d]thiazol-5-ylpropanoyl)oxazolidin-2-
one): δ 7.98 (s, 1H), 7.81 (d, J= 8.3 Hz, 1H), 7.43 (m, 1H), 7.37-7.13 (m, 
7H), 6.87 (d, J= 8.5 Hz, 2H), 5.44 (m, 1H), 4.70-4.60 (m, 1H), 4.52 (s, 2H), 
4.14 (m, 2H), 3.90 (t, J= 6.9 Hz, 2H), 3.80 (s, 3H), 3.79-3.70 (m, 0.5H), 
3.58-3.50 (m, 0.5 H), 3.40 (t, J= 6.9, 2H), 3.34- 3.20 (m, 1.5 H), 3.10-3.06 
(m, 0.5 H), 2.94- 2.65 (m, 1H), 0.87, 0.85 (2s, 9H), 0.08, 0.06 (s, 3H), -0.13, 
-0.16 (2s, 3H); IR (film, CHCl3): 2932 (m), 2858 (m), 1781 (s), 1702 (m), 
1515 (m), 1248 (s), 1090 (s), 833 (s); Rf 0.57, 0.46 of both isomers 
(Hexane/AcOEt 1:1). 
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Synthesis of (S)-3-acetyl-4-tert-butyl-5,5-diphenyloxazolidin-2-one (C) 
To a suspension of (S)-4-tert-butyl-5,5-diphenyloxazolidin-2-one in 3 ml 
THF, (0.45 ml, 0.71 mmol) of n-BuLi 1.6 M in hexane was slowly added at 
0°C in an ice bath. To the resulting clear solution, acetyl chloride (58 µl, 1.2 
mmol) was added in one portion. The mixture was allowed to warm slowly 
to r.t. overnight, treated with aq. sat. NH4Cl (3 ml), and diluted with Et2O 
(10 ml). The organic phase was washed with 1M HCl (3 ml), 1M NaOH (3 
ml), brine (3 ml), dried over MgSO4, and evaporated.  
Purification by fc EtOAc/Hexane 1:12, afforded the product as white solid 
(190 mg, 83%). 
1H NMR (400 MHz, CDCl3): δ 7.52-7.47 (m, 3H), 7.36-7.23 (m, 7H), 5.33 
(s, 1H), 2.33 (s, 3H), 0.82 (s, 9H), 13C NMR (400 MHz, CDCl3): δ 169.8, 
143.8, 137.8, 129.0, 128.6, 128.2, 128.1, 125.6, 90.5, 67.2, 37.2, 27.8, 23.4; 
Rf 0.37 (Hexane/EtOAc 10:1); M.p.: 166-167°C; [α] D19: -260. 59 °(c = 
0.67, CHCl3); MS (ESI): m/z = 338.1752 [M + H ]+ 
 
Aldol reaction of 24b with (S)-3-acetyl-4-tert-butyl-5,5-
diphenyloxazolidin-2-one (table X, entry 3). 
To (S)-3-acetyl-4-tert-butyl-5,5-diphenyloxazolidin-2-one (0.14 mmol, 46.4 
mg) in DCM (1.5 ml) was added di-n-butylboron triflate 1M in DCM (0.140 
ml, 0.14 mmol) and DIPEA (32 µl, 0.183 mmol) at 0°C. The pale yellow 
solution was cooled to -78°C and the aldehyde (30 mg, 0.092 mmol) in 1 ml 
of DCM was added dropwise. The solution was stirred for 5 ½ h at -78°C 
and as it was not moving anymore it was quenched at -78°C with phosphate 
buffer solution (1 ml) and (1ml) MeOH/ 30% H2O2 solution (2:1) and the 
resulting two layers were stirred for 20 min at 0°C.  
  Epothilones: experimental section 
147 
Sat. aq. NH4Cl solution (3 ml) and Et2O (9 ml) were added. The two layers 
were separated and the aq. layer was extracted with Et2O (3x 5 ml). The 
combined organic layers were washed with brine (2 ml), dried over MgSO4 
and concentrated under reduced pressure. Purification of 120 mg of crude 
by fc (AcOEt/Hexane 1:3 → 1:2) to mg 32.7 (54%, 85% brsm) of product 
as white foam (dr = 3:7, the two diasteroisomers are not separable). 
1H NMR (400 MHz, CDCl3), data for major isomer (S)-4-tert-butyl-3-((S)-
3-hydroxy-3-(2-(2-4.methoxybenzyloxy)ethyl)benzo[d]-thiazol-5-
yl)propanoyl)-5,5-diphenyloxazolidin-2-one) δ 7.92 (d, J= 1.8 Hz, 1H), 7.75 
(d, J= 8.5 Hz, 1H), 7.52-7.45 (m, 3H), 7.36-7.23 (m, 10 H), 6.87 (d, J= 9.15 
Hz, 2H), 5.37 (s, 1H), 5.26 (m, 1H), 4.50(s, 2H), 3.90 (, J= 6.62 Hz, 2H), 
3.79 (s, 3H), 3.39 (t, J=6.62 Hz, 2H), 3.36 -3.3 (m, 1H), 3.0 (m, 1H), 0.83 
(s, 9H). 
IR (film, CHCl3): 2959 (w), 1780 (s), 1703 (m), 1512 (m), 1338 (m), 
1246.8 (s), 1182 (m), 1164 (m), 730 (s), 702 (s); Rf 0.42 (Hexane/AcOEt 
1:1); Rt: 17.14 (28.7%), 17.41 (71.3%) (50-60% method); MS (ESI): m/z = 
665.2672. 
 
Synthesis of the corresponding O-TBS derivative. 
To a solution of (S)-4-tert-butyl-3-((S),(R)-3-hydroxy-3-(2-(2-
4.methoxybenzyloxy)ethyl)benzo[d]-thiazol-5-yl)propanoyl)-5,5-
diphenyloxazolidin-2-one  (9 mg, 0.013 mmol) in 10 µl of DMF, was added 
imidazole (2.04 mg, 0.03 mmol), TBS-Cl (2.15 mg, 0.014 mmol), and the 
reaction mixture was stirred at r.t. overnight. The crude was directly 
purified by fc (AcOEt/Hexane 1:2) to obtain an inseparable mixture of  two 
diastereoisomers (mg 7.1, 57% yield) as colourless oil. 
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1H NMR (400 MHz, CDCl3): δ 7.86, 7.83 (d, J= 1.6 Hz, 1H), 7.73, 7.69 (d, 
J= 8.5 Hz, 1H), 7.52, 7.33 (m, 3H), 7.36-7.23 (m, 10 H), 6.87 (d, J= 8.7Hz, 
2H), 5.31, 5.30 (s, 1H), 5.27 (m, 1H), 4.53,4.52 (s, 2H), 3.90 (t, J= 6.62 Hz, 
2H), 3.80, 3.79 (s, 2H), 3.39 (t, J= 6.62 Hz, 2H), 3.25 -3.18 (m, 1H), 0.83 
(s, 9H), 0.76 (s, 9H), -0.017 (3H), -0.23 (3H); IR (film, CHCl3): 2955.4 (m), 
2931 (m), 1785 (s), 1710 (w), 1513 (w), 1249 (s), 1090 (s); Rf 0.66, 0.62 
(Hexane/AcOEt 1:1) and Rf 0.84 (AcOEt/Hexane 1:2); MS (ESI): m/z 
=779.3538 
 
Synthesis of (4S, 5S)-3-((S)-3-hydroxy-3-(2-(2-4-
methoxybenzyloxy)ethyl)benzo[d]thiazol-5-yl)propanoyl-4-methyl-5-
phenyloxazolidin-2-one (47). 
To a solution of diisopropylamine (16.2 µl, 0.116 mmol) in 0.380 ml of 
THF was added n-BuLi 2.5 M in hexan (50 µl) at -30°C. After 15 min the 
mixture was cooled to -70°C and oxazolidinone39 (23.8 mg, 0.109 mmol) 
solved in 0.2 ml of THF was added slowly. After stirring for 15 min, 0.220 
ml of ZnCl2 0.5 M in THF was added and stirring continued for additional 
15 min,  
Afterwards, the aldehyde (22 mg, 0.067 mmol) in 0.25 ml of THF was 
added. The mixture was stirred for 30 min and poured into concentrated aq. 
NH4Cl (2 ml), extracted with AcOEt (8 ml), dried over MgSO4 and 
concentrated under reduced pressure. 
The crude was purified by fc (two colums, AcOEt/Hexane 1:2→ 1:1) to get 
23 mg (64%) of product as white foam (dr = 4:1). 
1H NMR (400 MHz, CDCl3): δ 8.02, (d, J = 1.6 Hz, 1H), 7.85 (d, J = 8.5 
Hz, 1H), 7.50 - 7.34 (m, 4H), 7.34 -7.23 (m, 4H), 6.87 (d, J = 8.6 Hz, 2H), 
5.68 (d, J= 7.4 Hz, 1H), 5.37 (m, 1H), 4.8 (m, 1H), 4.52 (s, 2H), 3.9 (t, J= 
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6.2 Hz, 2H), 3.6- 3.3 (m, 5H) 3.1 (s, 3 H), 0.94 (s, 3H); 13C NMR (400 
MHz, CDCl3): δ 159.5, 141.0, 133.2, 130.1, 129.5, 129.0, 128.9, 125.8, 
122.9, 121.8, 120.0, 114.0, 79.4, 73.1, 70.4, 68.4, 55.5, 55.1, 44.9, 35.3, 
14.6; IR (film, CHCl3): 1778 (s), 1700 (m), 1512 (w), 1366 (m), 1348 (m), 
1245 (w), 1195 (m); Rf 0.28 (AcOEt/Hexane 1:2 ); MS (ESI): m/z = 
547.1878 [M+ H]+ 
 
Synthesis of (4S, 5S)-3-((S)-3-(tert-butyldimethylsilyloxy)-3-(2-(2-4-
methoxybenzyloxy)ethyl)benzo[d]thiazol-5-yl)propanoyl-4-methyl-5-
phenyloxazolidin-2-one (48). 
To a solution of alcohol 34 (8 mg, 0.015 mmol) in  10 µl of DMF, was 
added imidazole (2.19 mg, 0.032 mmol), TBS-Cl (2.4 mg, 0.016 mmol), 
and the reaction mixture was stirred at r.t. overnight. The crude was directly 
purified by fc with AcOEt to get 6.1 mg of colourless oil (67% referred to 
the main diasteroisomer). 
1H NMR (400 MHz, CDCl3): δ 7.97 (d, J= 1.7 Hz, 1H), 7.81 (d, J= 8.3 Hz, 
1H), 7.47 (dd, J= 8.3, 1.6 Hz, 2H), 7.3-7.26 (m, 5H), 6.87 (d, J= 8.7 Hz, 
2H), 5.54 (d, J= 7.1 Hz , 1H), 5.42 (dd, J= 8.4, 3.1 Hz, 1H), 4.7 (m, 1H), 4.5 
(s, 2H), 3.9 (t, J= 6.5 Hz, ), 3.8 (s, 3H); 3.55 (m, 1H), 3.4 (t, J= 6.5 Hz, 2H), 
3.26 (m, 1H), 0.86 (s, 9H), 0.06 (s, 3H), -0.01 (s, 3H); 13C NMR (100 MHz, 
CDCl3): 170.2, 169.5, 159.4, 153.1, 142.7, 142.6, 134.7, 134.4, 130.2, 
129.5, 128.9, 128.86, 125.8, 123.3, 121.5, 120.2, 114, 79.1, 73.0, 71.6, 63.4, 
55.4, 35.0, 47.2, 35.2, 25.9, 18.3, 14.8, -4.3, -4.94. 
IR (film, CHCl3): 1780 (m), 1701 (m), 1346 (m), 907 (m), 728 (s); Rf 0.23 
(Hexane/AcOEt 3:1), 0.5 (Hexane/AcOEt 2:1); MS (ESI): m/z = 661.2746; 
Rt: 10.13 (19.19%), 10.18 (80.81%) 50-90% 
[α]19D = -36.62° (c = 0.475 M, CHCl3) 
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Synthesis of (S)-ethyl 3-(tert-butyldimethylsilyloxy)-3-(2-(2-(4-
methoxybenzyloxy)ethyl)benzo[d]thiazole-5-yl)propanoate (49) 
In a microwave vial to 35 (180 mg, 0.272 mmol) in 1 ml of EtOH was 
added titanium (IV) ethoxide (26 µl, 0.124 mmol) and the mixture was 
refluxed for 6 h at 78°C. 
3 ml of AcOEt and 1 ml of water were added  and after 30 minutes of 
stirring the organic layer was removed from the precipitate by filtration and 
concentrated under reduced pressure. The residue was purified by fc 
(hexane /AcOEt 1:3) to yield 134. 7 mg (94%) of pale yellow oil. 
1H NMR (400 MHz, CDCl3): δ 7.94 (d, J= 1.6 Hz, 1H), 7.79 (d, J= 8.3 Hz, 
1H), 7.40 (dd, J= 8.3, 1.6 Hz, 2H), 7.27 (d, J= 8.84 Hz, 2H), 6.87 (d, J= 
8.84 Hz, 2H), 5.29 (dd, J=13.4, 4.4 HZ, 1H), 4.52 (s, 2H), 4.14 (m, 2H), 3.9 
(t, J= 6.5 Hz, 2H), 3.8 (s, 3H); 3.4 (t, J= 6.5 Hz, 2H), 2.78 (m, 2H), 2.60 (m, 
1H), 1.25 (t, J= 6.3 Hz, 3H) 0.86 (s, 9H), 0.06 (s, 3H), -0.01 (s, 3H); 13C 
NMR (400 MHz, CDCl3): δ 171.75, 169.70, 159.5, 153.3, 142.8, 134.8, 
130.2, 129.5, 123, 121.5, 120, 114, 73.05, 72.3, 68.4, 60.7, 55.42, 46.84, 
35.15, 25.9, 18.2, 14.4, -4.4, -5.13; IR (film, CHCl3): 1735 (m), 1513 (m), 
1249 (s), 1092 (s), 1172 (m), 1039 (m), 833 (m), 780 (m); [α]D19= - 40.92° 
(c= 0.48 M, CHCl3); Rf 0.71 (Hexane/AcOEt 1:1); MS (ESI): m/z = 
530.2385 [M +H ]+ 
 
Synthesis of (S)-ethyl 3-(tert-butyldimethylsilyloxy)-3-(2-(2-(4-
methoxybenzyloxy)ethyl)benzo[d]thiazole-5-yl)propanale (23) 
To a stirred solution of 36 (39.60 mg, 0.075 mmol) in 0.65 ml of DCM at -
78°C was added 1.2 M DIBAL-H (90 µl, 0.187 mmol). The mixture was 
stirred for 3 h at -78°C, then it was quenched with MeOH (30 µl) and it was 
left to reach r.t. 
  Epothilones: experimental section 
151 
2ml of DCM and 1 ml of water were added and the mixture was stirred for 
½ h to get a precipitate that was filtered on celite. The two phases were 
separated and the organic phase was washed with water (1 ml), brine (1 ml), 
dried over MgSO4 and concentrated to get a yellow oil as crude. 
Purification by fc (AcOEt/Hexane 1:3) to get 18 mg (50%) of pale yellow 
oil. 
1H-NMR (400 MHz, CDCl3): δ 9.8 (t, 1H, J= 2.5 Hz), 7.44 (d, J= 8.84 
Hz,1H), 7.82 (d, J= 8.4 Hz, 1H), 7.37 (dd, J= 8.37, 1.86 Hz, 1H), 7.27 (d, 
J= 8.8 Hz, 2H), 6.87 (d, J= 8.8 Hz, 2H), 5.35 (dd, J= 8.0, 4.0 Hz, 1H ), 4.53 
(s, 1H), 3.9 (t, J= 6.34 Hz, 2H), 3.8 (s, 1H), 3.4 (t, J= 6.34 Hz, 2H), 2.9 (m, 
1H), 2.68 (m, 1H), 0.88 (s, 9H), 0.06 (s, 3H), -0.13 (s, 3H); 13C NMR (400 
MHz, CDCl3): δ 201.2, 170.0, 159.5, 153.3, 142.3, 135.0, 130.2, 129.54, 
122.80, 121.72, 119.80, 114.01, 73.05, 70.84, 68.32, 55.46, 54.43, 35.14, 
28.85, 25.97, 18.25, -4.35, -4.96; IR (film, CHCl3): 1725 (m), 1513 (m), 
1248 (s), 1092 (s), 1034 (m), 836 (s), 778 (m), 2931 (w); Rf 0.70 
(Hexane/AcOEt 1:1).  
[α]D19= -56.5 ° (c = 0.50 M, CHCl3); MS (ESI): m/z = 518.2569 (this 
aldehyde isn’t so stable). 
 
Synthesis of (S, Z)-methyl 5-(tert-butyldimethylsilyloxy)-5-(2-(2-(4-
(methoxybenzyloxy)ethyl)benzo[d]thiazol-5-yl)-2-methylpent-2-enoate 
(50). 
A solution of phosphonate (16 mg, 0.48 mmol), 18-crown-6 (63.7 mg, 0.24 
mmol) in 1 ml of dry THF is cooled at -78°C under nitrogen and treated 
with KHMDS (9.6 mg, 0.048 mmol). After ½ h, the aldehyde (23.4 mg, 
0.048 mmol) in 0.5 ml was added and the resulting mixture was stirred for 3 
h at-78°C. 
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The reaction was cautiously quenched by addition of 1 ml sat. NH4Cl, the 
aq. layer was extracted with Et2O (5 ml x 3) and the combined ethereal 
layers were dried over MgSO4. Purification by fc (AcOEt/Hexane 1:8 → 
1:7) afforded 9.3 mg (35%) of product as a colourless oil. 
1H-NMR (400 MHz, CDCl3): δ 7.92 (s, 1H), 7.78 (d, J= 8.2 Hz, 1H), Hz, 
1H), 7.36 (dd, J= 8.27, 1.70 Hz, 1H), 7.27 (d, J= 8.8 Hz, 2H), 6.87 (d, J= 
8.7 Hz, 2H), 6.04 (m, 1H), 4.92 (m, 1H), 4.53 (s, 2H), 3.91 (t, J= 6.6 Hz, 
2H), 3.80 (s, 3H), 3.70 (s, 3H), 3.41 (t, J= 6.6 Hz, 2H), 2.9 (m, 2H),1.88 (s, 
3H), 0.90 (s, 9H), 0.04 (s, 3H), -0.11 (s, 3H); 13 C NMR (400 MHz, CDCl3): 
δ 190.0, 169.4, 168.3, 159.5, 153.2, 143.7, 139.3, 134.2, 130.2, 129.5, 
128.7, 123.1, 121.3, 119.9, 114.0, 74.7, 73.1, 68.4, 55.4, 51.4, 41.06, 35.2, 
26.0, 20.9, 18.4, - 4.40, - 4.8; Rf  0.49 (Hexane/AcOEt 2:1). 
[α]D19= -140.90° (c = 0.59 M, CHCl3); MS (ESI): m/z = 556.2538 [M + H]+ 
 
Synthesis of (S,  Z)-methyl 5-(tert-butyldimethylsilyloxy)-5-(2-(2-(4-
(methoxybenzyloxy)ethyl)benzo[d]thiazol-5-yl)-2-methylpent-2-en-1-ol 
(22). 
To a solution of 32 (9 mg, 0.016 mmol) in 120 µl of DCM, was added 
slowly (40 µl, 0.039 mmol) of DIBAL-H 1 M in DCM at -78°C. The 
reaction mixture was left to stir at this temperature for 1 h ½ and then 
warmed at 0°C and kept at that temperature for 30 min. 
1 ml of ethylic ether was added, cooled to 0°C and after the addition of  
1.56 µl of water, 1.56 µl of NaOH15%, 3.9 µl of water, the mixture was 
warmed to r.t. and stirred for 15’. 
MgSO4 was added, the mixture stirred for further 15 min and at the end it 
was filtered on a very small plug of celite. The crude was directly purified 
by fc (AcOEt/Hexane 1:2) to get mg 5.7 (67%) of product as colourless oil. 
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1H NMR (400 MHz, CDCl3): δ 7.87 (d, J= 1.7 Hz, 1H), 7.92 (d, J= 8.1 Hz, 
1H), 7.35 (dd, J= 8.37, 1.56 Hz, 1H), 7.28 (d, J= 8.6 Hz, 2H), 6.87 (d, J= 
8.6 Hz, 2H), 5.33 (m, 1H), 4.82 (m, 1H), 4.53 (s, 2H), 4.06 (d, J= 11.8 Hz, 
1H), 3.96-3.88 (m, 3H), 3.8 (s, 3H), 3.41 (t, J= 6.9 Hz, 2H), 2.65- 2.54 (m, 
1H), 2.43-2.35 (m, 1H), 1.8 (s, 3H), 0.88 (s, 9H), 0.01 (s, 3H), -0.08 (s, 3H); 
13C NMR (400 MHz, CDCl3): δ 159.4, 143.5, 138.0, 134.2, 130.1, 
129.5.124.2, 123, 121.2, 119.8, 113.9, 74.9, 73.0, 68.3, 61.9, 55.4, 39.8, 
35.2, 29.8, 26.0, 22.1, 18.5, -4.5, -4.8; IR (film, CHCl3): 3369 (w), 2929 
(m), 2857 (m), 1512 (m), 1461 (w), 1248 (s), 1087 (s), 1030 (m), 831 (s), 
780 (m); Rf 0.31 (Hexane/AcOEt 1:2); [α]D19= -55.97 ° (c = 0.25M, CHCl3) 
 
Synthesis of ((1S, 2S)-2-((S)-2-(tert-butyldimethylsilyloxy)-2-(2-(2-(4-
methoxybenzyloxy)ethyl)benzo[d]thiazol-5-yl)ethyl-1-
methylcyclopropyl)methanol (15).  
To a stirred solution of Et2Zn 1M in hexane (17 µl, 0.106 mmol) in 0.5 ml 
of dry DCM at 0°C was added CH2I2 (12.7 µl, 0.158 mmol). The mixture 
was stirred at 0°C for 10 min and a preformed solution of Charette ligand (3 
mg, 0.012 mmol) and 38 in 0.2 ml of dry DCM was rapidly added via 
syringe. The resulting mixture was allowed to reach r.t and stirred for 1½ h. 
Aq. Sat. NH4Cl (1 ml) was added and the mixture extracted with (3 ml x 3) 
of DCM. The combined organic extracts were dried over MgSO4 and 
concentrated under reduced pressure to give after purification by fc 
(AcOEt/Hexane 1:3 →1:2) 4 mg of product as white foam. 
1H NMR (400 MHz, CDCl3): 7.87 (d, J= 1.66 Hz, 1H), 7.8 (d, J= 8.3 Hz, 
1H), 7.37 (dd, J= 8.2, 1.5 Hz, 1H), 7.2 (d, J= 8.4 HZ, 2H), 6.87 (d, J= 8.4 
Hz, 2H), 4.90 (m, 1H), 4.53 (s, 1H), 3.9 (t, J= 6.2 Hz, 2H), 3.8 (s, 3H), 3.67 
(m, 1H), 3.4 (t, J= 6.2 Hz, 2 H), 3.3 (d, J= 12.3 , 1H), 1.9 (m, 1H), 1.7- 1.57 
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(m, 2H), 1.2 (s, 3H), 0.89 (s, 9 H); 0.45 (m, 1H), 0.04 (s, 3H), -0.07 (s, 3H); 
13C NMR (400 MHZ, CDCl3): 169.6, 159.5, 153.1, 144.2, 134.4, 130.2, 
129,5, 123.0, 121.5, 119.8, 114, 73.07, 68.37, 67.02, 55.4, 41.5, 35.2, 29.9, 
26.2, 23.2, 22.8, 22.0, 18.53, 16.54, 14.3, -4.32; IR (film, CHCl3): 1761 (s), 
1716 8s), 1390, 1355, (m), 1259, 1199 (m); Rf 0.35 (Hexan/AcOEt 2:1); 
MS (ESI): m/z = 542.2754 [M +H ]+; [α]D19= -72. 02 ° (c = 0.19M; CHCl3). 
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List of abbreviation. 
9-BBN-H                                9-Borabicyclo[3.3.1]nonane 
(S)-BINOL S-(-)-1,1'-Bi-2-naphthol  
Bn Benzyl 
Boc t-Butyloxycarbonyl  
BTAF Benzyltrimethylammonium Fluoride 
CA-4 Combretastatine A-4 
Cbz Carbobenzyloxy 
CDI Carbnyldiimidazole 
DDQ  2,3-Dichloro-5,6-dicyano-1,4-benzoquinone 
DIBAL (DIBAH) Diisobutylaluminum Hydride  
DIPEA N,N-diisopropylethylamine 
DMA  Dimethylacetamide  
DMAP 4-Dimethylaminopyridine 
DMF Dimethylformamide 
DMSO Dimethyl Sulfoxide 
de Diastereomeric excess  
EDCI 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide 
ee     Enantiomeric Excess 
ESI Electrospray ionization  
GTP Guanosine-5’-triphosphate 
FDA Food and Drug Administration 
HBT Hydroxybenzotriazole 
Ipc2BH Bisisopinocampheylborane 
KHMDS Potassium bis-trimethylsilylamide 
Lawesson’ s reagent  2,4-bis(4-methoxyphenyl)-1,3,2,4-
Appendix  
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dithiadiphosphetane-2,4-disulfide 
LDA Lithium Diisopropylamide 
Leu Leucine 
LHMDS Lithium Hexamethyldisilazide 
Lys Lysine  
MS Mass spectrometry 
NMP N-methyl-2-pyrrolidone 
NMR Nuclear Magnetic Resonance 
PCC Pyridinium chlorochromate 
PG Protecting group  
PMB p-Methoxybenzyl 
PPTS Pyridinium p-toluensulfonate 
Rf Retention factor 
RCM Ring closure methatesis 
r.t.  Room temperature (23°C) 
SAR Structure activity relationship 
TBAF Tetra-n-butylammonium fluoride 
TBS t-Butyldimethylsilyl (also TBDMS) 
TEA Triethylamine 
TFA Trifluoroacetic(yl) 
THF tetrahydofurane 
TMAC Tymethylacethyl chloride 
TPAP Tetra-n-propylammonium Perruthenate 
Val Valine 
Z Cis 
 
